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1GENERAL INTRODUCTION AND 
OUTLINE OF THE THESIS
PERSONALIZED ANTI-CANCER TREATMENT
This thesis describes pharmacokinetic and pharmacogenetic studies on four anti-
cancer drugs that are commonly used in the systemic treatment of cancer in the 
gastrointestinal tract. The overarching aim of these studies is to truly ‘personalize’ anti-
cancer treatment in daily clinical practice. Personalized medicine attempts to identify 
the right treatment, at the right time, and in the right dose for each individual patient. 
In oncology, this could be based on different aspects of the tumor itself, but patient 
characteristics are at least equally important and therefore the latter aspect will be 
emphasized in this thesis. 
For most chemotherapeutic agents it is assumed that systemic exposure (expressed 
as pharmacokinetic parameters like area under the time concentration curve and drug 
clearance), is correlated with treatment response, resulting in a therapeutic window 
balancing between toxicity on one hand and undertreatment on the other.1 In general, 
there is a large inter-individual variety in treatment efficacy and drug-related toxicity, 
which could be related to differences in systemic exposure (amongst other factors). 
Systemic exposure to anticancer drugs is determined by many patient-related factors 
such as patient characteristics (e.g. gender, age, size), organ function, life-style (e.g. 
smoking, us of certain foods and alternative agents), co-medication, and genetic factors 
concerning drug transporters or metabolizing enzymes (i.e. pharmacogenetics).1 
Ideally, all these factors should be incorporated in novel dosing strategies to reach a 
personalized dose for every patient. Although recent advances have been made, this is 
still far from daily clinical care, unfortunately. 
Traditionally, dosing of chemotherapy is based on the patient’s body surface area (BSA). 
This dosing-strategy aims to minimize inter-individual variability in exposure as a result 
of differences in body composition, thereby trying to achieve more similar exposure 
across patients, resulting in a maximal efficacy and limited toxicity.2 However, many 
researchers have concluded that for the majority of anticancer agents there is no 
clear relationship between individual exposure and a BSA-based dose.3-9 In fact, this 
is not surprising since there is no solid ground for several BSA-formula’s proposed. 
From the first equations to quantify human body surface by Marcus Vitruvius Pollio 
(85-20 BC) till the Mosteller derivative used nowadays, they all represent a huge 
oversimplification of the human body and should only be used to adjust dosing if BSA 
is actually demonstrated to influence the inter-individual pharmacokinetic variability.7, 
10 This is also the case for the newer (oral) agents which are usually flat dosed, or dosed 
on kg weight.7 
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Therefore, it is important to investigate which other factors influence exposure and 
treatment effect of a specific drug and adjust dosing recommendations based on that 
knowledge to come to a true personalized dose. 
PART I: FLUOROPYRIMIDINES
Fluoropyrimidines are a group of classic chemotherapeutic agents including the 
intravenous administered 5-fluorouracil (5-FU) and orally administered capecitabine 
and tegafur, which act as pro-drugs for 5-FU. Fluoropyrimidines are widely used in the 
treatment of colorectal, pancreatic, gastric and breast cancer amongst other solid tumor 
types. Capecitabine is nowadays more favored than 5-FU, as it has equal effectiveness 
and is more user friendly compared to 5-FU, resulting from its oral formulation. 
Depending on the different types of treatment regimens, capecitabine is given either as 
monotherapy, in combination with other chemotherapeutic agents, or it is combined 
with radiotherapy. Like other chemotherapeutic agents, capecitabine is registered 
in a BSA-based dose to reduce inter-individual variability in its pharmacokinetics. 
However, Baker et al. demonstrated that inter-individual variability in the clearance 
of capecitabine, expressed as coefficient of variation, is even increased from 31.3% to 
36.5% when BSA was taken into account. Therefore, the rationale to use a BSA-based 
dosing strategy for capecitabine is not valid.6 An alternative dosing strategy could be 
fixed-dosing, which means that the dose is not adjusted for body size, and every patient 
receives the same dose despite one’s body size measures. In Chapter 2 the safety and 
effectiveness of a fixed-dosed dose of capecitabine is described in a large cohort of 
patients with different tumor types, and compared with BSA-based dosed patients in a 
comparable cohort of patients.
Fluoropyrimidines are mainly metabolized by the enzyme dihydopyrimidine 
dehydrogenase (DPD) which converts more than 80% of 5-FU into the inactive metabolite 
dihydrofluorouracil, which is converted further into other inactive metabolites and 
eventually excreted via urine. Around 20% of 5-FU is also directly excreted via urine. As a 
result, only a small proportion (1 to 5%) of 5-FU is converted into the active metabolites 
fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) 
and fluorouridine triphosphate (FUTP). The cytotoxic effects of 5-FU result from the 
inhibition of the enzyme thymidylate synthetase by FdUMP, and the incorporation 
of FdUTP in DNA and FUTP in RNA.11 However, when DPD activity is reduced, 5-FU 
clearance is significantly reduced and the amount of 5-FU which is converted in 
these active metabolites will increase, followed by a largely increased risk of severe 
13
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or even fatal treatment related toxicity.12, 13 A reduced DPD activity can be the result of 
polymorphisms in the DPYD gene, which encodes for the DPD enzyme. DPYD is a large 
gene with many variants described, which not all have functional consequences. Based 
on a meta-analysis by Meulendijks et al., four DPYD variants are considered clinically 
relevant (DPYD*2A, c.1679T>G, c.2846A>T, and c.1236G>A) in Caucasian patients.14 It 
has already been demonstrated that prospective genotyping for the DPYD*2A variant 
and dose-reductions in heterozygote DPYD*2A carriers improves treatment safety and 
is cost-effective.15 However, for the other variants this is currently unknown. In Chapter 
3 the results of a large prospective trial, performed in 17 Dutch centers, on personalized 
fluoropyrimidine dosing based on these four DPYD variants are described. Furthermore, 
a cost-analysis of this study cohort is described in Chapter 4.
In addition to DPYD genotyping, DPD deficiency can also be identified using different 
phenotyping tests that measure the DPD activity (in)directly. Several phenotyping 
methods are currently described, of which DPD activity measurement in peripheral 
blood monocytes is the most direct one.16 More indirect phenotyping tests are 
related to the measurement of the endogenous DPD substrate uracil or its product 
dihydrouracil.16 In Chapter 5, different phenotyping tests are prospectively evaluated 
for their additional value to identify DPD deficiency and patients at risk for severe 
fluoropyrimidine-induced toxicity. Finally, although it is rare, one patient can carry 
multiple DPYD variants (i.e. homozygote or compound heterozygote variant carriers), 
which makes it difficult to predict the DPD enzyme activity and the optimal dose. 
In Chapter 6, several cases of patients with multiple variants and their phenotyping 
results, who were treated with personalized fluoropyrimidine treatment are described. 
PART II: IRINOTECAN
Since the clinical introduction in 1998, the camptothecin derivative irinotecan is 
widely used in the treatment of solid tumors including colorectal and pancreatic 
cancer.17 Irinotecan belongs to the class of topoisomerase-I inhibitors; inhibition 
of this enzyme involved in DNA replication induces DNA damage and eventually 
cell death.18 Irinotecan is a prodrug of SN-38, which is 100-1,000 fold more active 
compared to irinotecan itself.19 Several phase I and phase II enzymes including CYP3A4 
and UGT1A, are involved in the highly complex irinotecan metabolism which makes 
it prone to environmental and genetic influences.17 These factors will partly explain 
the large inter-individual variability in irinotecan pharmacokinetics. Although many 
years of research gave more insight in these factors, the full story about differences in 
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irinotecan exposure is not yet unraveled. In Chapter 7 an overview of current evidence 
on irinotecan pharmacokinetics, pharmacodynamics, and pharmacogenetics is given. 
Irinotecan treatment is characterized by several dose-limiting toxicities such as severe 
neutropenia and diarrhea in up to a quarter of patients.20, 21 Several interventions 
to reduce treatment related toxicities have been investigated including dietary 
adjustments. Preclinical studies in animals have demonstrated that by fasting before 
irinotecan treatment, toxicity can be reduced while preserving the anti-tumor 
effects.22, 23 After 72 hours of fasting, mice experienced significantly less side effects 
of irinotecan chemotherapy, intra-tumoral SN-38 concentrations tended to be higher, 
and concentrations in both plasma and healthy liver were significantly lower.23 The 
mechanisms behind the protective effects of dietary restriction are not completely 
understood and are actively being studied. One of the theories about the difference in 
response to dietary restriction between cancer and normal cells is that by starvation 
in normal cells the growth factor pathways (i.e. AKT, RAS, proto-oncogenes) can be 
down regulated as response to reduction in growth factors such as IGF-I, in contrast 
to cancer cells where oncogenic mutations will lead to continuous growth in the 
absence of growth factors.24 However, it is currently unknown if fasting or short-term 
dietary restriction might help to reduce toxicity in patients treated with chemotherapy. 
A small case-series of 10 patients who had voluntarily fasted prior and/or after different 
chemotherapy regimens suggested that subjective wellbeing was improved without 
affecting the anti-cancer effects.25 Furthermore, a randomized pilot study in 13 
patients demonstrated that 24 hours fasting before chemotherapy resulted in reduced 
hematological toxicity.26 Based on the preclinical evidence, we hypothesized that 
fasting might help to reduce toxicity in patients treated with irinotecan, due to lower 
irinotecan concentrations in healthy tissues and plasma, while preserving its intra-
tumoral concentrations. Therefore, in a prospective pharmacokinetic crossover study 
we studied the effects of a short-term dietary restriction regimen in cancer patients 
with liver metastases treated with irinotecan as described in Chapter 8.
PART III: REGORAFENIB
Compared to the other (chemotherapeutic) agents in this thesis, regorafenib is a 
relatively new drug and not a classic chemotherapeutic agent. Regorafenib is an oral 
multi-kinase inhibitor that targets angiogenic, stromal and oncogenic receptor tyrosine 
kinases (e.g. VEGFR, KIT, BRAF, PDGFR and FGFR).27 Regorafenib is currently worldwide 
used in the treatment of colorectal cancer (except for the Netherlands), gastro-
intestinal stromal tumors, and hepatocellular carcinoma.28-30 After oral administration, 
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regorafenib is rapidly absorbed, with a maximum concentration reached at 3-4 
hours.31, 32 Most tyrosine kinase inhibitors (TKIs) exhibit pH-dependent solubility, which 
makes them prone for drug-drug interactions with acid suppressive agents like proton 
pump inhibitors.33 Up to one third of all cancer patients concomitantly also uses acid-
suppressive therapy, both as prophylaxis for gastro-intestinal bleeding and as treatment 
for gastresophageal reflux disease.34, 35 For many TKIs, a pharmacokinetic interaction 
with an acid-suppressive agent has already been demonstrated, for example erlotinib 
combined with omeprazole resulted in 46% decrease in systemic exposure.33 Those 
drug-drug interactions could have serious clinical consequences, because when 
exposure is decreased, treatment efficacy could potentially decrease also.31 However, 
for regorafenib there is no evidence of a possible drug-drug interaction with acid-
reducing drugs. Therefore, in Chapter 9 we describe a prospective cross-over study 
on the potential pharmacokinetic interaction between the proton pump inhibitor 
esomeprazole and regorafenib, with special interest in the influence of timing of 
esomeprazole intake relative to that of regorafenib. 
Furthermore, in more than half of all patients, treatment with regorafenib is associated 
with severe and dose-limiting toxicities such as hypertension and hand foot skin 
reactions which not always outweigh treatment benefit.36 Therefore, there is an urgent 
need for biomarkers predictive for response to identify specific patients who will, and 
who will not, benefit from regorafenib treatment. Multiple studies demonstrated that 
the detection of circulating tumor DNA (ctDNA) could be a powerful tool to monitor 
and understand the response to anti-cancer agents.37 In metastatic colorectal cancer 
patients, high amounts of circulating cell free DNA (cfDNA) and ctDNA before initiation 
of treatment are correlated with shorter overall survival.38 However, most of these studies 
only measured cfDNA and ctDNA at baseline and not during treatment. When looking 
at changes in the amount of ctDNA during treatment, two small studies demonstrated 
that an early and sustained decline in ctDNA during regorafenib treatment is correlated 
with an improved survival.39, 40 Furthermore, an increase in ctDNA concentration after 
14 days of regorafenib treatment is associated with a significantly decreased median 
progression free survival and overall survival.41 We hypothesized that dynamic changes 
in cfDNA/ctDNA early during the treatment with regorafenib may be related to drug 
exposure and toxicity. In Chapter 10 we describe an explorative analysis on early 
cfDNA/ctDNA dynamic changes and correlation with regorafenib pharmacodynamics 
in metastatic colorectal patients.
16
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PART IV: CARBOPLATIN / PACLITAXEL
The combination of carboplatin and paclitaxel is used as treatment regimen in several 
solid cancers including esophageal, ovarium, and lung cancer. In this thesis, treatment 
with carboplatin and paclitaxel (with or without radiotherapy) is only discussed in 
relation to (gastro)esophageal cancer. Esophageal cancer is the 8th most common 
cancer worldwide, the incidence is still rising and mortality is high.42-44 Although the 
prognosis of esophageal cancer has improved over the last decades, prognosis still 
remains poor with an overall 5-year survival of 20%.43, 45 This survival improvement 
seems to be limited to patients with early stage (gastro)esophageal cancer, which might 
be caused by the recent advances in the treatment of resectable (gastro)esophageal 
cancer by introduction of neoadjuvant chemoradiotherapy according to the CROSS-
regimen.46, 47 However, almost half of all patients have already non-resectable (gastro)
esophageal cancer at diagnosis (i.e. locally advanced tumors or distant metastasis).48 
For patients with locally advanced disease, systemic treatment can be considered in 
an attempt to downstage the tumor (i.e. induction treatment), which can be followed 
by surgery or chemoradiotherapy in case of a good response. For patients with distant 
metastases, palliative chemotherapy can be considered. Palliative systemic treatment 
improves survival compared to best supportive care, although survival benefit is 
limited and toxicity of treatment should not outweigh the treatment benefit.45, 49 Many 
different induction or palliative treatment regimens are described, which are often 
fluoropyrimidine- or platinum-based doublet or triplet combination regimens.45, 49, 50 A 
study of the Netherlands Cancer Registry demonstrated that already in the Netherlands 
up to 69 different palliative treatment regimens are administered in metastatic (gastro)
esophageal cancer patients.51 This clearly demonstrates that optimal palliative treatment 
in esophageal cancer is not well defined, and the same is probably true for induction 
chemotherapy.
Fifteen years ago, our research group performed a phase-1 study of weekly paclitaxel 
and carboplatin as palliative treatment for patients with metastatic esophageal 
cancer resulting in a recommended dose of carboplatin targeted at an area under 
the curve (AUC) of 4 and paclitaxel of 100 mg/m2.52 This weekly regimen was very 
tolerable and effective with an over-all response rate of 54%. Therefore, this regimen 
was implemented as standard of care for all patients with advanced or metastatic 
(gastro)esophageal cancer at the Erasmus University Medical Center, Rotterdam, The 
Netherlands. Chapter 11 describes the efficacy and toxicity of this weekly carboplatin 
and paclitaxel regimen as induction or palliative treatment option in a real-world 
treatment setting.
17
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Paclitaxel is also characterized by a large inter-individual variability in exposure, which 
will be in part explained by patient related factors.53 Although a dose-response relation 
has been suggested for paclitaxel, it is currently unknown if treatment outcome is 
related to the variation in paclitaxel exposure.1, 53 Therefore, in Chapter 12 the 
association between systemic paclitaxel exposure and treatment outcome in patients 
with esophageal cancer was described. This was done in patients in several clinical 
settings (e.g. neo-adjuvant chemoradiotherapy, induction and palliative chemotherapy). 
Hopefully the readers of this thesis will appreciate the clinical studies that are reported. 
It is my wish that the results of these studies will further contribute to personalized 
medicine in patients treated for cancer of the gastro-intestinal tract, and that this may 
boost efficacy and reduce toxicity.
18
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SURFACE AREA-BASED DOSE 
CAPECITABINE
ABSTRACT 
BACKGROUND
Capecitabine is generally dosed based on body-surface area (BSA). This dosing 
strategy has several limitations; however, evidence for alternative strategies is lacking. 
Therefore, we analyzed the toxicity and effectiveness of fixed-dose capecitabine and 
compared this strategy with BSA-based dose of capecitabine in a large set of patients. 
METHODS
Patients treated with fixed-dose capecitabine between 2003 and 2015 were studied. A 
comparable group of patients, dosed based on BSA, was chosen as a control cohort. 
A total of two combined scores were used: capecitabine-specific toxicity (diarrhea, 
National Cancer Institute Common Toxicity Criteria grade ≥3, hand-foot syndrome 
≥2, or neutropenia ≥2), and clinically relevant events due to toxicity, that is, hospital 
admission, dose reduction, or discontinuation. Per treatment regimen, patients were 
divided into three BSA groups based on BSA quartiles corrected for sex. Toxicity scores 
were compared by a Chi-square test between cohorts, and within cohorts using BSA 
groups. Progression-free survival (PFS) was estimated by the Kaplan-Meier method.
RESULTS
A total of 2,319 patients was included (fixed dosed n=1,126 and BSA-based dose 
n=1,193). Overall, four regimens were evaluated: capecitabine-radiotherapy (n=1,178), 
capecitabine-oxaliplatin (n=519), capecitabine-triplet (n=181) and capecitabine 
monotherapy (n=441). The incidence of capecitabine-specific toxicity and clinically 
relevant events was comparable between fixed-dose and BSA-based dose patients, 
while a small difference (7.1%) in absolute dose was found. Both cohorts showed only 
a higher incidence of both toxicity scores in the lowest BSA group of the capecitabine-
radiotherapy group (P<0.05). Subgroups of the fixed-dose cohort analyzed for PFS, 
showed no differences between BSA groups. 
CONCLUSIONS
Fixed-dose capecitabine is comparably well tolerated and effective as BSA-based 
dosing and could be considered as a reasonable alternative for BSA-based dosing.
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INTRODUCTION
Capecitabine is an oral prodrug for the cytotoxic agent 5-fluorouracil (5-FU) and 
is widely used in the treatment of colorectal cancer and other solid tumors (e.g. 
breast and gastric cancer).1-4 Capecitabine has equal effectiveness and shows, in 
general, a more favorable toxicity profile compared with intravenous 5-FU, except 
for the incidence of hand-foot-syndrome (HFS).5 Depending on the different types 
of treatment regimens, capecitabine is given either as monotherapy, in combination 
with other cytotoxic agents, or it is combined with radiotherapy. Worldwide, dosing 
of capecitabine for the individual patient is based on the patient’s body surface area 
(BSA). However, both effectiveness and toxicity depend on the individual exposure to 
capecitabine and therefore the rationale for dosing based on solely height and weight 
has been questioned for decades.6-13 
BSA-guided dosing of anticancer agents aims to minimize inter-individual variability in 
exposure as a result of differences in body composition, thereby trying to achieve more 
similar exposure across patients, resulting in a maximal effect and limited toxicity.14 
However, this dosing strategy has several drawbacks. Firstly, there is limited evidence 
for the base of the BSA-formula since the first formula to calculate BSA (by Du Bois 
and Du Bois, more than a century ago) was based on only nine individuals.15 Still, it 
forms the backbone for all (other) BSA-formulas, of which the Mosteller derivative 
is currently the most frequently used.16 Secondly, BSA-dosing encounters increased 
costs and a larger chance of calculation errors compared with fixed dosing.6 Thirdly 
and most importantly, although BSA dosing was intended to reduce the inter-individual 
variability in drug exposure, many researchers have concluded that for the majority of 
anticancer agents there is no clear relationship between an individual’s exposure and a 
BSA-based dose.7-13 Indeed, Baker et al. demonstrated by modeling that inter-individual 
variability in clearance of capecitabine expressed as coefficient of variation (CV) was 
even increased when BSA was taken into account (31.3% versus 36.5%).10 In other 
words, there is fair skepticism regarding the question whether this dosing strategy 
really contributes to reducing inter-individual pharmacokinetic and consequent 
pharmacodynamic variability of anticancer agents.11, 13
BSA-based dosing is for many anticancer agents not evidence based, and especially 
for frequently used drugs such as capecitabine, there is a need for alternative dosing 
strategies to standardize the dose.17 Fixed dosing means that the dose is not adjusted 
for body size, so that every adult patient with the same malignancy receives the same 
(fixed) dose. A major benefit of dose standardization by fixed dosing is that it will lead 
to less prescribing errors and a reduction in preparation and storage costs.18-20 Fixed 
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dosing is already implemented in the majority of newly developed oral anticancer 
drugs.21 However, unless there is more evidence that a fixed dose can safely be applied 
without compromising effectiveness, then conventional chemotherapy regimens will 
remain to be dosed based on BSA according to the registration studies, even though 
BSA-guided dosing is in many cases not evidence based. 
To the best of our knowledge, there are no published studies with a sufficiently large 
sample size evaluating the outcomes of a fixed dose of capecitabine. In 2003, the 
Erasmus University Medical Center, Rotterdam, the Netherlands, implemented a fixed 
dose of capecitabine in different treatment regimens, as there was no evidence that 
BSA-based dosing was better. This resulted in a unique ‘real-life’ cohort of patients 
treated with a fixed dose of capecitabine, with a long follow-up period. Therefore, the 
aim of our present study was to evaluate the toxicity and effectiveness of fixed-dose 
capecitabine in several treatment schedules in this cohort of patients. Additionally, we 
compared this cohort with another large cohort of Dutch cancer patients, in which 
patients were dosed based on BSA and treated in the same time period, in order to 
determine whether fixed-dose capecitabine is as equally well tolerated and effective as 
BSA-based dosing of capecitabine.
METHODS
The cohorts for this analysis were obtained from the Erasmus University Medical Center, 
Rotterdam, The Netherlands for the fixed-dose cohort, and from the Netherlands Cancer 
Institute, Antoni van Leeuwenhoek, Amsterdam; Slotervaart Hospital, Amsterdam; and 
Canisius Wilhelmina Hospital, Nijmegen, all in the Netherlands for the BSA-based dose 
cohort, respectively. 
The primary study endpoint was the incidence of treatment-related toxicity in a fixed-
dose cohort compared with a BSA-based dose cohort. Secondary endpoints included 
the comparison of the absolute amount of capecitabine administered in the fixed-dose 
cohort compared to BSA-dosing strategies, incidence of toxicity between BSA groups 
within both cohorts, and the effectiveness of fixed-dose capecitabine compared 
between BSA groups in terms of disease-free survival (DFS) in (neo)adjuvant care and 
progression-free survival (PFS) in palliative care.  
PATIENTS AND TREATMENTS
All patients treated with capecitabine between 2003 and 2015 at the Erasmus University 
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Medical Center were identified by the hospital pharmacy based on drug-dispensing 
data and evaluated for inclusion in the fixed-dose cohort. As fixed-dose capecitabine 
is considered routine clinical care at the Erasmus University Medical Center, no ethics 
approval or informed consent was required to retrospectively collect and analyze 
these patient data for research purposes. Patients in the BSA-based dose cohort were 
prospectively included in a previously conducted trial in three large hospitals in the 
Netherlands (ClinicalTrials.gov identifier: NCT00838370), this trial was approved by the 
medical ethical committees of all participating hospitals.22 All patients of the BSA-based 
dose cohort provided informed consent for the prospective trial, including consent for 
additional analyses outside the subject of this trial. Patients were excluded from both 
cohorts when they had a World Health Organization (WHO) performance status of 3 or 
4, when they were previously treated with fluoropyrimidines, when they were treated 
in an experimental treatment setting outside standard-of care; or when limited data 
on important parameters required for the current analysis were available (i.e. length, 
weight, toxicity evaluation). 
In both cohorts, patients were divided into four groups based on treatment regimen: 
capecitabine monotherapy (CAPE MONO), capecitabine combined with radiotherapy 
(CAPE+RT), capecitabine combined with oxaliplatin (CAPOX), and capecitabine 
triplet therapy (CAPE TRIPLET). The CAPE TRIPLET group consisted of capecitabine 
combined with epirubicin and cisplatin or oxaliplatin (ECC/EOX) in both cohorts, and in 
the BSA-based dose cohort also patients treated with capecitabine with docetaxel and 
oxaliplatin (DOC) were included. Capecitabine was administered as fixed daily dose 
(divided over two doses daily) of 3,000 mg for CAPE+RT; 3,500 mg for CAPOX and 
ECC/EOX; 3,500 mg or 4,000 mg for CAPE MONO. Detailed descriptions of included 
treatment types are given in Supplementary Table 1. 
DATA
All data for the fixed-dose cohort were retrospectively collected from the electronic 
health records. For the BSA-based dose cohort all data was prospectively collected 
in a previously conducted trial by Deenen et al 22. Data on patient demographics (i.e. 
length, weight, WHO performance status) had to be known within one month before 
the start of capecitabine. BSA was calculated per patient using the Mosteller formula 
16. Renal function was expressed as estimated glomerular filtration rate (eGFR). For 
the fixed-dose cohort the eGFR was calculated according to the Cockcroft Gault 
formula23, and for the BSA-based dose cohort according to the MDRD-formula.24 
Toxicity was defined as all possible capecitabine-related adverse events and laboratory 
abnormalities occurring during treatment with capecitabine until one month after end 
of treatment or until the start of a new treatment, whichever occurred first. Toxicity was 
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graded according to the Common Terminology Criteria for Adverse Events (CTC-AE) 
version 4.03.25 Overall, two combined scores were created to evaluate severe toxicity 
and clinically relevant events due to toxicity. Capecitabine-specific toxicity was defined 
as toxicity grade for diarrhea ≥ 3, HFS ≥ 2, or neutropenia ≥ 2. Clinically relevant events 
consisted of hospital admission, dose reduction, or discontinuation caused by possible 
capecitabine-related adverse events. Data on DFS in (neo)adjuvant treated patients or 
PFS in palliative treated patients was collected to asses effectiveness of fixed-dose 
capecitabine. DFS was defined as time till disease recurrence. PFS was defined as time 
till disease progression or death from any cause. Disease recurrence or progression 
had to be pathologically proven or by imaging evaluated according to the response 
evaluation criteria in solid tumors (RECIST) 1.1.26
STATISTICAL ANALYSIS
Demographic characteristics were compared between the two cohorts by using the 
Chi-square test for categorical variables, and an unpaired T-test or Mann-Whitney U 
test for continuous variables. Per treatment, toxicity was compared between the fixed-
dose and BSA-based dose cohort using the Chi-square or Fisher’s exact test. In the 
fixed-dose cohort, patients were divided in three groups based on BSA quartiles per 
sex and treatment: lowest 25%, middle 50% and highest 25%. In the BSA-based dose 
cohort, patients were divided in the same treatment groups based on the BSA limits per 
sex obtained from the fixed-dose cohort. Toxicity was compared between the three 
BSA groups within both cohorts using the Chi-square test for trend. 
For regimens were BSA was found to be predictive for toxicity, other relationships 
between known risk factors from literature and toxicity were studied within both 
cohorts using univariate and multivariate binary logistic regression analysis, where the 
assumption of linearity was checked for each continuous risk factor. Significant risk 
factors with P < 0.05 detected in the univariate analysis of the fixed-dose cohort, were 
included in the multivariate analysis of both cohorts. In the fixed-dose cohort; the mean 
given fixed daily capecitabine dose was compared to a calculated (‘fictional’) mean 
daily capecitabine dose based on patient’s BSA and according to clinical guidelines per 
treatment type, by using a paired sample T-test. 
Survival analysis was only performed in the fixed-dose cohort in separate groups per 
tumor type, indication and treatment regimen (i.e. CAPE+RT for locally advanced 
colorectal cancer (laCRC), CAPOX for metastatic colorectal cancer (mCRC), and ECC/
EOX for gastric cancer). For the BSA-based dose cohort, this analysis could not be 
performed because these data were not collected. Survival analysis between three BSA 
groups was done by the Kaplan-Meier method. Only, treatment regimens per indication 
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with at least 20 events were included in this analysis. 
P-values < 0.05 were considered statistically significant. All statistical analyses were 
performed using SPSS (version 24.0.0.1). 
RESULTS
PATIENT AND TREATMENT CHARACTERISTICS
A total of 3,583 patients were screened for inclusion of whom 1,264 patients were 
excluded, mainly because of previous fluoropyrimidine treatment (Figure 1). This 
resulted in a total of 2,319 patients enrolled in the analysis of whom 1,126 patients were 
included in the fixed-dose cohort and 1,193 patients in the BSA-based dose cohort 
(Figure 1). Patient characteristics for both cohorts per treatment group are described 
in Table 1. Overall, more male patients were included in the fixed-dose cohort (61%) 
than in the BSA-based dose cohort (48%; P < 0.001). The mean age was comparable 
in most treatment groups, but patients treated with capecitabine monotherapy were 
slightly older in the fixed-dose cohort (65 versus 61 years, P = 0.019). The majority of 
patients were from Caucasian origin (91%), but fewer in the fixed-dose cohort (85%) 
compared with the BSA-based dose cohort (96%) (P <0.001). The BSA of patients was 
normally distributed per sex and treatment. The mean BSA of patients was comparable 
in most treatment groups, but in the CAPE+RT group the BSA was slightly higher in 
the fixed-dose cohort compared to the BSA-based dose cohort (1.94 m2 and 1.91 m2, 
respectively, P = 0.013). 
Overall, the most common tumor type was colorectal cancer (75%), and capecitabine 
combined with radiotherapy was the most often used treatment regimen in both 
cohorts. The median capecitabine daily dose was 3,000 mg in the fixed-dose cohort, 
and 3,500 mg in the BSA-based dose cohort. Only in the CAPE MONO group, was 
no significant difference in the median capecitabine daily dose identified between 
both cohorts. Overall, the mean given fixed dose capecitabine was 7.2% lower than 
calculated dose based on BSA (P < 0.001); the results detailed per treatment are shown 
in Supplementary Table 2. 
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Figure 1. STROBE diagram of included patients
Abbreviations: 5-FU = 5-fluorouracil; BSA = body surface area; 
STROBE = strengthening the reporting of observational studies in epidemiology
Table 1. Patient characteristics [Table on the next page]
P-values < 0.05 are considered statistically significant and are depicted in bold.
a BSA was calculated according to the Mosteller formula16 
b eGFR was calculated according to the Cockcroft-Gault formula in the fixed-dose cohort 23, and calculated 
according to the CKD-EPI formula in the BSA-based dose cohort 24
c The administered treatment regimens are described in more detail in supplementary table 1
d Total daily capecitabine dose at start of first cycle
Abbreviations: BC = breast cancer; BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine 
combined with oxaliplatin; CRC = colorectal cancer; ECC = capecitabine combined with epirubicin and cisplatin; 
eGFR = estimated glomerular filtration rate; EOX = capecitabine combined with epirubicin and oxaliplatin; GC 
= gastric cancer; IQR = interquartile range; mono = monotherapy; SD = standard deviation; RT = radiotherapy 
TOXICITY BETWEEN THE FIXED-DOSE AND BSA-BASED DOSE COHORT
No differences in the incidence of capecitabine-specific toxicity or clinically relevant 
events could be identified between the fixed-dose and BSA-based dose cohort per 
treatment group (Table 2). Only in the CAPE MONO and CAPE TRIPLET group, were 
some minor differences in the single toxicity incidences identified. In the fixed-dose 
patients of the CAPE MONO group, a lower incidence of HFS ≥ 2 (22% versus 33%, P 
= 0.026) and a higher incidence of neutropenia ≥ 2 (14% versus 6%, P = 0.005) was 
observed than in the BSA-based dose patients (Table 2). Fixed-dose patients of the 
CAPE TRIPLET group had a higher incidence of neutropenia ≥ 2 (82% versus 61%, P 
= 0.003), and more discontinuation of treatment due to toxicity (37% versus 23%, P = 
0.043) compared to the BSA-based dose patients (Table 2). Importantly, no difference 
in toxicity or clinically relevant events could be identified when toxicity was compared 
between the lowest BSA quartile of the fixed-dose and BSA-based dose cohort per 
treatment, indicating that patients with a low BSA did not receive too much capecitabine 
in the fixed-dose cohort (Supplementary Table 3). 
34
PART I | CHAPTER 2
Table 1. Patient characteristics
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Table 2. Toxicity compared between fixed-dose and BSA-based dose patients per treatment 
regimen
TREATMENT TOXICITY
Diarrhea
≥ 3 (%)
HFS
≥ 2 
(%)
Neutropenia 
≥ 2 
(%)
Cape-
specific
toxicity
(%)a
Dose 
reduction 
(%)
Stop 
(%)
Hospital 
admission 
(%)
Clinically 
relevant 
events 
(%)b
CAPE+RT*
FIXED
N=769
75 
(9.8)
17 
(2.2)
17 
(2.2)
95 
(12.4)
9 
(1.2)
106 
(13.8)
68 
(8.8)
127 
(16.5)
BSA
N=409
39 
(9.5)
15 
(3.7)
6 
(1.5)
52 
(12.7)
9 
(2.2)
50 
(12.2)
29
(7.1)
59 
(14.4)
P-value 0.904 0.143 0.380 0.859 0.162 0.452 0.298 0.349
CAPOX*
FIXED
N=189
17 
(9.0)
25 
(13.2)
48 
(25.4)
78 
(41.3)
43 
(22.8)
43 
(22.8)
34 
(18.0)
82 
(43.4)
BSA
N=330
41 
(12.4)
56 
(17.0)
82 
(24.8)
146 
(44.2)
97 
(29.4)
64 
(19.4)
39 
(11.8)
141 
(42.7)
P-value 0.233 0.258 0.890 0.511 0.101 0.372 0.053 0.884
CAPE MONO*
FIXED
N=97
1 
(1.0)
21 
(21.6)
14 
(14.4)
34
(35.1)
17 
(17.5)
16 
(16.5)
6 
(6.2)
31 
(32.0)
BSA
N=344
17 
(4.9)
115 
(33.4)
20 
(5.8)
140 
(40.7)
87 
(25.3)
58 
(16.9)
24 
(7.0)
128
(37.2)
P-value 0.141 0.026 0.005 0.315 0.112 0.932 0.785 0.342
CAPE 
TRIPLET*
FIXED
N=71
5 
(7.0)
11 
(15.5)
58 
(81.7)
59 
(83.1)
12 
(16.9)
26 
(36.6)
19 
(26.8)
35 
(49.3)
BSA
N=110
12 
(10.9)
15 
(13.6)
67 (
60.9)
78 
(70.9)
26 
(23.6)
25 
(22.7)
21 
(19.1)
53 
(48.2)
P-value 0.444 0.728 0.003 0.062 0.277 0.043 0.225 0.884
P-values < 0.05 are considered statistically significant and are depicted in bold. * The administered treatment 
regimens are described in more detail in supplementary table 1 
a Capecitabine-specific toxicity was defined as at least one of the following toxicity scores: diarrhea ≥ 3, HFS ≥ 
2, neutropenia ≥ 2
b Clinically relevant events was defined as at least one of the following events due to toxicity: dose reduction, 
stop with capecitabine, hospital admission 
Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; 
HFS = hand-foot syndrome; mono = monotherapy; 
RT = radiotherapy
TOXICITY COMPARED BETWEEN BSA GROUPS WITHIN BOTH COHORTS 
No differences could be identified for CAPOX, CAPE MONO and CAPE TRIPLET when 
the incidence of capecitabine-specific toxicity and clinically relevant events was 
compared between the low, middle and high BSA group per treatment and cohort. 
However, only in the CAPE+RT group a significant difference in capecitabine-specific 
and clinically relevant events could be identified between BSA groups within the fixed-
dose cohort (P = 0.009 and P = 0.013, respectively) and within the BSA-based dose 
cohort (P = 0.022 and P = 0.035, respectively; Table 3), demonstrating a higher risk of 
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toxicity in the lowest BSA quartile of patients from the CAPE+RT group of both cohorts. 
Table 3. Toxicity compared between BSA groups within the fixed-dose cohort and the BSA-
based dose cohort
TOXICITY per treatment FIXED-dose cohorta BSA-based dose cohortb
Low
BSA
Middle
BSA
High
BSA
P-value Low
BSA
Middle
BSA
High
BSA
P-value
CAPE + RT*
 Cape-specific toxicity (%)c
 Clinically relevant events (%)d
N=204
33 (16.2)
45 (22.1)
N=378
48 (12.7)
58 (15.3)
N=187
14 (7.5)
24 (12.8)
0.009
0.013
N=117
20 (17.1)
21 (17.9)
N=219
28 (12.8)
34 (15.5)
N=73
4 (5.5)
4 (5.5)
0.022
0.035
CAPOX*
 Cape-specific toxicity (%)c
 Clinically relevant events (%)d
N=48
18 (37.5)
25 (52.1)
N=96
39 (40.6)
36 (37.5)
N=45
21 (46.7)
21 (46.7)
0.373
0.573
N=84
33 (39.3)
32 (38.1)
N=158
73 (46.2)
72 (45.6)
N=88
40 (45.5)
37 (42.0)
0.423
0.612
CAPE MONO*
 Cape-specific toxicity (%)c
 Clinically relevant events (%)d
N=25
9 (36)
11 (44.0)
N=49
15 (30.6)
15 (30.6)
N=23
10 (43.5)
5 (21.7)
0.609
0.099
N=97
41 (42.3)
38 (39.2)
N=173
75 (43.4)
64 (37.0)
N=74
24 (32.4)
26 (35.1)
0.233
0.585
CAPE TRIPLET*
 Cape-specific toxicity (%)c
 Clinically relevant events (%)d
N=17
13 (76.5)
11 (64.7) 
N=37
31 (83.8)
18 (48.6)
N=17
15 (88.2)
6 (35.3)
0.363
0.089
N=12
11 (91.7)
6 (50.0)
N=68
45 (66.2)
33 (48.5)
N=30
22 (73.3)
14 (46.7)
0.536
0.830
P-values < 0.05 are considered statistically significant and are depicted in bold.
* The administered treatment regimens are described in more detail in supplementary table 1
a BSA groups were based on the lowest 25%, middle 50% and highest 25% BSA per sex and treatment in the 
fixed-dose cohort
b BSA groups within the BSA-based dose cohort were based on BSA-distribution and limits set in the fixed-dose 
cohort per sex and treatment
c Capecitabine-specific toxicity was defined as at least one of the following toxicity scores: diarrhea ≥ 3, HFS 
≥ 2, neutropenia ≥ 2
d Clinically relevant events was defined as at least one of the following events due to toxicity: dose reduction, 
stop with capecitabine, hospital admission 
Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; 
HFS = hand-foot syndrome; mono = monotherapy; RT = radiotherapy
RISK FACTORS FOR TOXICITY IN PATIENTS TREATED WITH CAPE+RT 
Only in the CAPE+RT group, an increased toxicity risk was demonstrated in the low 
BSA group in both cohorts. Therefore, in this group additional analyses for other risk 
factors than BSA were performed. Univariate regression analysis, demonstrated that 
BSA was predictive for toxicity in the CAPE+RT group of both cohorts (Table 4). Sex, 
age, and kidney function were also significantly related to toxicity in the fixed-dose 
cohort, but not in the BSA-based dose cohort. After correction for these factors in 
a multivariate model, BSA remained significantly predictive for capecitabine-specific 
toxicity in the fixed-dose patients (OR = 0.25, 95%CI = 0.07-0.86, P = 0.028) and BSA-
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based dose patients (OR = 0.09, 95% CI = 0.01-0.74, P = 0.025). Interestingly, fixed-
dose women treated with CAPE+RT (and the same diagnosis) had a doubling of the 
toxicity risk compared with men for both capecitabine-specific toxicity (OR = 2.02, 
95%CI = 1.22-3.37, P = 0.007) and clinically relevant events (OR = 2.12, 95%CI = 1.35-
3.32, P = 0.001; Table 4). 
   
EFFECTIVENESS
Overall, for mCRC patients treated with CAPOX, the median PFS was 8.6 months (95% 
CI 6.9-10.3 months) and for patients with gastric cancer treated with ECC/EOX, the 
median PFS was 24.6 months (95% CI 6.1-43.0 months). For patients with laCRC treated 
with CAPE+RT, the median DFS was not reached; the five-year survival probability was 
0.56. No statistical differences between BSA groups in PFS for CAPOX for mCRC or ECC/
EOX for gastric cancer, nor for the DFS with CAPE+RT for laCRC, could be identified 
(Figure 2). These results indicate that, in the fixed-dose regimens evaluated, there was 
no inadequate dosing of patients. Other fixed-dose treatment regimens could not be 
evaluated for survival due to too low number of events per treatment and indication. 
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Table 4. Risk factors for toxicity in patients treated with capecitabine and radiotherapy within 
the fixed-dose cohort and the BSA-based dose cohort
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P-values < 0.05 are considered statistically significant and are depicted in bold.
a Capecitabine-specific toxicity was defined as at least one of the following toxicity scores: diarrhea ≥ 3, HFS ≥ 
2, neutropenia ≥ 2
b Clinically relevant events was defined as at least one of the following events due to toxicity: dose reduction, 
stop with capecitabine, hospital admission 
Abbreviations: BSA = body surface area; CAPE = capecitabine; eGFR = estimated glomerular filtration rate; F = 
female; HFS = hand-foot syndrome; M = male; RT = radiotherapy
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 Figure 2.  Survival compared between BSA groups within the fixed-dose cohort 
Disease free survival in CAPE+RT for laCRC (Figure 2A.). Progression free survival in CAPOX for 
mCRC (Figure 2B.) and in ECC/EOX for gastric cancer (Figure 2C.).
Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; 
ECC = capecitabine combined with epirubicin and cisplatin; EOX = capecitabine combined with epirubicin and 
oxaliplatin; F = number of events; laCRC = locally advanced colorectal cancer; mCRC = metastatic colorectal 
cancer; N = number of patiens; RT = radiotherapy
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DISCUSSION
This relatively large cohort study demonstrates that a fixed dose of capecitabine is as 
comparably well tolerated as dosing based on BSA in several treatment regimens (i.e. 
CAPOX, CAPE TRIPLET and CAPE MONO). Only in the CAPE+RT group, was a low BSA 
predictive for capecitabine-specific toxicity and clinically relevant events. In addition, 
our data suggest that a fixed dose of capecitabine was equally effective compared with 
dosing based on BSA. Therefore, we demonstrated that this fixed dosing strategy of 
capecitabine is feasible in a large ‘real life’ population with common treatment regimens.
Beforehand, the observed association between BSA and toxicity when capecitabine 
was combined with radiotherapy was not expected. It is remarkable that an increased 
incidence of capecitabine-specific and clinically relevant events was not only found in 
the low BSA group in the fixed-dose cohort, but also in the low BSA group in the BSA-
based dose cohort (Table 3). The fact that also in the latter group a higher risk of toxicity 
was observed in the lowest BSA quartile of patients, suggests that this effect is likely 
to be caused by the interaction of the two treatment modalities. When capecitabine is 
combined with radiotherapy, the absolute dose of capecitabine used is lower compared 
to the other regimens, because it is used as radiosensitizer. The enzyme thymidine 
phosphorylase in the tumor tissue is responsible for the final metabolic step in the 
conversion of capecitabine into 5-FU. This conversion is boosted by radiotherapy and 
therefore mostly local effects of 5-FU will be seen.27 Occurrence of diarrhea during 
RT could be explained by (at least) two reasons. The first reason is that there is a clear 
relationship between radiated small bowel volume and the incidence of diarrhea in 
chemoradiotherapy for rectal tumors, and possibly, this is also related to BSA, since 
hypothetically a higher small bowel volume is exposed to radiotherapy in patients with 
a low BSA.28, 29 Another reason is a possible relation with rectal irritation by the tumor 
itself.30 Finally, in the CAPE+RT group of both cohorts, diarrhea was the most frequent 
severe adverse event with an incidence of 10%. As a result, this finding might be biased 
because of diarrhea being the major side-effect of radiotherapy. Unfortunately, no 
studies have been performed on the mechanism of toxicity related to capecitabine 
combined with radiotherapy. Further research should therefore be conducted on the 
potential effects of radiotherapy and BSA on toxicity of this combination treatment.
 
Several factors are known to influence the risk of toxicity caused by capecitabine. 
Older age, female sex and decreased renal function have been related to the risk of 
toxicity.31-33 In our multivariate analysis in the CAPE+RT group of fixed-dose patients, 
we have also confirmed an increased risk of toxicity with female sex, but we could not 
clearly confirm the role of age and renal function. This could potentially be explained 
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by the limited range of these two factors. In addition, in the BSA-based dose cohort all 
these risk factors could not be confirmed in the CAPE+RT group. 
Secondly, another factor that strongly influences the risk of toxicity is genetic variation 
in capecitabine metabolism. The enzyme dihydropyrimidine dehydrogenase (DPD) is 
largely responsible for the inactivation of 5-FU, and with a decreased activity of this 
enzyme related to polymorphisms in the DPYD gene, the risk of severe toxicity largely 
increases.34, 35 Only recently, genotyping of the four most common DPYD polymorphisms 
associated with DPD deficiency has been implemented as routine screening clinical care 
in The Netherlands prior to start of treatment with capecitabine. In patients carrying 
one of these polymorphisms, dose-adjustments are made according to the gene-
activity score.36, 37 Unfortunately, we have no knowledge about the genotype of the 
patients in the fixed dose cohort because they were treated before the implementation 
of upfront genotyping. Prevalence of partial DPD deficiency is around 3-5%. Therefore, 
we have to assume that a small group of patients in our cohort had indeed a partial 
DPD deficiency. The DPYD genotype is known for all the patients from the BSA-based 
dose cohort, and the mutant patients received a dose reduction; we do not think that 
this will influence our results. As all patients treated with a fixed dose in the mentioned 
time period were included in our analysis, we assume that the genetic distribution is 
comparable in the fixed-dose group of patients. However, these patients could not 
have received a dose reduction in case of DPD deficiency and therefore this could lead 
to a small increase in toxicity risk in the fixed-dose group. 
Besides toxicity, we also have investigated effectiveness of given treatments. We 
hypothesized that if a fixed dose would (positively or negatively) influence effectiveness 
of the treatment a survival difference should occur between the patients with a low and 
a high BSA value per treatment and indication. Of interest, we have found no statistical 
differences in BSA subgroups in progression-free survival for CAPOX for mCRC or 
ECC/EOX for gastric cancer, nor for the disease-free survival for CAPE+RT for laCRC. 
In addition, the observed progression-free survival for CAPOX for mCRC and ECC/
EOX for gastric cancer was comparable to literature (8.6 and 24.6 months versus 8.0 
and 19.2 months, respectively).38, 39 Although we have found no major differences in 
effectiveness in all subgroups analyzed, not all regimens could be evaluated due to 
small sample sizes and therefore we have to interpret these results with caution. 
Our study has some limitations that need to be mentioned. Firstly, the retrospective 
nature of our data collection makes it difficult or even impossible to obtain toxicity and 
effectiveness data in a standardized fashion. However, we have evaluated combined 
toxicity scores, which consisted of severe capecitabine-specific toxicities or clinically 
42
PART I | CHAPTER 2
relevant events due to toxicity. In general, these scores are well documented because 
of the large impact on the patient and treatment decisions. Moreover, patients were 
excluded when their patient file was not available or when visits were poorly documented. 
In the survival analysis there was a frequent loss to follow-up and censoring of patients. 
Nevertheless, we found comparable survival probabilities for all subgroups as described 
in the literature. In addition, survival outcomes between different BSA groups were not 
different. However, the survival analysis was performed without a control-group as in 
the BSA-based dose cohort survival data were not collected. Another limitation, is the 
risk of confounding by hospital, treatment indication and dosing strategy. Although the 
fixed-dose cohort patients were included in a single hospital, we cannot argue that this 
might have influenced our results, because no major differences with the BSA-based 
dose cohort were identified. 
Our study evaluated a large population of cancer patients treated with frequently used 
treatment regimens, thereby representing daily clinical care. In addition, we confirmed 
our results in another large and comparable cohort of patients. Although BSA-based 
dosing has been the standard choice in oncology for decades, there is little evidence 
for this approach. Therefore, there is a need for evidence that a fixed dose could be 
a well-tolerated alternative strategy for already existing anticancer agents such as 
capecitabine. Earlier, three small prospective studies demonstrated that a fixed-dose 
capecitabine is feasible.40-42 However, these studies have not been translated into daily 
clinical care, probably because of their limited sample sizes. Sharma et al. showed that 
a fixed dose of capecitabine monotherapy in advanced colorectal cancer was safe and 
effective in a cohort of 55 patients.40 Also, capecitabine in a fixed dose as monotherapy 
and in combination with vinorelbine was shown to be safe and effective in metastatic 
breast cancer patients.41, 42 Additionally, a small retrospective study demonstrated 
that even a low fixed dose of 1,000 mg twice daily for 14 days might have effectivity 
in metastatic breast cancer patients.43 In a study by Rudek et al., a large interpatient 
variability in capecitabine pharmacokinetics was shown without any influence of BSA, 
which also favors the fixed dosing strategy.42 Furthermore, it would be interesting 
to investigate whether a fixed dosing strategy for capecitabine would lead to fewer 
prescribing mistakes and possibly to reducing costs, as has been demonstrated for 
some other drugs.18-20 
In conclusion, we have shown that a fixed dose of capecitabine is equally well-tolerated 
as a BSA-based dose of capecitabine in several treatment regimens. Also, we have no 
data indicating that a fixed dose of capecitabine is less effective than a BSA-based dose. 
Our results indicate that fixed dosing of capecitabine is a reasonable and practical 
alternative for BSA-based dosing. Therefore, we would recommend implementing 
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fixed dosing in future clinical studies and we have found no arguments why it could 
not be used in daily clinical care. 
44
PART I | CHAPTER 2
REFERENCES
1. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and 
folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29: 1465-71.
2. Arkenau HT, Arnold D, Cassidy J, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/
leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin 
Oncol. 2008; 26: 5910-7.
3. Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individual patient data from capecitabine 
monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2012; 
136: 777-88.
4. Ocvirk J, Rebersek M, Skof E, Hlebanja Z and Boc M. Randomized prospective phase II study to compare 
the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, 
and capecitabine in patients with advanced or metastatic gastric cancer. Am J Clin Oncol. 2012; 35: 237-
41.
5. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus 
leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 
2001; 19: 4097-106.
6. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin 
Oncol. 1998; 16: 2297-8.
7. Grochow LB, Baraldi C and Noe D. Is dose normalization to weight or body surface area useful in adults? 
J Natl Cancer Inst. 1990; 82: 323-5.
8. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an 
alternative. J Clin Oncol. 1996; 14: 2590-611.
9. Sawyer M and Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest 
New Drugs. 2001; 19: 171-7.
10. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer 
agents in adults, 1991-2001. J Natl Cancer Inst. 2002; 94: 1883-8.
11. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J and Sparreboom A. Flat-fixed dosing versus 
body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist. 2007; 
12: 913-23.
12. Felici A, Verweij J and Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-
surface area. Eur J Cancer. 2002; 38: 1677-84.
13. Bins S, Ratain MJ and Mathijssen RH. Conventional dosing of anticancer agents: precisely wrong or just 
inaccurate? Clin Pharmacol Ther. 2014; 95: 361-4.
14. Reilly JJ and Workman P. Normalisation of anti-cancer drug dosage using body weight and surface area: is 
it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol. 1993; 
32: 411-8.
15. Dubois D and Dubois EF. A formula to estimate the approximate surface area if height and weight be 
known. Arch Intern Med. 1916; 17: 863-71.
45
2
COMPARISON OF TOXICITY AND EFFECTIVENESS BETWEEN FIXED-DOSE AND BODY SURFACE AREA-BASED DOSE CAPECITABINE
16. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987; 317: 1098.
17. Gurney H. Developing a new framework for dose calculation. J Clin Oncol. 2006; 24: 1489-90.
18. Parsad SD and Ratain MJ. Prescribing oral chemotherapy. BMJ. 2007; 334: 376.
19. Pouliquen AL, Escalup L, Jourdan N, Cottu P, Faure P and Madelaine-Chambrin I. Dose standardisation of 
anticancer drugs. Int J Clin Pharm. 2011; 33: 221-8.
20. Mayor S. National Health Service England introduces dose banding. Lancet Oncol. 2016; 17: e271.
21. Leveque D. Evaluation of fixed dosing of new anticancer agents in phase I studies. Anticancer Res. 2008; 
28: 3075-7.
22. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine 
Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016; 34: 227-34.
23. Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 
16: 31-41.
24. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation 
for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 
766-72.
25. U.S. department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.03. June 14, 2010.
26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-47.
27. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral 
administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000; 45: 291-7.
28. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA and Robertson JM. The dose-volume relationship 
of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal 
cancer. Int J Radiat Oncol Biol Phys. 2002; 52: 176-83.
29. Banerjee R, Chakraborty S, Nygren I and Sinha R. Small bowel dose parameters predicting grade >/= 
3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent 
validation study comparing peritoneal space versus small bowel loop contouring techniques. Int J Radiat 
Oncol Biol Phys. 2013; 85: 1225-31.
30. Xu B, Guo Y, Chen Y, et al. Is the irradiated small bowel volume still a predictor for acute lower 
gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using 
intensity-modulated radiation therapy? Radiat Oncol. 2015; 10: 257.
31. Meulendijks D, van Hasselt JG, Huitema AD, et al. Renal function, body surface area, and age are associated 
with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based 
anticancer regimens in daily clinical care. Eur J Cancer. 2016; 54: 120-30.
32. Ilich AI, Danilak M, Kim CA, et al. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol 
Pharm Pract. 2016; 22: 454-60.
33. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability 
of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002; 49: 225-34.
34. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/
46
PART I | CHAPTER 2
HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review 
and meta-analysis of individual patient data. Lancet Oncol. 2015; 16: 1639-50.
35. Henricks LM, Lunenburg C, de Man FM, et al. DPYD genotype-guided dose individualisation of 
fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018; 19: 
1459-67.
36. Lunenburg CA, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of 
fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016; 54: 40-8.
37. Henricks LM, Lunenburg CA, Meulendijks D, et al. Translating DPYD genotype into DPD phenotype: using 
the DPYD gene activity score. Pharmacogenomics. 2015; 16: 1277-86.
38. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin 
compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal 
cancer. J Clin Oncol. 2008; 26: 2006-12.
39. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for 
resectable gastresophageal cancer. N Engl J Med. 2006; 355: 11-20.
40. Sharma R, Rivory L, Beale P, Ong S, Horvath L and Clarke SJ. A phase II study of fixed-dose capecitabine 
and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J 
Cancer. 2006; 94: 964-8.
41. Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V and Baker LH. Combination vinorelbine and capecitabine 
for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 
2006; 58: 129-35.
42. Rudek MA, Connolly RM, Hoskins JM, et al. Fixed-dose capecitabine is feasible: results from a 
pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. 2013; 
139: 135-43.
43. Ambros T, Zeichner SB, Zaravinos J, et al. A retrospective study evaluating a fixed low dose capecitabine 
monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat. 2014; 
146: 7-14.
47
2
COMPARISON OF TOXICITY AND EFFECTIVENESS BETWEEN FIXED-DOSE AND BODY SURFACE AREA-BASED DOSE CAPECITABINE
SUPPLEMENTARY INFORMATION
Supplementary Table 1. Detailed description administered treatment regimens
Treatment Schedule Fixed dose 
(mg/day)* 
BSA-based dose
(mg/ m2/day/)*
CAPE + RT
Capecitabine Continuous** 3,000 1,650
CAPOX
Capecitabine
Oxaliplatin
D1-14 (Q3W)
D1 (Q3W)
3,500 2,000
130
MONO
Capecitabine D1-14 (Q3W) 3,500 (BC)
4,000 (CRC)
2,000
TRIPLET
ECC
Capecitabine 
Epirubicin
Cisplatin
D1-14 (Q3W)
D1 (Q3W)
D1 (Q3W)
3,500 2,000
50
60
EOX
Capecitabine 
Epirubicin
Oxaliplatin
D1-21 (Q3W)
D1 (Q3W)
D1 (Q3W)
3,500 2,000
50
130
DOC
Capecitabine
Docetaxel
Oxaliplatin
D1-14 (Q3W)
D1 (Q3W)
D1 (Q3W)
*** 1,700
50
100
* Capecitabine total daily dose was divided over two daily doses according to standard of care
** For the fixed-dose cohort was capecitabine administered continuously the whole period of radiotherapy 
(also on non-radiotherapy days), for the BSA-based dose cohort was capecitabine administered continuous 
only on days of radiotherapy 
*** The DOC-regimen was not administered in the fixed-dose cohort
Abbreviations: BC = breast cancer; BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine 
combined with oxaliplatin; CRC = colorectal cancer; D = day; HFS = hand-foot syndrome; mono = monotherapy; 
RT = radiotherapy; Q3W = 3-weekly schedule
Supplementary Table 2. Fixed daily dose compared to calculated BSA-based daily dose
Treatment Mean fixed dose 
(mg/day) 
Mean BSA-based dose
(mg/day)
Difference (%) Difference 95% 
CI (%)
P-value
CAPE + RT* 3,000mg 3,202mg 6.3 3.7-7.1 <0.001
CAPOX* 3,500mg 3,796mg 7.8 6.3-9.4 <0.001
CAPE MONO* 3,701mg 4,128mg 10.3 7.5-13.1 <0.001
CAPE TRIPLET* 3,500mg 3,839mg 8.8 6.3-11.4 <0.001
Total 3,175mg 3,421mg 7.2 6.5-7.9 <0.001
P-values < 0.05 are considered statistically significant and are depicted in bold.
* The administered treatment regimens are described in more detail in supplementary table 1
Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; 
HFS = hand-foot syndrome; mono = monotherapy; RT = radiotherapy
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Supplementary Table 3. Toxicity compared between lowest BSA quartile of the fixed-dose 
cohort and BSA-based dose cohort per treatment regimen
TREATMENT TOXICITY
Diarrhea
≥ 3 (%)
HFS
≥ 2 (%)
Neutropenia 
≥ 2 (%)
Cape-
specific
toxicity
(%)a
Dose 
reduction 
(%)
Stop 
(%)
Hospital 
admission 
(%)
Clinically 
relevant 
events 
(%)b
CAPE+RT*
FIXED
N=204
26 (12.7) 6 (2.9) 8 (3.9) 33 (16.2) 2 (1.0) 37 (18.1) 33 (16.2) 45 (22.1)
BSA
N=117
13 (11.1) 7 (6.0) 1 (0.9) 20 (17.1) 4 (3.4) 17 (14.5) 11 (9.4) 21 (17.9)
P-value 0.666 0.183 0.163 0.831 0.196 0.406 0.089 0.381
CAPOX*
FIXED
N=48
7 (14.6) 4 (8.3) 8 (16.7) 18 (37.5) 15 (31.3) 12 (25.0) 9 (18.8) 25 (52.1)
BSA
N=84
11 (13.1) 9 (10.7) 23 (27.4) 33 (39.3) 18 (21.4) 20 (23.8) 12 (14.3) 32 (38.1)
P-value 0.811 0.768 0.162 0.839 0.210 0.878 0.500 0.119
CAPE 
MONO*
FIXED
N=25
0 7 (28.0) 4 (16.0) 9 (36.0) 7 (28.0) 6 (24.0) 2 (8.0) 11 (44.0)
BSA
N=97
9 (9.3) 34 (35.1) 5 (5.2) 41 (42.3) 26 (26.8) 20 (20.6) 9 (9.3) 38 (39.2)
P-value 0.201 0.506 0.084 0.570 0.904 0.713 1.000 0.661
CAPE 
TRIPLET*
FIXED
N=17
1 (5.9) 2 (11.8) 13 (76.5) 13 (76.5) 3 (17.6) 9 (52.9) 6 (32.3) 11 (64.7)
BSA
N=12
1 (8.3) 0 10 (83.3) 11 (91.7) 3 (25.0) 3 (25.0) 3 (25.0) 6 (50.0)
P-value 1.000 0.498 0.653 0.286 0.669 0.251 1.000 0.428
a Capecitabine-specific toxicity was defined as at least one of the following toxicity scores: diarrhea ≥ 3, HFS ≥ 
2, neutropenia ≥ 2
b Clinically relevant events was defined as at least one of the following events due to toxicity: dose reduction, 
stop with capecitabine, hospital admission 
* The administered treatment regimens are described in more detail in Apendix table 1
Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; 
HFS = hand-foot syndrome; mono = monotherapy; RT = radiotherapy
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ABSTRACT 
BACKGROUND 
Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and 
is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine 
dehydrogenase (DPD), mostly caused by genetic DPYD variants. In a prospective 
clinical trial, we investigated whether upfront screening for four DPYD variants and 
DPYD-guided dose individualization can reduce fluoropyrimidine-induced toxicity. 
METHODS 
Prospective genotyping for DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A was 
performed in adult cancer patients for which fluoropyrimidine-based chemotherapy 
was considered in their best interest. All patients about to start with a fluoropyrimidine 
regimen (capecitabine or 5-fluorouracil as single agent or in combination with other 
chemotherapeutic agents and/or radiotherapy) could be included in the study. 
Heterozygous DPYD variant allele carriers received an initial dose reduction of 25% 
(c.2846A>T, c.1236G>A) or 50% (DPYD*2A, c.1679T>G), DPYD wild-type patients were 
treated according to standard of care. The primary endpoint of the study was the 
incidence of severe (CTC-AE grade≥3) overall fluoropyrimidine-related toxicity. This 
toxicity incidence was compared between DPYD variant allele carriers and DPYD wild-
type patients in the study in an intention-to-treat analysis, and relative risks for severe 
toxicity were compared between the current study and a historical cohort of DPYD 
variant allele carriers treated with full dose fluoropyrimidine-based therapy (derived 
from a previously published meta-analysis). This trial is registered under clinicaltrials.
gov identifier NCT02324452 and is completed.
RESULTS 
In total, 1103 evaluable patients were enrolled, of whom 85 DPYD variant carriers 
(7.7%). Overall grade ≥ 3 toxicity was higher in DPYD variant carriers than in wild-type 
patients (39% versus 23%, P = 0.0013). The relative risk (RR) for grade ≥ 3 toxicity was 
1.31 (95% confidence interval [95%CI]: 0.63–2.73) for genotype-guided dosing versus 
2.87 (95%CI: 2.14–3.86) in the historical cohort for DPYD*2A, no toxicity versus 4.30 
(95%CI: 2.10–8.80) in c.1679T>G, 2.00 (95%CI:1.19–3.34) versus 3.11 (95%CI: 2.25–
4.28) for c.2846A>T, and 1.69 (95%CI: 1.18–2.42) versus 1.72 (95%CI: 1.22–2.42) for 
c.1236G>A. 
 
CONCLUSIONS
Upfront DPYD genotyping was feasible in routine clinical practice, and improved patient 
safety of fluoropyrimidine treatment. For DPYD*2A and c.1679T>G carriers, a 50% initial 
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dose reduction seems adequate. For c.1236G>A and c.2846A>T carriers, a larger dose 
reduction of 50% (instead of 25%) needs to be investigated. As fluoropyrimidines are 
among the most commonly used anticancer agents, the findings of this study are of 
high clinical importance, as they endorse implementing DPYD genotype-guided dosing 
as the new standard of care. 
FUNDING
This study was funded by the Dutch Cancer Society (Alpe-d’HuZes/KWF-fund, 
NKI2013-6249).
INTRODUCTION 
Fluoropyrimidine anticancer drugs, including 5-fluorouracil (5-FU) and its oral prodrug 
capecitabine, have been widely used for over sixty years in the treatment of different 
solid tumor types, such as colorectal, breast, and gastric cancer. Although these drugs 
are relatively well tolerated, up to 30% of patients experience severe treatment-related 
toxicity, including diarrhea, mucositis, myelosuppression, and hand-foot syndrome.1–3 
In addition, severe fluoropyrimidine-related toxicity can lead to treatment-related 
death in up to 1% of patients.4,5 The occurrence of these severe side-effects can lead to 
treatment discontinuation and toxicity-related hospitalization, which in addition puts a 
heavy burden on health-care costs. 
Fluoropyrimidine-related toxicity is often caused by reduced activity of the 
enzyme dihydropyrimidine dehydrogenase (DPD), the main metabolic enzyme for 
fluoropyrimidine inactivation.6,7 A partial DPD deficiency (e.g. a ~50% reduced DPD 
activity compared to normal) is present in 3-5% of the Western population. These 
DPD deficient patients have a highly increased risk of developing severe treatment-
related toxicity when treated with a standard dose of fluoropyrimidines.8–10 Complete 
DPD deficiency is much rarer, with an estimated prevalence of 0.01-0.1%.8,11,12 DPD 
deficiency is most often caused by genetic variants in DPYD, the gene encoding 
DPD. The four DPYD variants currently considered most clinically relevant and with 
convincingly demonstrated association with severe toxicity are DPYD*2A (rs3918290, 
c.1905+1G>A, IVS14+1G>A), c.2846A>T (rs67376798, D949V), c.1679T>G (rs55886062, 
DPYD*13, I560S), and c.1236G>A (rs56038477, E412E, in haplotype B3).10,13,14 For these 
variants, available evidence suggests that heterozygous carriers of these variants 
have an average reduction in DPD enzyme activity of approximately 25% (c.2846A>T, 
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c.1236G>A) to 50% (DPYD*2A, c.1679T>G).14 
Prospective DPYD genotyping and dose reduction in heterozygous DPYD variant 
allele carriers is a promising strategy for preventing severe and potentially fatal 
fluoropyrimidine-related toxicity without affecting treatment efficacy. In a previous 
study prospective genotyping and dose-individualization for one DPYD variant, 
DPYD*2A, in a cohort of 1631 patients showed that severe fluoropyrimidine-related 
toxicity could be decreased from 73% in DPYD*2A carriers receiving a standard 
fluoropyrimidine dose (N = 48) to 28% by genotype-guided dosing, i.e. DPYD*2A 
carriers receiving a 50% dose reduction (N = 18, P<0.001).15 This study showed that by 
reducing the fluoropyrimidine dose by 50% in DPYD*2A variant allele carriers, severe 
toxicity was reduced to a frequency (28%) comparable to that in DPYD*2A wild-type 
patients treated with a standard fluoropyrimidine dose (23%). 
It is expected that patient safety can be further improved by expanding the number 
of prospectively tested DPYD variants beyond DPYD*2A alone. The objective of the 
current study was to assess the impact on patient safety of prospective screening for 
the four most relevant DPYD variants and subsequent DPYD genotype-guided dose 
individualization in daily clinical care. 
PATIENTS AND METHODS
STUDY DESIGN AND PARTICIPANTS
This study was a prospective multicenter clinical trial in which 17 hospitals in the 
Netherlands participated. The study was approved by the institutional review board 
of The Netherlands Cancer Institute, Amsterdam, the Netherlands, and approval from 
the board of directors of each individual hospital was obtained for all participating 
centers. All patients provided written informed consent before enrollment in the 
study. Additional informed consent was obtained for DPYD variant allele carriers who 
participated in pharmacokinetic and DPD enzyme activity measurements.
The study population consisted of adult cancer patients (≥18 years) intended to 
start with a fluoropyrimidine-based anticancer therapy, either as single agent or in 
combination with other chemotherapeutic agents and/or radiotherapy. Patients with 
all tumor types for which fluoropyrimidine-based therapy was considered in their 
best interest could be included. Prior chemotherapy was allowed, except for prior use 
of fluoropyrimidines. Patients had to have a WHO performance status of 0, 1 or 2, a 
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life expectancy of at least 12 weeks, and acceptable safety laboratory values. There 
were no restrictions on comorbidities, except for diseases expected to interfere with 
study or the patient’s safety. Full inclusion and exclusion criteria can be found in the 
Supplementary Methods.
PROCEDURES
Patients were genotyped before start of fluoropyrimidine therapy for the previously 
mentioned four DPYD variants. Heterozygous DPYD variant allele carriers received an 
initial dose reduction of either 25% (for c.2846A>T and c.1236G>A) or 50% (for DPYD*2A 
and c.1679T>G), in line with current recommendations from Dutch and international 
pharmacogenomic guidelines.13,16 To achieve a maximal safe exposure, dose escalation 
was allowed after the first two cycles provided that treatment was well tolerated, and 
the decision to escalate was left to the discretion of the treating physician. The dose 
of other anticancer agents or radiotherapy were left unchanged at start of treatment. 
Homozygous or compound heterozygous DPYD variant allele carriers were excluded 
from the study and could be treated with personalized regimens outside this protocol.17 
Non-carriers of the above mentioned DPYD variants are considered wild-type patients 
in this study and were treated according to existing standard of care. 
Toxicity was graded by participating centers according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTC-AE),18 and severe toxicity 
was defined as grade three or higher. Patients were followed for toxicity during the 
entire treatment period and until toxicity was resolved. Toxicity scored by the treating 
physician or qualified nurse practitioner as possibly, probably or definitely related to 
fluoropyrimidine-treatment was considered treatment-related toxicity (definitions 
ini Supplementary Methods). Toxicity-related hospitalization and treatment 
discontinuation due to adverse events were also investigated. Standard laboratory 
assessments were performed prior to start of treatment and each new cycle according 
to routine clinical care, for evaluation of treatment safety. 
Genotyping for the four DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and 
c.1236G>A was performed before start of treatment. Genotyping was performed in 
a clinical laboratory of the local hospital or in one of the other participating centers 
of this trial. Validated assays were used and all laboratories participated in a Dutch 
national proficiency testing program for all four DPYD variants.19 In DPYD variant 
allele carriers who provided written informed consent for additional tests, plasma 
levels of capecitabine, 5-FU, and their metabolites were determined at the first day of 
a capecitabine/5-FU cycle (preferably the first cycle) to assess the pharmacokinetic 
profile in these patients. A validated ultra-performance liquid chromatography tandem 
55
3
DPYD GENOTYPE-GUIDED DOSE INDVIDUALISATION
mass-spectrometry (UPLC-MS/MS) method was used (details in Supplementary 
Methods). Results of pharmacokinetic parameters, including the area under the 
plasma concentration-time curve (AUC) and half-life (t
1/2
) were calculated using non-
compartmental analysis, and compared to control values derived from literature.20 DPD 
enzyme activity in peripheral blood mononuclear cells (PBMCs) was determined in a 
pretreatment sample in the DPYD variant allele carriers and compared to DPD enzyme 
activity measured in wild-type patients in this study, using a validated assay.21 
OUTCOMES
The primary endpoint of the study was the frequency of severe overall fluoropyrimidine-
related toxicity across the entire treatment duration. A comparison was made between 
the incidence of severe toxicity in DPYD variant allele carriers treated with reduced dose 
and in wild-type patients treated with standard dose in this study. In addition to this, the 
relative risk for severe toxicity of these DPYD variant allele carriers treated with reduced 
dose compared to non-carriers in the study was calculated. A comparison between 
this calculated relative risk and a similarly calculated relative risk for DPYD variant 
allele carriers treated with full dose in a historical cohort derived from a previously 
published meta-analysis10 was made. Secondary endpoints included pharmacokinetics 
of capecitabine and 5-FU in DPYD variant allele carriers and measurements of DPD 
enzyme activity. Another secondary endpoint was a cost-analysis on individualized 
dosing based on upfront DPYD genotyping, of which results will be reported separately. 
STATISTICAL ANALYSIS 
The sample size was based on a one stage A’Hern (phase II) design22 and calculated 
under the assumption that overall fluoropyrimidine-related severe toxicity could be 
reduced from 60% (in DPYD variant allele carriers receiving standard dose)10,15 to 20% by 
individualized dosing in DPYD variant allele carriers. This resulted in a required sample 
size of 11 variant carriers. To reach this number of variant carriers, we used a single DPYD 
variant (c.2846A>T, assumed variant frequency of 1%) to calculate the total sample size, 
resulting in a total expected sample size of 1100 evaluable patients. Detailed information 
on the sample size calculation can be found in the Supplementary Methods. Patients 
were considered evaluable when meeting the inclusion and exclusion criteria, and if 
they received at least one fluoropyrimidine drug administration.
Associations between dichotomous outcomes, e.g. occurrence of severe toxicity or 
hospitalization, and genotype status were tested using χ2 or Fisher’s exact test (Fisher’s 
exact test was chosen when the smallest cell count was 5 or lower; for this test the 
double one-tailed exact probability was reported). Baseline characteristics between 
DPYD variant allele carriers and wild-type patients in the study were compared using 
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either χ2 test, Fisher’s exact test or Kruskal-Wallis rank sum test depending on the type 
of variable. DPD enzyme activity was compared between carriers of individual DPYD 
variants and wild-type patients using Student’s t-tests. P-values <0.05 were considered 
statistically significant. Statistical analyses on an intention-to-treat population were 
performed using SPSS (version 22.0.) and R (version 3.1.2). This study is registered with 
ClinicalTrials.gov, number NCT02324452. 
RESULTS 
Between April 30th, 2015 and December 21st, 2017 a total of 1181 patients intended to 
start fluoropyrimidine-based treatment were enrolled in this study. In total, 78 patients 
were considered non-evaluable (Figure 1), as they retrospectively were identified 
as not meeting the inclusion criteria (N = 48), did not start fluoropyrimidine-based 
treatment (N = 26), or were homozygous or compound heterozygous DPYD variant 
allele carriers (N = 4). This resulted in a total of 1103 evaluable patients, of whom 85 
were heterozygous DPYD variant allele carriers (7.7%). 
Figure 1. Trial profile
On the left our study, on the right the previous conducted meta-analysis by Meulendijks et al.
Abbreviations: DPYD : gene encoding dihydropyrimidine dehydrogenase; N: number
Baseline characteristics of DPYD variant allele carriers and DPYD wild-type patients are 
described in Table 1 and Supplementary Table 1. The most common tumor type was 
colorectal cancer (64%). In total, 83% of patients were treated with a capecitabine-
based regimen. 
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Mean relative dose intensities for each patient group are presented in Table 2. In 
general, dose recommendations as described in the study protocol were followed by 
the treating physicians, which resulted in mean dose intensities in the first cycle of 74%, 
73%, 51%, and 50% for c.1236G>A, c.2846A>T, DPYD*2A and c.1679T>G, respectively. 
The performed dose reductions were therefore in line with the pre-specified dose 
reductions of 25% (for c.1236G>A and c.2846A>T) or 50% (for DPYD*2A and c.1679T>G) 
However, for four patients carrying DPYD variants, dose reductions were not applied 
at start of treatment (details in Supplementary Methods). One of these patients, 
(c.2846A>T carrier) was treated by mistake with a full capecitabine dose for the first 
two cycles, which resulted in fatal fluoropyrimidine-related toxicity. Although dosing 
recommendations were not followed in these four patients, all results were included in 
the analysis (intention-to-treat analysis). 
Doses were escalated during treatment in 11 out of 85 DPYD variant allele carriers 
(13%). In five of these patients (two DPYD*2A and three c.1236G>A carriers) the higher 
dose was not well tolerated, leading to a dose reduction. Also, one patient (c.2846A>T 
carrier) discontinued treatment after the dose escalation due to toxicity. Five patients 
(one c.2846A>T, one c.1236G>A, one c.1679T>G, and two DPYD*2A carriers) were able 
to continue treatment with the escalated dose. 
The median follow-up period (similar to the entire treatment duration or when toxicity 
was resolved) was 71 days (interquartile range [IQR]: 36-161 days). For wild-type 
patients median follow-up was 69 days (IQR 36-161 days) and for DPYD variant allele 
carriers 90 days (IQR 35-168 days). 
Frequencies of severe toxicity for DPYD variant allele carriers who received genotype-
guided dosing and wild-type patients who received standard dosing are depicted in 
Table 2. A total of 33 out of 85 (39%) DPYD variant allele carriers experienced severe 
(grade≥3) fluoropyrimidine-related toxicity, which was significantly higher than the 
frequency in wild-type patients (23%), P=0.0013. The incidence of grade ≥4 toxicity 
was low but was comparable between both groups as well (4 out of 85 (5%) for DPYD 
variant allele carriers vs 29 out of 1018 3% for wild-type patients, P=0.49, Table 2). 
The percentage of toxicity in DPYD variant allele carriers was mainly driven by the two 
most common variants, who also had higher toxicity frequencies. In total, 20 out of 
51 c.1236G>A carriers experienced severe toxicity (39%) and eight out of 17 c.2846A>T 
carriers (47%). For DPYD*2A carriers, five out of 16 patients (31%) experienced severe 
toxicity. The single c.1679T>G carrier, who did receive reduced-dose treatment, 
tolerated the treatment well and did not experience severe treatment-related toxicity 
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over the course of treatment (three cycles). 
For 16 out of 85 DPYD variant allele carriers (19%) fluoropyrimidine-related toxicity 
resulted in hospitalization, compared to 140 out of 1018 wild-type patients (14%), 
P=0.26. Median duration of hospitalization was five days for both DPYD variant allele 
carriers and wild-type patients (IQR 3-7 days, and 3-10 days, respectively). For 15 out 
of 85 DPYD variant allele carriers (18%) fluoropyrimidine treatment was stopped due 
to fluoropyrimidine-related toxicity, compared to 175 out of 1018 wild-type patients 
(17%), which was comparable between both groups (P=1.0). 
As described above, one c.2846A>T carrier experienced fatal fluoropyrimidine-related 
toxicity, but the intended dose reductions were not applied for this patient. When 
disregarding this patient for the critical protocol violation, no treatment-related death 
occurred in DPYD variant allele carriers. In the wild-type cohort, three patients died 
due to fluoropyrimidine-related toxicity (0.3%), which is comparable to literature.4,5 
59
3
DPYD GENOTYPE-GUIDED DOSE INDVIDUALISATION
Table 1. Demographic and clinical characteristics of patients
Characteristic DPYD variant allele carriers Wild-type patients Total P-value a
N = 85 N = 1018 N = 1103
Sex  
Male 48 (56%) 545 (54%) 593 (54%)
0.68
Female 37 (44%) 473 (46%) 510 (46%)
Age
Median [IQR] 63 [54-71] 64 [56-71] 64 [56-71] 0.61
Ethnic origin
Caucasian 84 (99%) 964 (95%) 1048 (95%)
0.61
African 0 19 (2%) 19 (2%)
Asian 1 (1%) 23 (2%) 24 (2%)
Other b 0 12 (1%) 12 (1%)
Tumor type
Non-metastatic CRC 32 (38%) 440 (43%) 472 (43%)
0.48
Metastatic CRC 24 (28%) 208 (20%) 232 (21%)
BC 10 (12%) 131 (13%) 141 (13%)
GC 6 (7%) 57 (6%) 63 (6%)
Other c 13 (15%) 182 (18%) 195 (18%)
Type of treatment regimen
CAPE mono 14 (16%) 191 (19%) 205 (19%)
0.40
CAPE + RT 18 (21%) 246 (24%) 264 (24%)
CAPOX 31 (36%) 343 (34%) 374 (34%)
CAPE other 5 (6%) 67 (7%) 72 (7%)
5-FU mono 1 (1%) 1 (0%) 2 (0%)
5-FU + RT 6 (7%) 57 (6%) 63 (6%)
FOLFOX 5 (6%) 38 (4%) 43 (4%)
5-FU other 5 (6%) 75 (7%) 80 (7%)
BSA
Median [IQR] 1.9 [1.8-2.1] 1.9 [1.8-2.1] 1.9 [1.8-2.1] 0.60
WHO performance status
0 39 (46%) 515 (51%) 554 (50%)
0.68
1 36 (42%) 412 (40%) 448 (41%)
2 4 (5%) 38 (4%) 42 (4%)
NS d 6 (7%) 53 (5%) 59 (5%)
Number of treatment cycles
Median [IQR] 4 [1-8] 3 [1-8] 3 [1-8] 0.97
DPYD status
Wild-type 0 1018 (100%) 1018 (92%)
NA
c.1236G>A heterozygous 51 (60%) 0 51 (5%)
c.2846A>T heterozygous 17 (20%) 0 17 (2%)
DPYD*2A heterozygous 16 (19%) 0 16 (1%)
c.1679T>G heterozygous 1 (1%) 0 1
a P-value comparing DPYD variant allele carriers to DPYD wild-type patients. A Kruskal-Wallis rank sum test was 
used for age, BSA, and number of treatment cycles, a Fisher’s exact test was used for ethnic origin and WHO 
performance status and a χ2 test for sex, tumor type, and treatment regimen. 
b Other ethnic origins included Hispanic descent, mixed-racial parentage and unknown ethnic origin. 
c Other tumor types included anal cancer, esophageal cancer, head and neck cancer, pancreas cancer, bladder 
cancer, unknown primary tumor, vulva carcinoma, and several rare tumor types. 
d WHO performance status was not specified for these patients, but was either 0, 1, or 2, as this was required by 
the inclusion criteria of the study. 
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Abbreviations: 5-FU mono: 5-fluorouracil monotherapy; 5-FU other: 5-fluorouracil combined with other 
anticancer drugs (excluding the FOLFOX regimen); 5-FU + RT: 5-fluorouracil combined with radiotherapy (with 
or without mitomycin); BC: breast cancer; BSA: body surface area; CAPE mono: capecitabine monotherapy 
(with or without bevacizumab); CAPOX: capecitabine combined with oxaliplatin (with or without bevacizumab); 
CAPE other: capecitabine combined with other anticancer drugs; CAPE + RT: capecitabine combined with 
radiotherapy (with or without mitomycin); CRC: colorectal cancer; DPYD: gene encoding dihydropyrimidine 
dehydrogenase; FOLFOX: 5-fluorouracil combined with oxaliplatin and leucovorin (with or without 
bevacizumab); GC: gastric cancer; IQR: interquartile range; NA: not applicable; NS: not specified.
 
Table 2. Treatment outcome of patients included in this study
Type of event DPYD 
variant allele 
carriers
Wild-type 
patients 
P-value c.1236G>A c.2846A>T DPYD*2A c.1679T>G 
N = 85 N = 1018 N = 51 N = 17 N = 16 N = 1
Relative dose intensity whole 
treatment: mean [range] c
69.1% 
[36.7% - 
96.6%]
94.1% 
[48.8% - 
127.6%]
NA
73.6%
[50.9% - 
96.6%]
71.6%
[48.8% - 
96.2%]
52..9%
[36.7% - 
74.1%]
54.2%
Relative dose intensity first 
cycle:   
mean [range] c
69.3% 
[24.8% - 
96.2%]
96.3%
[37.2% - 
127.6%]
NA
74.0%
[50.9% - 
87.5%]
73.4%
[55.3% - 
96.2%]
51.1%
[24.8% - 
81.5%]
50.0%
Overall grade≥3 toxicity d 33 (39%) 231 (23%) 0.0013 a 20 (39%) 8 (47%) 5 (31%) 0 
Grade≥3 gastrointestinal 
toxicity
17 (20%) 86 (8%)
0.00089 
a
11 (22%) 4 (24%) 2 (13%) 0 
Grade≥3 hematological toxicity 13 (15%) 65 (6%) 0.0043 a 7 (14%) 4 (24%) 2 (13%) 0
Grade 3 hand-foot syndrome e 1 (1%) 36 (4%) 0.41 b 0 1 (6%) 0 0
Grade≥3 cardiac toxicity 1 (1%) 9 (1%) 1.0 b 1 (2%) 0 0 0
Grade≥3 other treatment-
related toxicity 
9 (11%) 78 (8%) 0.45 a 7 (14%) 1 (6%) 1 (6%) 0
Overall grade ≥4 toxicity d 4 (5%) 29 (3%) 0.49 b 3 (6%) 1 (6%) 0 0
Grade≥4 gastrointestinal 
toxicity
1 (1%) 8 (1%) 1.0 b 1 (2%) 0 0 0
Grade≥4 hematological toxicity 1 (1%) 12 (1%) 1.0 b 1 (2%) 0 0 0
Grade≥4 cardiac toxicity 0 1 (0%) NA 0 0 0 0
Grade≥4 other treatment-
related toxicity
3 (4%) 9 (1%) 0.12 b 2 (4%) 1 (6%) 0 0
Fluoropyrimidine-related 
hospitalization
16 (19%) 140 (14%) 0.26 a 10 (20%) 4 (24%) 2 (13%) 0 
Stop of fluoropyrimidines due 
to adverse events
15 (18%) 175 (17%) 1.0 a 8 (16%) 3 (18%) 4 (25%) 0
Fluoropyrimidine-related death 1 (1%) f 3 (0%) 0.55 b 0 1 (6%) f 0 0 
a P-value determined with χ2 test, with Yates’ continuity correction. Values in bold are statistically significant (P 
< 0.05).
b P-value determined with Fisher’s exact test with one-sided probability (with the P-value multiplied by two). 
Values in bold are statistically significant (P < 0.05). 
c The relative dose intensity is calculated as the given dose in mg/m2 divided by the standard dose in mg/m2 
given for the indication and treatment schedule which was applicable for the patient. The relative dose intensity 
was calculated for the first cycle alone and for the entire treatment duration. 
d Overall toxicity includes all toxicities evaluated as possibly, probably or definitely related to fluoropyrimidine-
treatment. 
e Defined as palmar-plantar erythrodysesthesia syndrome by the Common Terminology Criteria for Adverse 
Events (CTC-AE) version 4.03.18
f This patient (c.2846A>T carrier) was wrongly treated with a full capecitabine dose for two cycles, which 
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resulted in fatal fluoropyrimidine-related toxicity. 
Abbreviations: DPYD: gene encoding dihydropyrimidine dehydrogenase; NA: not applicable. 
As another primary comparison, the relative risk for severe toxicity of DPYD variant 
allele carriers with genotype-guided dosing was compared with the corresponding 
relative risk for severe toxicity of DPYD variant allele carriers from a historical cohort 
of a previously performed meta-analysis.10 DPYD variant allele carriers described in 
the meta-analysis were not identified prior to start of treatment and were therefore 
treated with a full dose. Relative risks for severe toxicity for each DPYD variant obtained 
in the meta-analysis10 are described in Table 3 (incidences of toxicity can be found in 
Supplementary Table 2) and were compared to calculated relative risks in the current 
study. This analysis showed that genotype-guided dosing reduced the relative risk 
for severe toxicity in DPYD*2A carriers from 2.87 (95% confidence interval [95%CI]: 
2..14-3.86)10 when treated with full dose to 1.31 (95%CI: 0.63-2.73) when treated with 
individualized dose, thus showing a clinically relevant reduction of toxicity risk. 
Interestingly, for c.1236G>A and c.2846A>T, a reduction in toxicity risk comparable to 
that of DPYD wild-type patients could not be demonstrated. The risk for c.1236G>A in 
the historical cohort was 1.72 (95%CI: 1.22-2.42),10 and in our study it was 1.69 (95%CI: 
1.18-2.42), showing that the toxicity risk was still increased even when applying a 25% 
dose reduction. For c.2846A>T, the risk of severe toxicity determined in the meta-
analysis was 3.11 (95%CI: 2.25-4.28),10 which was decreased to 2.00 (95%CI: 1.19-3.34) 
after 25% dose reduction. However, this risk was still higher compared to non-carriers 
of this variant. 
For the c.1679T>G variant no relative risk could be calculated, as only one patient with 
this variant was included. 
A total of 26 DPYD variant allele carriers (of which 16 c.1236G>A carriers, five c.2846A>T 
carriers, four DPYD*2A carriers and one c.1679T>G carrier) treated with a reduced 
fluoropyrimidine dose gave informed consent to draw blood for pharmacokinetic 
analysis. Mean AUC values of the DPYD variant allele carriers and control values are 
depicted in Figure 2. Mean exposure to capecitabine and all metabolites, including 
5-FU, was comparable between patients dosed based on DPYD genotype and control 
values,20 suggesting that mean drug exposure of all combined DPYD variant allele 
carriers treated with a reduced dose was adequate. However, in line with toxicity 
data, AUC values for 5-FU were markedly higher for c.1236G>A carriers and especially 
for c.2846A>T carriers, compared to DPYD*2A and c.1679T>G carriers as shown in 
Supplementary Table 3. 
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Table 3. Relative risk for severe toxicity of DPYD variant carriers compared to a historical cohort 
DPYD variant
DPYD variant carriers treated with reduced 
dose (this study)
DPYD variant carriers treated with full dose 
(meta-analysis)
Relative risk overall grade≥3 toxicity (95%CI) a Relative risk overall grade≥3 toxicity 
(95%CI) b
c.1236G>A 1.69 (1.18 – 2.42) 1.72 (1.22 – 2.42)
c.2846A>T 2.00 (1.19 – 3.34) 3.11 (2.25 – 4.28)
DPYD*2A 1.31 (0.63 – 2.73) 2.87 (2.14 – 3.86)
c.1679T>G NA c 4.30 (2.10 – 8.80)
a Relative risk for overall grade≥3 fluoropyrimidine-related toxicity compared to non-carriers of this variant as 
described in Table 2. 
b Relative risk for overall grade≥3 fluoropyrimidine-related toxicity compared to non-carriers of this variant, as 
determined in a random-effects meta-analysis by Meulendijks et al.10 Unadjusted relative risks for the meta-
analysis are depicted, as the relative risk in the current study was also calculated as an unadjusted value (as 
patient numbers were low). 
c Relative risk cannot be calculated as only one patient who carried c.1679T>G was present. This patient did not 
experience severe toxicity. 
Abbreviations: 95%CI: 95% confidence interval; NA: not applicable. 
Figure 2. Pharmacokinetics of DPYD-guided capecitabine dosing
Depicted are the mean AUCs of capecitabine, and the metabolites 5’DFCR, 5’DFUR, 5-FU and 
FBAL of the DPYD variant allele carriers treated with DPYD-genotype guided dose (blue) and 
control values from wild-type patients from a published study (red).20 Error bars represent the 
standard deviation. 
Abbreviations: 5’DFCR: 5-deoxy-5-fluorocytidine; 5’DFUR: 5-deoxy-5-fluorouridine; 5-FU: 5-fluorouracil; AUC: 
area under the plasma concentration-time curve; CAP: capecitabine; FBAL: fluoro-β-alanine
In 56 DPYD variant allele carriers and 82 wild-type patients (participating in a subgroup of 
the study where DPD phenotyping tests were investigated), pretreatment DPD enzyme 
activity was determined (Figure 3). Mean DPD activity (with standard deviation) in DPYD 
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wild-type patients was 9.4 (3.6) nmol/(mg*h), similar to as previously published.23 For 
the c.1236G>A variant (N = 35), the mean DPD activity was 7.5 (2.8) nmol/(mg*h) (i.e. 
a 20% reduction compared to wild-type). The mean DPD activity for c.2846A>T (N = 
12) was 6.2 (1.9) nmol/(mg*h) (34% reduction), and for DPYD*2A (N = 8) 5.2 (0.6) nmol/
(mg*h) (45% reduction). The single patient carrying c.1679T>G had a DPD enzyme 
activity of 3.8 nmol/(mg*h) (60% reduction). For c.1236G>A, c.2846A>T, and DPYD*2A, 
the mean DPD enzyme activity was significantly lower than the mean for wild-type 
patients. Statistical analysis was not possible for c.1679T>G. No correlation between 
DPD enzyme activity and the occurrence of severe fluoropyrimidine-related toxicity in 
DPYD variant allele carrying patients was seen (Figure 3 and Supplementary Table 4). 
Figure 3. DPD enzyme activity in DPYD variant allele carriers and wild-type patients. 
Wild-type patients were wild-type for the four DPYD variants that were prospectively tested. Mean 
DPD enzyme activity was statistically significantly lower than wild-type (mean 9.4 (3.6) nmol/
[mg*h]) for the DPYD variants as determined by a t-test: c.1236G>A (7.5 (2.8) nmol/[mg*h], P = 
0.0050), c.2846A>T (6.2 (1.9) nmol/[mg*h], P = 0.0034), and DPYD*2A (5.2 (0.6) nmol/[mg*h], 
P = 0.0012). As only one patient carried c.1679T>G, no statistical test could be performed for 
this variant. However, the single measurement in this patient was in the range of DPD deficiency 
(3.8 nmol/[mg*h]). Patients with grade ≥3 fluoropyrimidine-related toxicity are depicted by 
closed triangles, patients without grade <3 toxicity by open circles; wild-type patients are treated 
with standard fluoropyrimidine doses, DPYD variant allele carriers with initially reduced  doses 
according to protocol. PBMCs: peripheral blood mononuclear cells. 
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DISCUSSION 
This is, to our knowledge, the first prospective study to investigate the effect on 
fluoropyrimidine-related toxicity by dose individualization based on four DPYD variants. 
Our results demonstrate that genotype-guided dosing is feasible in clinical practice. 
Dose individualization markedly decreased the risk of severe toxicity for DPYD*2A 
carriers, was safe in the single c.1679T>G carrier, and moderately decreased the toxicity 
risk in c.2846A>T carriers. For c.1236G>A carriers, a 25% dose reduction was not enough 
to decrease severe treatment-related toxicity. This shows that DPYD genotype-guided 
dose-individualization is able to improve patient safety, as toxicity risk was reduced 
for three of the four variants in our study. Although sample sizes of variant allele 
carriers were modest and not all reductions in toxicity risk were statistically significant, 
these findings imply high clinical relevance. Also, implementation of DPYD genotype-
guided dosing resulted in similar frequencies of toxicity-related hospitalization and 
discontinuation of treatment due to fluoropyrimidine-related toxicity for wild-type 
patients and DPYD variant allele carriers. 
Interestingly, for DPYD*2A carriers, the frequency of severe toxicity found in this study 
was 31%; drastically lower than the frequency in the historical cohort (72%). DPD 
enzyme activity measurements in this study showed that activity for DPYD*2A carriers 
was approximately 50% reduced compared to wild-type patients, which endorses the 
dose recommendation of 50% for this variant. 
As only one carrier of the rare c.1679T>G variant was identified in our current study, 
this made statistical comparisons impossible. However, while a relative risk for severe 
toxicity of 4.30 has been reported in literature, we showed that this patient did not 
experience severe toxicity in a completed treatment with 50% reduced dose. The DPD 
enzyme activity was about 50% decreased as well in this patient, which is in line with 
expectations based on previous studies.24
For carriers of the c.1236G>A and c.2846A>T variant, risk of severe toxicity remained 
relatively high despite dose individualization based on our dosing recommendations 
(25% reduction). In this study, 39% of the c.1236G>A carriers experienced severe 
toxicity and 47% of the c.2846A>T carriers. For these two variants, an initial dose 
reduction of 25% was applied in this study, because these variants are considered 
to have a less deleterious effect on DPD activity than the non-functional variants 
DPYD*2A and c.1679T>G.14,16 However, the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) mentions that evidence is limited regarding the optimal degree of 
dose reduction for the decreased function variants c.1236G>A and c.2846A>T, and 
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a 25% dosing recommendation is mainly based on one small retrospective study.25 
Therefore, they advise a 25%-50% dose reduction in heterozygous c.1236G>A and 
c.2846A>T carriers.13 Our current results suggest that applying 25% dose reduction 
might be insufficient for some patients, as toxicity risk was increased for carriers of 
c.1236G>A and c.2846A>T, compared to wild-type patients. In line with these findings, 
our pharmacokinetic analyses showed that exposure to 5-FU was markedly higher in 
c.2846A>T carriers than in DPYD wild-type controls. Exposure to 5-FU in the variant 
allele carriers was at least equal to levels observed in wild-type patients receiving 
standard dose, which is circumstantial evidence that the applied genotype-guided 
dose-reduction will not result in under-treatment. However, these pharmacokinetic 
results need to be interpreted with caution for some reasons. In patients with reduced 
DPD activity, 5-FU metabolism is affected, with 5-FU being the third metabolite 
derived from the parent compound capecitabine, which limits the interpretation of 
5-FU exposure. Furthermore, pharmacokinetics of capecitabine and its metabolites 
exhibit a high inter-individual variability in exposure, even in wild-type patients, and 
are therefore difficult to interpret. In addition, based on the limited number of patients 
with a DPYD variant of whom we also obtained pharmacokinetic data (Supplementary 
Table 3) firm conclusions on the basis of pharmacokinetic measurements alone cannot 
be drawn. 
The mean DPD enzyme activity for c.1236G>A was approximately 20% reduced, but a 
large variation in DPD activity was found (Figure 3), which suggests that a proportion 
of patients needs a larger dose reduction, while other patients might even tolerate 
a full dose. This is also in line with the large variation in pharmacokinetic exposure 
seen in c.1236G>A carriers. Individual dose titration is important to ensure an adequate 
and safe dose for all patients. Therefore, we recommend a more cautious initial dose 
reduction of 50%, followed by close monitoring and individual dose titration. 
The mean value for c.2846A>T DPD enzyme activity was approximately 35% reduced 
compared to normal. These DPD activity measurements show that 25% dose reduction 
might not be sufficient for most of the patients, and this could be an explanation for 
the higher toxicity risk in this patient group. A more cautious initial dose reduction of 
50% should be considered in these patients as well. 
In this study, initially reduced doses were escalated in 11 out of 85 (13%) DPYD variant 
allele carriers, although only five patients were able to tolerate this escalated dose. In 
DPYD wild-type patients dose escalations are uncommon in clinical practice (3% in 
our study, mostly patients who started with an initially reduced dose as a precaution 
measure). 
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Our study was performed in a daily clinical care setting in general regional hospitals 
and a few academic centers, demonstrating the feasibility of implementation of upfront 
DPYD screening. In order to make DPYD-guided dosing feasible in all hospitals, it is 
important that the turn-around time for DPYD genotyping is short to prevent a delay in 
the start of treatment. Participating laboratories in our study had a turn-around time of 
a few days to a maximum of a week. 
A limitation of this study is that a historical cohort of DPYD variant allele carriers treated 
with full dose was used as control, and no direct comparison was made with a control 
cohort within the study. Inherently to this chosen design, differences between the 
study populations could have influenced the observed toxicity outcomes. However, 
this study design was chosen as a randomized clinical trial is considered unethical in 
this context, since it is known that DPYD variant allele carriers are at increased risk 
of severe toxicity when treated with a full dose of fluoropyrimidines.26 A previously 
performed clinical study was stopped prematurely as a patient in the arm without dose 
individualization died due to treatment-related toxicity.27 
This study focused on toxicity and did not evaluate survival or other effectiveness 
outcomes, as this was considered not feasible due to the large variation in tumor types 
and treatment regimens. We did, however, perform pharmacokinetic measurements, 
which suggest that applied dose reductions in DPYD variant allele carriers did not result 
in under-dosing.
The four DPYD variants investigated in this study are especially relevant to Caucasian 
populations. For ethnicities other than Caucasians, more research on the frequency 
and clinical relevance of these and other DPYD variants is recommended.28 In our 
current study, homozygous and compound heterozygous DPYD variant allele carriers 
were not included and were treated with individualized fluoropyrimidine dosing or 
alternative treatment outside this study.17 However, for this group of patients DPYD 
genotype-guided dosing is of even greater importance than for heterozygous DPYD 
variant allele carriers, as these patients in general have less remaining DPD activity or 
even complete absence of DPD activity, and a full fluoropyrimidine dose, when not 
identified as DPD deficient patients, is therefore likely to be fatal. 
Although our study revealed that the applied approach of genotype-guided adaptive 
dosing significantly reduced severe fluoropyrimidine-induced toxicity and prevented 
treatment related death, additional methods should be explored and prospectively 
tested to further reduce treatment related toxicity not only in poor metabolizers, but 
also in DPYD wild-type patients.
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In conclusion, we showed safety of patients treated with fluoropyrimidines was 
improved by dose individualization based on DPYD genotype. Dose reduction of 50% 
in heterozygous DPYD*2A and c.1679T>G carriers reduced toxicity risk markedly. The 
applied dose reductions of 25% in heterozygous c.1236G>A and c.2846A>T carriers 
appear to be insufficient to lower the risk of fluoropyrimidine-related toxicity to 
the background risk in wild-type patients. A larger initial dose reduction of 50% for 
c.2846A>T and c.1236G>A carriers with subsequent individual dose titrations should 
therefore be considered. 
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SUPPLEMENTARY INFORMATION
SUPPLEMENTARY METHODS
INCLUSION AND EXCLUSION CRITERIA
Patients with a pathologically confirmed malignancy for which treatment with a 
fluoropyrimidine drug was considered to be in the patient’s best interest could be 
included in this study. Eligible patients were 18 years or older and were willing to undergo 
blood sampling for the purpose of this study (pharmacogenetic and phenotyping 
analysis). Patients had to have a WHO performance status of 0, 1 or 2, a life expectancy 
of at least 12 weeks, and acceptable safety laboratory values (neutrophil count of ≥1.5 
x 109/L, platelet count of ≥100 x 109/L, hepatic function as defined by serum bilirubin 
≤1.5 x upper limit of normal (ULN), alanine aminotransferase (ALAT), and aspartate 
aminotransferase (ASAT) ≤2.5 x ULN, or in case of liver metastases ALAT and ASAT≤5 x 
ULN, renal function as defined by serum creatinine ≤1.5 x ULN, or creatinine clearance 
≥60 ml/min (by Cockcroft-Gault formula).
Exclusion criteria were prior treatment with fluoropyrimidines, patients with known 
substance abuse, psychotic disorders, and/or other diseases expected to interfere with 
study or the patient’s safety, women who were pregnant or breast feeding, man and 
women who refused to use reliable contraceptive methods throughout the study, and 
patients with a homozygous polymorphic DPYD genotype or compound heterozygous 
DPYD genotype. 
TOXICITY ASSESSMENTS
For causality assessment of toxicity the following definitions were used: 
•	 Possible: the event follows a reasonable temporal sequence from the time of 
drug administration, but could have been produced by other factors such as the 
patient’s clinical state, other therapeutic interventions or concomitant drugs.
•	 Probable: the event follows a reasonable temporal sequence from the time of 
drug administration, and follows a known response pattern to the study drug. 
The toxicity cannot be reasonably explained by other factors such as the patient’s 
clinical state, therapeutic interventions or concomitant drugs.
•	 Definite: the event follows a reasonable temporal sequence from the time of drug 
administration, and follows a known response pattern to the study drug, cannot be 
reasonably explained by other factors such as the patient’s condition, therapeutic 
interventions or concomitant drugs; AND occurs immediately following study 
drug administration, improves on stopping the drug, or reappears on re-exposure.
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SAMPLE SIZE CALCULATION
A sample size calculation was made based on the primary aim of the study, which 
was to determine whether fluoropyrimidine-related severe toxicity can be reduced 
by individualized dosing in DPYD variant allele carriers compared to standard dosing 
in these patients. Using a one stage A’Hern (phase II) design and a null hypothesis 
of a probability of toxicity of 60% (the estimated severe treatment-related toxicity 
probability if DPYD variant allele carriers received standard dose)1,2 and an alternative 
hypothesis of 20% (estimated toxicity probability of DPYD variant allele carriers 
receiving individualized dose), a sample size of 11 DPYD variant allele carriers would 
give a one-sided type I error probability α of 2.93% and power of 83.9%. It was decided 
that the frequency of c.2846A>T carriers (approximately 1.0%)3 would determine the 
total number of patients required in the study. These patients would then arise from an 
expected minimum population of 1100 treated patients. To account for a proportion of 
patients not evaluable for the study, the target accrual was set at 1250 patients. Given 
the very low allele frequency of the c.1679T>G variant, it was considered not feasible to 
power this study for this particular variant. The estimated frequency of c.1236G>A is 3% 
and of DPYD*2A 1%, which means that the calculated sample size would be adequate 
for those individual variants, or when analyzing all four variants together (estimated 
frequency of 5%). 
PHARMACOKINETIC ANALYSES
For pharmacokinetic analyses, peripheral blood was collected on the first day of 
treatment. Blood was collected in lithium heparin tubes at nine different time points up 
to eight hours after capecitabine intake (pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, and 8 hours 
after capecitabine intake). Samples were centrifuged immediately after the blood was 
drawn and plasma was stored at -80°C until analysis. 
Capecitabine and the metabolites 5’-deoxy-5-fluorocytidine (5’DFCR), 5’-deoxy-5-
fluorourdine (5’DFUR), 5-fluorouracil (5-FU), and fluoro-β-alanine (FBAL) were quantified 
in plasma samples using a validated ultra-performance liquid chromatography (UPLC)-
tandem mass spectrometry (MS/MS) method. Lower limit of quantifications were 25 
ng/ml for capecitabine, 10 ng/ml for 5’DFCR, 5’DFUR and 5-FU, and 50 ng/ml for FBAL. 
Stable isotopes were used as internal standard for all analytes. To a sample volume of 
300 μl of plasma, 900 μl of methanol-acetonitrile (50:50 v/v) was added to precipitate 
the plasma proteins. Samples were vortex-mixed for 10 s, shaken for 10 min at 1,250 
rpm and centrifuged at 14,000 rpm for 10 minutes. The clear supernatants were dried 
under a stream of nitrogen at 40°C and reconstituted in 100 μl of 0.1% formic acid 
in water. An Acquity UPLC® HSS T3 column (150 x 2.1 mm ID, 1.8 μlm particles) was 
used for chromatographic separation, at a flow rate of 300 μl/min and a gradient of 
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0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile 
phase B). The following gradient was applied: 100% A from 0-2.5 min, an increase from 
0% to 90% B from 2.5-7.5 min, and 100% A from 7.5-9 min. For detection an API5500 
triple quadruple mass spectrometer (Sciex) equipped with a turbo ionspray interphase 
was used, using optimized mass transitions m/z 360.0 à 243.9 for capecitabine, 244.9 
à 128.8 for 5’DFUR, 128.9 à 42.1 for 5-FU, and 105.9 à 85.9 for FBAL. 
Pharmacokinetic parameters were calculated using non-compartmental analysis and 
the calculated area under the plasma concentration-time curve (AUC) and half-life (t
1/2
) 
were compared with pharmacokinetic data described in literature,4 measured at the 
same laboratory as the current study. 
DATA SHARING STATEMENT
Data collected in the study, including individual participant data, will not be made 
available to others, except to researchers involved in the study. However, upon request, 
data sharing for additional research is possible and will be supported. Requests will 
be judged on scientific and clinical rationale and may need to be reviewed by an 
authorized institutional review board (IRB) prior to data sharing. The study protocol 
of this study is publicly available (as online supplement available with this publication).
SUPPLEMENTARY RESULTS
DETAILED INFORMATION OF DPYD VARIANT ALLELE CARRIERS NOT TREATED 
ACCORDING TO DOSING RECOMMENDATIONS
For four patients dosing recommendations were not followed according to protocol. 
One patient carrying DPYD*2A started with a full dose as genotyping results were not 
awaited before start of treatment. After one week of treatment the DPYD genotyping 
result became available and the dose was reduced to 50%. The patient did not 
experience severe treatment-related toxicity in this course. However, from the third 
cycle onwards the dose was quickly titrated upwards (75% in the third cycle and 90% in 
the fourth cycle), hereafter treatment-related toxicity (anorexia grade 2, fatigue grade 
3) occurred and the dose was reduced again. A second patient (DPYD*2A carrier) 
also started with a full dose as genotyping results were not awaited before starting 
treatment. As results were known the following day, the patient had only taken a full 
dose for one day, which did not result in severe toxicity. The patient was treated with a 
50% dose from the second day onwards. A third patient carrying c.2846A>T, used a full 
dose for four days, but continued with a 50% dose after an interruption of 5 days. The 
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overall dose intensity of this cycle was approximately 55% and no toxicity occurred. 
The fourth patient (c.2846A>T carrier) was wrongly treated with a full dose for two 
cycles due to miscommunication with the patient. The patient experienced severe 
diarrhea, pancytopenia and sepsis, and passed away. 
PHARMACOKINETIC ANALYSES
A total of 26 DPYD variant allele carriers treated with reduced dose of capecitabine was 
included in the analysis. Pharmacokinetic results are shown in Supplementary Table 3. 
In 24 out 26 patients (92%) pharmacokinetic sampling was performed at day 1 of cycle 
1. In two patients this was done at day 1 of another cycle, after a resting period of one 
week without capecitabine intake. 
Of five patients who were treated with 5-FU, pharmacokinetic blood samplings was 
performed as well, but results were considered unreliable, most likely as drawing of 
blood was not done correctly. Results of the 5-FU treated patients are therefore not 
included in the analysis. 
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Supplementary Table 1. Demographic and clinical characteristics of DPYD variant allele carriers 
Characteristic
DPYD variant allele 
carriers 
c.1236G>A c.2846A>T DPYD*2A c.1679T>G
N = 85 N = 51 N = 17 N = 16 N = 1
Sex
   Male 
   Female
48 (56%)
37 (44%)
26 (51%)
25 (49%)
11 (65%)
6 (35%)
10 (63%)
6 (38%)
1 (100%)
0
Age
   Median [IQR] 63 [54-71] 62 [52-71] 62 [53-72] 64 [58-70] 70
Ethnic origin
   Caucasian
   African 
   Asian
   Other a
84 (99%)
0 
1 (1%)
0
51 (100%)
0
0
0
17 (100%)
0
0
0
15 (94%)
0
1 (6%)
0
1 (100%)
0
0
0
Tumor type
   Non-metastatic CRC
   Metastatic CRC
   BC
   GC
   Other b
32 (38%)
24 (28%)
10 (12%)
6 (7%)
13 (15%)
15 (29%)
17 (33%)
5 (10%)
4 (8%)
10 (20%)
7 (40%)
4 (24%)
3 (18%)
1 (6%)
2 (12%)
9 (56%)
3 (19%)
2 (13%)
1 (6%)
1 (6%)
1 (100%)
0
0
0
0
Type of treatment regimen
   CAPE mono 
   CAPE + RT
   CAPOX
   CAPE other
   5-FU mono 
   5-FU + RT
   FOLFOX
   5-FU other
14 (16%)
18 (21%)
31 (36%)
5 (6%)
1 (1%)
6 (7%)
5 (6%)
5 (6%)
8 (16%)
8 (16%)
19 (37%)
3 (6%)
0
6 (12%)
2 (4%)
5 (10%)
4 (24%)
5 (29%)
5 (29%)
1 (6%)
0
0
2 (12%)
0
2 (13%)
5 (31%)
6 (38%)
1 (6%)
1 (6%)
0
1 (6%)
0
0
0
1 (100%)
0
0
0
0
0
BSA
   Median [IQR] 1.9 [1.8-2.1] 1.9 [1.7-2.1] 2.0 [1.7-2.1]
2.0 [1.5-
2.5]
2.1
WHO performance status
   0
   1
   2
   NS c
39 (46%)
36 (42%)
4 (5%
6 (7%)
26 (51%)
18 (35%)
3 (6%)
4 (8%)
8 (47%)
9 (53%)
0
0 
4 (25%)
9 (56%)
1 (6%)
2 (13%)
1 (100%)
0
0
0
Number of treatment cycles
   Median [IQR] 4 [1-8] 4 [2-8] 3 [1-7] 3 [1-7] 3
a Other ethnic origins included Hispanic descent, mixed-racial parentage and unknown ethnic origin. 
b Other tumor types included anal cancer, esophageal cancer, head and neck cancer, pancreas cancer, bladder 
cancer, unknown primary tumor, vulva carcinoma, and several rare tumor types. 
c WHO performance status was not specified for these patients, but was either 0,1, or 2, as this was required by 
the inclusion criteria of the study. 
Abbreviations: 5-FU mono: 5-fluorouracil monotherapy; 5-FU other: 5-fluorouracil combined with other 
anticancer drugs (excluding the FOLFOX regimen); 5-FU + RT: 5-fluorouracil combined with radiotherapy (with 
or without mitomycin); BC: breast cancer; BSA: body surface area; CAPE mono: capecitabine monotherapy 
(with or without bevacizumab); CAPOX: capecitabine combined with oxaliplatin (with or without bevacizumab); 
CAPE other: capecitabine combined with other anticancer drugs; CAPE + RT: capecitabine combined with 
radiotherapy (with or without mitomycin); CRC: colorectal cancer; DPYD: gene encoding dihydropyrimidine 
dehydrogenase; FOLFOX: 5-fluorouracil combined with oxaliplatin and leucovorin (with or without 
bevacizumab); GC: gastric cancer; IQR interquartile range; NS: not specified. 
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Supplementary Table 2. Incidences of severe toxicity in DPYD variant allele carriers in this study 
and the historical cohort
DPYD variant
DPYD variant carriers treated with reduced dose 
(this study)
DPYD variant carriers treated with full dose
(meta-analysis)
N of patients with overall grade≥3 toxicity / total 
N of patients with this variant (%)
N of patients with overall grade≥3 toxicity / 
total N of patients with this variant (%)
c.1236G>A 20 / 51 (49%) 65 / 177 (37%)
c.2846A>T 8 / 17 (47%) 53 / 85 (62%)
DPYD*2A 5 / 16 (31%) 43 / 60 (72%)
c.1679T>G 0 / 1 (0%) 6 / 11 (55%)
Supplementary Table 3. Pharmacokinetic parameters of capecitabine and metabolites in DPYD 
variant allele carriers and controls
Mean AUC
0-∞
 (ng*h/ml) [CV%] a Mean T
1/2
 (h) [CV%]
Metabolite DPYD variant allele 
carriers (N=26)
Wild-type control 
patients (N=23) b
DPYD variant allele 
carriers (N=26)
Wild-type control 
patients (N=23) b
Capecitabine 6007 [60%] 4281 [31%] 0.73 [49%] 0.76 [55%]
5’DFCR 7792 [56%] 8192 [30%] 0.83 [43%] 1.0 [45%]
5’DFUR 8243 [45%] 7673 [29%] 0.85 [38%] 0.9 [34%]
5-FU 398 [77%] 381 [40%] 0.92 [112%] 1.0 [57%]
FBAL 14295 [41%] 14177 [31%] 2.2 [133%] 2.6 [33%]
Mean AUC
0-∞
 (ng*h/ml) [CV%] a Mean T
1/2
 (h) [CV%]
Metabolite c.1236G>A 
(N=16)
c.2846A>T 
(N=5)
DPYD*2A 
(N=4)
c.1679T>G 
(N=1)
c.1236G>A 
(N=16)
c.2846A>T 
(N=5)
DPYD*2A 
(N=4)
c.1679T>G 
(N=1)
Capecitabine 6579 [65%] 5944 [26%] 4460 [51%] 3350 0.77 [48%] 0.68 [50%] 0.66 [61%] 0.53
5’DFCR 9162 [45%] 8320 [50%] 2552 [25%] 4185 0.84 [51%] 0.88 [28%] 0.83 [21%] 0.51
5’DFUR 9319 [41%] 8150 [46%] 4824 [17%] 5161 0.84 [38%] 0.73 [41%] 0.84 [19%] 1.6
5-FU 346 [49%] 765 [64%] 197 [54%] 219 1.1 [120%] 0.75 [47%] 0.54 [20%] 0.82
FBAL 16217 [30%] 15627 [36%] 6244 [18%] 9082 2.9 [78%] 2.5 [14%] 2.2 [15%] 2.9
a Note that for all metabolites the AUC is calculated until infinity (AUC
0-∞
, extrapolated from the last time point). 
Only for FBAL, the metabolite with the longest half-life, this resulted in a difference between the AUC until last 
time point (AUC
0-t
) and AUC
0-∞
, with the AUC
0-∞
 being on average 26% higher than AUC
0-t
. For the metabolites 
capecitabine, 5’DFCR, 5’DFUR and 5-FU the difference between AUC
0-t
 and AUC
0-∞
 was respectively 0.5%, 0.8%, 
1%, and 4%. 
b Control values are derived from Deenen et al.4 for patients with advanced cancer of the stomach or 
gastresophageal junction after administration of capecitabine 850 mg/m2 (dose level 2 of the study). 
Abbreviations: 5’DFCR: 5’-deoxy-5-fluorocytidine; 5’DFUR: 5’-deoxy-5-fluorouridine; 5-FU: 5-fluorouracil; 
AUC: area under the plasma concentration-time curve; CV%: coefficient of variation; FBAL: fluoro-β-alanine; 
T
1/2
: half-life. 
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Supplementary Table 4. DPD enzyme activity in patients with and without severe toxicity 
DPYD genotype
Patients without severe toxicity a Patients with severe toxicity a
P-value b
Mean activity (SD) N of patients Mean activity (SD) N of patients
Wild-type 9.6 (3.6) 67 8.7 (3.7) 15 0.36
c.1236G>A 7.6 (3.0) 22 7.3 (2.6)    13 0.79
c.2846A>T 6.8 (1.9) 6 5.7 (1.8)    6 0.33
DPYD*2A 4.9 (0.7) 5 5.5 (1.1)    3 0.22
c.1679T>G NA 1 NA         0 NA
a Severe toxicity is defined as CTC-AE grade 3 or higher. 
b P value determined with t-test. 
Abbreviations: CTC-AE: National Cancer Institute Common Terminology Criteria for Adverse Events; NA: not 
applicable. 
Supplementary Table 5. Overview of participating centers in this study
Center Principal investigator
Number of eligible 
patients included
Erasmus Medical Center, Rotterdam, the Netherlands Prof. Ron H.J. Mathijssen, MD 264
The Netherlands Cancer Institute, Amsterdam, the 
Netherlands
Prof. Jan H.M. Schellens, MD 210
Catharina Hospital, Eindhoven, the Netherlands Geert-Jan Creemers, MD 118
Leiden University Medical Center, Leiden, the 
Netherlands
Prof. Hans Gelderblom, MD 93
Hospital Gelderse Vallei, Ede, the Netherlands Arnold Baars, MD 88
Reinier de Graaf Hospital, Delft, the Netherlands
Vincent O. Dezentjé, MD / 
Annelie J.E. Vulink, MD a
79
Haaglanden Medical Center, the Hague, the 
Netherlands
Frank J.F. Jeurissen, MD 46
Deventer Hospital, Deventer, the Netherlands Alexander L.T. Imholz, MD 41
Haga Hospital, the Hague, the Netherlands
Prof. Johanna E.A. Portielje, MD / 
Danny Houtsma, MD a
35
Maastricht University Medical Center, Maastricht, the 
Netherlands
Rob L.H. Jansen, MD 28
Franciscus Gasthuis and Vlietland, Rotterdam, the 
Netherlands
Paul Hamberg, MD 24
Amphia Hospital, Breda, the Netherlands Albert J. ten Tije, MD 20
Bravis Hospital, Roosendaal, the Netherlands Helga J. Droogendijk, MD 17
University Medical Center, Utrecht, the Netherlands Prof. Miriam Koopman, MD 14
Wilhelmina Hospital, Assen, the Netherlands Peter Nieboer, MD 13
Laurentius Hospital, Roermond, the Netherlands Marlène H.W. van de Poel, MD 9
Canisius-Wilhelmina Hospital, the Netherlands Caroline M.P.W. Mandigers, MD 4
a In these centers the principal investigator was switched during the study. 
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ABSTRACT 
BACKGROUND
Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in 
severe treatment-related toxicity in up to 30% of patients. Toxicity is often related 
to reduced activity of dihydropyrimidine dehydrogenase (DPD), the main metabolic 
fluoropyrimidine enzyme, primarily caused by genetic DPYD polymorphisms. In a large 
prospective study, it was concluded that upfront DPYD-guided dose individualization 
is able to improve safety of fluoropyrimidine-based therapy. In our current analysis, we 
evaluated whether this strategy is cost-saving. 
METHODS
A cost-minimization analysis from a health care payer perspective was performed as 
part of the prospective clinical trial (NCT02324452) in which patients prior to start 
of fluoropyrimidine-based therapy were screened for the DPYD variants DPYD*2A, 
c.2846A>T, c.1679T>G, and c.1236G>A, and received an initial dose reduction of 25% 
(c.2846A>T, c.1236G>A) or 50% (DPYD*2A, c.1679T>G). Data on treatment, toxicity, 
hospitalization and other toxicity-related interventions were collected. The model 
compared prospective screening for these DPYD variants with no DPYD screening. 
One-way and probabilistic sensitivity analyses were also performed. 
 
RESULTS
Expected total costs of the screening strategy were €2,599 per patient, compared to 
€2,650 for non-screening, resulting in a net cost-saving of €51 per patient. Results 
of the probabilistic sensitivity and one-way sensitivity analysis demonstrated that the 
screening strategy was very likely to be cost-saving or worst case cost-neutral.
CONCLUSIONS
Upfront DPYD-guided dose individualization, improving patient safety, is cost-saving 
or cost-neutral, but is not expected to yield additional costs. These results endorse 
implementing DPYD screening before start of fluoropyrimidine treatment as standard 
of care.
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INTRODUCTION 
The class of fluoropyrimidine anticancer drugs includes 5-fluorouracil (5-FU) and 
its oral prodrug capecitabine. These drugs are used by approximately two million 
patients yearly worldwide,1 and are the cornerstone of chemotherapeutic treatment 
for several solid tumor types, including colorectal, breast, gastric and head- and neck 
cancer. While fluoropyrimidine drugs are highly valuable treatment options, severe 
and potential fatal fluoropyrimidine-related toxicity remains a major clinical limitation. 
Around 15-30% of the patients develop severe treatment-related toxicity,2,3 usually 
associated with interruption or discontinuation of therapy and often hospitalization, 
resulting in increased health care costs. 
During the last decades it has become clear that safety of patients treated with 
fluoropyrimidine-based anticancer therapy is strongly affected by inter-individual 
variability in the enzyme dihydropyrimidine dehydrogenase (DPD), which is the main 
metabolic enzyme of fluoropyrimidines. The DPD enzyme is present in the liver and 
inactivates over 80% of 5-FU.4 DPD enzyme activity varies widely between patients, 
with an estimated 3 to 8% of the population having a reduced DPD activity.5,6 DPD 
deficiency results in reduced 5-FU clearance, and as a direct consequence, highly 
increased risk of severe treatment-related toxicity when DPD-deficient patients are 
treated with standard doses of a fluoropyrimidine drug.7
DPD deficiency can be caused by genetic polymorphisms in DPYD, the gene encoding 
DPD. Currently, four DPYD variants are considered as being clinically relevant and dosing 
recommendations are provided for these variants: DPYD*2A, c.1679T>G, c.2846A>T 
and c.1236G>A).8,9 Upfront genotyping followed by a fluoropyrimidine dose reduction 
in carriers in any of these four variants has proven a useful strategy to improve patient 
safety.10,11 However, this strategy has not yet been universally implemented in daily 
clinical care. 
One of the potential barriers that can make physicians reluctant to implement upfront 
DPYD screening as a routine test, is uncertainty on the cost-effectiveness of a DPYD 
screening strategy.12 Deenen et al. previously showed that upfront screening for one 
DPYD variant, DPYD*2A, is cost-saving, as average total medical costs in the screening 
arm were €2,772 per patient and therefore lower than the non-screening arm, for 
which the average total medical costs were €2,817 per patient. This shows that the 
reduction in toxicity-related costs outweighs the screening costs.10 In our current study, 
we aimed to investigate the medical costs associated with upfront screening for the 
four DPYD variants currently considered clinically relevant and dose individualization 
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in heterozygous carriers of a DPYD variant, therefore evaluating the net cost effects of 
this expanded DPYD genotyping strategy. 
PATIENTS AND METHODS
STUDY DESIGN AND PARTICIPANTS
The cost-analysis was performed as part of a recently published clinical trial.11 This 
was a multicenter study in which seventeen hospitals in the Netherlands participated 
(NCT02324452). Study approval was obtained by the institutional review board of The 
Netherlands Cancer Institute, Amsterdam, the Netherlands, and approval from the 
board of directors of each individual hospital was obtained for all participating centers. 
All patients provided written informed consent before inclusion in the study. 
The study population consisted of patients treated with a fluoropyrimidine-based 
anticancer therapy, either as single agent or in combination with other chemotherapeutic 
agents and/or radiotherapy. Prior chemotherapy was allowed, except for prior use of 
fluoropyrimidines. Before start of fluoropyrimidine therapy, patients were genotyped for 
four DPYD variants (DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A). Heterozygous 
DPYD variant allele carriers received an initial dose reduction of either 25% (for 
c.2846A>T and c.1236G>A) or 50% (for DPYD*2A and c.1679T>G), in line with current 
recommendations from Dutch and international pharmacogenomic guidelines.9,13 To 
achieve maximal safe exposure, dose escalation was allowed after the first two cycles, 
provided that treatment was well tolerated and was left at the discretion of the physician. 
The dose of other chemotherapeutic agents or radiotherapy was left unchanged at 
the start of treatment. Homozygous or compound heterozygous DPYD variant allele 
carriers were not included in the study. Non-carriers of the above mentioned DPYD 
variants were considered wild-type patients in this study, and were treated according 
to existing standard of care. 
Toxicity was graded by participating centers according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTC-AE),14 and severe toxicity 
was defined as grade three or higher. Patients were followed for toxicity during the 
entire treatment period. Toxicity defined as possibly, probably or definitely related 
to fluoropyrimidine-treatment was considered treatment-related toxicity. Toxicity-
related hospitalization and treatment discontinuation due to adverse events were also 
investigated. 
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The primary end point of the prospective study was the frequency of severe overall 
fluoropyrimidine-related toxicity across the entire treatment duration. A comparison 
was made between DPYD variant allele carriers treated with reduced dose and wild-
type patients treated with standard dose in this study, and also with DPYD variant allele 
carriers treated with full dose in a historical cohort derived from a previously published 
meta-analysis.8 Secondary endpoints of the prospective study included a cost-analysis 
of individualized dosing based on upfront genotypic assessment, and pharmacokinetics 
of capecitabine and 5-FU in DPYD variant allele carriers.
COST-ANALYSIS 
To compare the prospective screening for four DPYD variants (screening strategy) with 
no DPYD screening (non-screening strategy), a cost-analysis model was composed. 
This analysis consisted of a cost-minimization analysis using a decision analytical 
model from a health care payer perspective. 
A previously published model by Deenen et al.10 was used and updated with data 
from the current study and current prices. Estimated parameters incorporated in the 
model were derived from data of the present trial and relevant data from literature.15,16 
Interventions for treatment-related toxicity were prospectively collected for all patients 
during the trial. An overview of the decision tree is depicted in Figure 1. 
Figure 1. Decision tree for cost-analysis
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In the model, a comparison between the screening strategy (prospective screening for 
four DPYD variants and dose adjustments in heterozygous DPYD variant allele carriers) 
and the non-screening strategy was made. Expected differences in costs of both 
strategies were calculated. 
Costs included were restricted to direct medical costs only and included costs for 
genotyping, fluoropyrimidine drug therapy including visits to the medical doctor and 
day care, costs for treatment of adverse events (e.g. extra medication, extra doctor 
visits, extra assessments), and costs for hospitalization due to adverse events. Costs 
for other anticancer drugs than the fluoropyrimidine drugs were not included in the 
model, as they were expected to be equal in both arms. Cost-saving was calculated as 
the difference between the net direct costs of the DPYD screening strategy versus the 
non-screening strategy. 
To examine the effects on variations in parameter values, one-way and probabilistic 
sensitivity analyses were performed. In the one-way sensitivity analysis, each parameter 
was varied individually at ±20% of the baseline value. In the probabilistic sensitivity 
analysis, all parameters were varied simultaneously by running 1000 simulations 
(Monte Carlo). Since the parameter values of the wild-type patients for both the 
screening and the non-screening arm are identical, these parameters remained fixed 
in the probabilistic sensitivity analysis.
RESULTS
PATIENT CHARACTERISTICS AND TOXICITY INCIDENCE 
The study was open for inclusion between April 30th, 2015 and December 21st, 2017. In 
this period, a total of 1103 evaluable patients were enrolled in this study, of whom 85 
heterozygous DPYD variant allele carriers (7.7%) and 1018 wild-type patients (92.3%). 
The group of DPYD variant allele carriers included 51 c.1236G>A carriers, seventeen 
c.2846A>T carriers, sixteen DPYD*2A carriers and one c.1679T>G carrier. Details on 
patient characteristics, treatment and toxicity incidence are published separately.11 In 
short, 33 out of 85 DPYD variant allele carriers (39%) experienced grade ≥3 treatment-
related toxicity, while this was significantly lower in the group of wild-type patients 
with 231 out of 1018 patients (23%) experiencing severe toxicity (P=0.001). Compared 
to the historical cohort of DPYD variant allele carriers treated with full dose, DPYD 
genotype-guided dosing markedly decreased the risk of severe fluoropyrimidine-
related toxicity for three out of four variants (DPYD*2A, c.1679T>G and c.2846A>T; 
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Figure 2). No reduction in severe treatment-related toxicity was shown for c.1236G>A. 
Figure 2. Relative risk for severe treatment-related toxicity of DPYD variant allele carriers 
receiving dose-reduction (this study) and DPYD variant allele carriers treated with full dose 
(historical cohort)
The relative risk for overall grade ≥3 fluoropyrimidine-related toxicity compared to non-carriers 
of this variant was calculated with data from this study11 and for the historical cohort with data 
derived from a previously published random-effects meta-analysis.8 Unadjusted relative risks for 
the meta-analysis are depicted, as the relative risk in the current study was also calculated as an 
unadjusted value. For c.1679T>G no relative risk could be calculated in this study, as only one 
patient who carried c.1679T>G was present. This patient did not experience severe toxicity.
Abbreviations: 95%CI: 95% confidence interval. 
COST-ANALYSIS 
All parameter estimates used in the model are provided in Table 1. In the cost-analysis 
the expected total costs for the screening strategy were €2,599 per patient, compared 
to €2,650 per patient for the non-screening strategy, resulting in a net cost-saving of 
€51 per patient treated. 
Results of the one-way sensitivity analysis are depicted in Figure 3, demonstrating 
that the frequency of the DPYD variant allele genotype had the largest influence on 
outcome of the cost-analysis, followed by the risk of hospitalization at the nursing 
ward for DPYD variant allele carrier receiving standard dose, and DPYD genotyping 
costs. However, in all cases, the cost-saving remained positive. 
Results of the simulations for the probabilistic sensitivity analysis are depicted in Figure 
4. Average cost-savings from the simulation in the probabilistic sensitivity analysis were 
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€52 per patient (95%-interval range -€38 to €176). Average gain in safety was 0.89% 
(95%-interval range -0.04% to 1.79%). This gain in safety represents the difference 
between the proportion of patients treated without severe toxicity (both wild-type 
patients and DPYD variant allele carriers taken together) in the screening strategy and 
the non-screening strategy.
Figure 3. One-way sensitivity analysis of upfront DPYD genotyping versus non-screening
All parameters were individually varied by ±20% (-20% depicted in blue, +20% depicted in green), 
effects of which cost-savings are indicated by horizontal bars. The vertical line indicates the 
baseline costs savings of €50.
Figure 4. Probabilistic sensitivity analysis of the cost-analysis 
For this sensitivity analysis, all parameters were varied simultaneously by running 1000 Monte 
Carlo simulations. The red square indicates the observed values.
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Table 1. Cost and probability parameters used in the cost-analysis 
Probabilities and other parameters
Variable Baseline 
value
Standard 
errora
Sensitivity rangeb Reference
Frequency DPYD genotype 
   DPYD wild-type
   DPYD variant allele carrier
0.9229
0.0771
0.0080
0.0080
fixed
0.0617 – 0.0925
This study11
This study11
Risk severe toxicity
   DPYD wild-type
   DPYD variant allele carrier, reduced dose
   DPYD variant allele carrier, standard dose
0.2269
0.3882
0.5015
fixed
0.0526
0.0274
fixed
0.3106 – 0.4658
0.4012 – 0.6018
This study11
This study11
Meta-analysis8
DPYD wild-type
   Hospitalization nursing ward
   Mean duration (days)
   Hospitalization ICU
   Mean duration (days)
0.1356
7.9855
0.0088
3.1111
fixed
fixed
fixed
fixed
fixed
fixed
fixed
fixed
This study11
This study11
This study11
This study11
DPYD variant allele carrier, reduced dose
   Hospitalization nursing ward
   Mean duration (days)
   Hospitalization ICU
   Mean duration (days)
0.1647
5.7857
0.0235
1.0000
0.0400
1.3350
0.0163
0.1000
0.1318 – 0.1976
4.6286 – 6.9428
0.0188 – 0.0282
0.8000 – 1.2000
This study11
This study11
This study11
This study11
DPYD variant allele carrier, standard dose
   Hospitalization nursing ward
   Mean duration (days)
   Hospitalization ICU
   Mean duration (days)
0.2350
13.1000
0.0310
7.0000
0.0422
3.0000
0.0172
3.0000
0.1880 – 0.2820 
10.4800 – 15.7200
0.0248 – 0.0372
5.6000 – 8.4000
Analysis on previous study10,20
Analysis on previous study10,20
Analysis on previous study10,20
Analysis on previous study10,20
Mean number of cycles
   Capecitabine
   5-FU
5.0208
5.0426
0.1567
0.3639
4.0166 – 6.0250
4.0341 – 6.0511
This study11
This study11
Type of fluoropyrimidine drug
   Capecitabine
   5-FU
0.83
0.17
fixed
fixed
fixed
fixed
This study11
This study11
Mean dose intensity for DPYD variant allele 
carriers 0.6910 0.0124 0.5528 – 0.8292 This study11
Cost parameters (expressed in €)
Variable Baseline 
value
Standard 
errora
Sensitivity rangeb Reference
DPYD genotyping costs 100 Fixed 80-120 This study11
Hospitalization nursing ward (per day) 636 Fixed Fixed Guideline15
Hospitalization ICU (per day) 2,015 Fixed Fixed Guideline15
Additional costs for interventions related to 
toxicity (expect hospitalization)
   Grade 0-2
   Grade ≥3
86
234
fixed
fixed
fixed
fixed
This study11
This study11
Treatment costs capecitabine (per cycle)
   Capecitabine medication
   Medical doctor visit
144.06
132
30
Fixed
fixed
fixed
This study11 / Price info 
drugs16
Guideline15
Treatment costs 5-FU per cycle
   5-FU medication + pharmacy  
   preparation
   Administration at day care
   Medical doctor visit
59.29
276
132
20
fixed
fixed
fixed
fixed
fixed
This study/Price info drugs16
Guideline15
Guideline15
a The standard error was calculated on data of this study, or otherwise estimated for parameters not derived 
from this study. The standard error is used for the probabilistic sensitivity analysis.
89
4
COST ANALYSIS OF UPFRONT DPYD GENOTYPE-GUIDED DOSE INDVIDUALISATION
b The sensitivity range is calculated by varying the baseline value ±20%. The sensitivity range is used for the one 
way sensitivity analysis. 
Abbreviations: 5-FU: 5-fluorouracil; DPYD: gene encoding dihydropyrimidine dehydrogenase; ICU: intensive 
care unit.
DISCUSSION
The cost-analysis performed in this study showed that prospective DPYD screening 
for these four variants and dose individualization is cost-saving. This confirms that 
upfront DPYD screening does not result in an increase in healthcare costs, while it 
can significantly improve patient safety and prevent toxicity-related deaths, as shown 
previously.11 Results of the probabilistic sensitivity analysis and one-way sensitivity 
demonstrated that, even when varying parameters in the model, the screening strategy 
is unlikely to result in an increase in costs.
However, the net saving for the screening strategy in our cost-analysis was with €51 
relatively small. One of the determinants for this finding is that in our clinical study 
patients carrying a DPYD variant were still at increased risk of developing severe 
treatment-related toxicity, compared to wild-type patients (39% versus 23%, P=0.001).11 
The higher incidence of toxicity in DPYD variant allele carriers was mainly driven by 
carriers of the variants c.1236G>A and c.2846A>T. For these two variants a 25% dose 
reduction was applied in the study, which was concluded to be probably insufficient 
to reduce the incidence of toxicity to the background incidence in wild-type patients. 
Our results are in line with four previous studies investigating costs of DPYD genotyping 
and toxicity.10,17 Deenen et al. previously confirmed that upfront screening for one 
DPYD variant (DPYD*2A) is cost-saving.10 Another study, by Cortejoso et al. investigated 
screening for three variants (DPYD*2A, c.2846A>T, c.1679T>G) and compared 
genotyping costs and costs for treating severe neutropenia in a retrospective analysis. 
Occurrence of severe neutropenia resulted in average costs for treatment for this 
side effect of €3,044 per patient (drug and hospitalization costs). Genotyping costs 
for the three DPYD variants were only €6.40 per patient (approximately sixteen times 
less expensive than in our study). The authors calculated that DPYD genotyping would 
be cost-effective, provided that at least 2.1 cases of severe neutropenia per 1000 
treated patients are prevented by upfront genotyping for the three variants.17 This was, 
however, not validated in a prospective setting. 
The third study, by Murphy et al., investigated the cost implications for reactive DPYD 
screening (i.e. screening patients for DPYD variants after experiencing severe toxicity) 
versus prospective screening.18 In a period of three years, all patients experiencing 
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severe (grade ≥3) fluoropyrimidine-related toxicity in an Irish hospital were screened 
for four DPYD variants (DPYD*2A, c.2846A>T, c.1679T>G and c.1601G>A). Genotyping 
costs if prospective DPYD screening for all patients would have been performed were 
calculated. Total costs of hospitalization for five DPYD variant allele carriers (identified 
after experiencing severe toxicity) were €232,061, while prospectively testing would 
have cost in total €23,718 for the 134 included patients (€177 per patient), showing 
that hospitalization costs are significantly higher than costs for prospective DPYD 
screening.18 The main difference between their study and our study was that the study 
by Murphy et al. did not collect data on the prospective DPYD screening strategy, but 
only on reactive DPYD screening. 
The fourth study was a retrospective study as well, performed by Toffoli et al.19 Toxicity-
related costs on 550 colorectal cancer patients were investigated and genotyping for 
the same four variants as in our study was performed, but this was done retrospectively 
and not used for dose adjustments. This showed that average costs for treatment of 
toxicity were higher in DPYD variant allele carriers (€2,972) than in non carriers (€825), 
P<0.0001.19 
To conclude, in addition to the important finding that upfront DPYD genotype-
guided dose individualization is able to markedly increase patient safety, this study 
now confirms that this upfront DPYD screening strategy does not result in an increase 
in direct medical costs. This further endorses that DPYD genotyping should be 
implemented as routine clinical care. 
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INTRODUCTION
Fluoropyrimidines, including 5-fluorouracil (5-FU) and its oral prodrug capecitabine, are 
widely used in the treatment of several types of cancer. The enzyme dihydropyrimidine 
dehydrogenase (DPD) is responsible for over 80% of 5-FU conversion into inactive 
metabolites.1 Pathogenic single nucleotide polymorphisms (SNPs) in DPYD, the gene 
encoding DPD, can result in decreased function of DPD and are associated with a 
strongly increased risk of severe and potentially fatal fluoropyrimidine-induced toxicity.2 
Pretreatment screening for DPYD SNPs and reduction of the starting fluoropyrimidine 
dose in DPYD variant carriers has significantly improved patient safety.3 In a recent 
perspective, we recommended reduction of the starting fluoropyrimidine dose in 
heterozygous carriers of one of four clinically relevant DPYD variants by 25% (c.2846A>T 
or c.1236G>A/haplotypeB3) or 50% (DPYD*2A or c.1679T>G).4 
However, for homozygous DPYD variant carriers, or for patients who carry multiple 
variants simultaneously, no dosing guidelines are available yet, because experimental 
data about the magnitude of the effect of these genotypes on DPD activity are scarce. 
In the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline, 
fluoropyrimidine-treatment in homozygous DPYD variant carriers is discouraged, which 
implies that a potentially effective anticancer therapy is withheld from these patients.5 
In this article, six unique patients with a homozygous or compound heterozygous DPYD 
variant allele genotype who were treated with tailored fluoropyrimidine treatment 
are described. For three patients, pharmacokinetics, DPD-phenotyping and clinical 
course are included. Data about the other three homozygous DPYD variant carriers are 
provided in the Supplementary Information. 
METHODS
Detailed methods are in the Supplementary Information. Before the start of 
fluoropyrimidine treatment, genotyping for four DPYD SNPs (DPYD*2A, c.2846A>T, 
c.1679T>G, c.1236G>A/haplotypeB3) was performed as part of routine clinical care. 
Written informed consent for additional sample collection and use of clinical data was 
obtained for all patients. Analyses were part of individual patient care, so institutional 
review board approval was not applicable.
Genotyping results showed a homozygous or compound heterozygous DPYD genotype, 
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and the functional effects of these genotypes were uncertain. Therefore pretreatment 
DPD activity was measured in peripheral blood mononuclear cells (PBMCs). DPD 
activity was used to reach an individualized dose, in which the percentage of remaining 
DPD activity was used as guideline for the starting dose (expressed as percentage of 
the originally planned dose). 
Pharmacokinetic analyses in three of six patients were performed to investigate whether 
applied dose reductions were adequate. Pretreatment plasma uracil, the endogenous 
DPD substrate, and dihydrouracil levels were quantified; results were unknown before 
the start of treatment. 
RESULTS
CLINICAL COURSE OF TREATMENT
Patient characteristics are listed in Table 1. 
Patient 1. A male patient with metastatic colorectal carcinoma was scheduled for 
palliative chemotherapy (capecitabine, oxaliplatin and bevacizumab). DPYD screening 
showed that the patient was homozygous for DPYD*2A; measurement of DPD activity 
in PBMCs of this patient indicated absence of DPD activity. Therefore, it was decided to 
drastically reduce the capecitabine dose from 2,300 mg (1,000 mg/m2) twice daily to 
150 mg twice daily (6.5% of planned dose) and to start with capecitabine monotherapy. 
Seven days after the start of treatment, the patient experienced severe toxicity (grade 
3 diarrhea, grade 3 oral mucositis, and grade 4 neutropenia). Capecitabine was 
discontinued immediately. The adverse events resolved within 1 week (neutropenia) to 
2 months (diarrhea, mucositis). 
After a 2-month period without any anticancer therapy, the patient had fully recovered, 
and monotherapy with capecitabine was restarted. On the basis of the severe toxicity 
and the pharmacokinetic results of the first cycle, the dose was further reduced to 
150 mg once every 5 days (ie, 0.65% of originally planned dose). This was tolerated 
well for 1 month, but the patient then experienced diarrhea (grade 2), after which 
capecitabine was stopped for 3 weeks. The capecitabine schedule was then adjusted 
again to introduce a rest period of 5 days after every two intakes (every third intake was 
skipped). This schedule was tolerated well; thus, it was decided to add bevacizumab 
and oxaliplatin. This addition was well tolerated and resulted in stable disease as the 
best treatment response.
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Patient 2. This female patient with locally advanced colorectal carcinoma had a planned 
treatment that consisted of neoadjuvant chemotherapy (capecitabine 825 mg/m2 
twice daily, or 1,500 mg) combined with radiotherapy (5-week schedule). Pretreatment 
DPYD-screening revealed that the patient was homozygous for c.2846A>T; DPD 
activity was reduced to 29%. It was decided to reduce the capecitabine dose to 500 
mg once daily, (ie, 17% of planned dose  ̶ slightly lower than recommended dose of 29% 
on the basis of DPD activity, as decided by physician and patient). DPD activity was not 
immediately known, so chemotherapy started on day 7 of the radiotherapy schedule. 
Treatment was completed and tolerated well without occurrence of severe toxicity. 
After treatment, surgery was performed.
Patient 3. A male patient with metastatic colorectal cancer had a treatment plan to 
start capecitabine and oxaliplatin. The patient carried both c.2846A>T and c.1236G>A 
variants heterozygously. DPD activity was reduced to 45%. Remaining DPD activity was 
more than 50% reduced, so it was considered likely that this patient was a compound 
heterozygous carrier (variants present on different alleles). In the first cycle, capecitabine 
was reduced to 1,800 mg daily (51% of planned daily dose of 3,500 mg; 1,750 mg/m2), 
which was tolerated without toxicity. When the dose in cycle 2 was increased to 71% 
of planned dose (2,500 mg), grade 3 thrombocytopenia occurred. Therefore the dose 
was reduced again, to 57% of the planned dose (2,000 mg). This dose was continued 
during the third cycle. However, the patient developed grade 2 thrombocytopenia after 
8 days, and the daily capecitabine dose was adjusted to 1,000 mg for the rest of the 
cycle. Platelets increased again until normal values were reached. After three cycles, 
disease progression was established, and capecitabine treatment was discontinued.
PHARMACOKINETIC RESULTS
In all three patients, additional pharmacokinetic measurements were performed 
(Figure 1). For patient 1, only levels of capecitabine and of the metabolites 5’-deoxy-
5-fluorocytidine, 5’-deoxy-5-fluorouridine and 5-FU could be quantified; other 5-FU 
metabolites were not detectable. For patients 2 and 3, all metabolites were quantifiable. 
Results of noncompartmental analysis of the pharmacokinetic results in plasma are 
shown in Table 2 and include values normalized to control values.6 In patient 1, 5-FU 
exposure was highly increased: the mean area under the plasma concentration-
time curve (AUC) of 5-FU was 4,024 ng*h/ml, which is 10 times higher than in other 
pharmacokinetic studies with capecitabine.6–9 These results were used for the decision 
to lower the dose 10-fold in the second cycle. 
Baseline uracil and dihydrouracil levels are listed in Table 1. Results of urine analysis for 
patient 1 are shown in Supplementary Figure 1. 
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Table 1. Clinical characteristics of patients 1 through 6
Characteristic Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
DPYD genotype homozygous
DPYD*2A 
homozygous 
c.2846A>T 
heterozygous 
for c.2846A>T 
& c.1236G>A 
homozygous 
c.2846A>T 
homozygous 
c.1236G>A
homozygous 
c.1236G>A
Sex Male Female Male Female Female Female
Age (years) 47 52 61 69 75 58
Body surface area (m2) 2.3 1.8 2.0 1.5 1.8 1.5
Ethnicity White White White White White White
Tumor type CRC 
(metastatic)
CRC (locally 
advanced)
CRC 
(metastatic)
CRC (local) Vulva 
carcinoma 
(locally 
advanced)
Breast 
cancer (local) 
WHO performance status 0 0 1 0 1 0
Baseline DPD activity in 
PBMCs (nmol/(mg*h), % 
of reference activity
<LLOQ a (0%) 2.9 b (29%) 4.5 b (45%) 0.97 a (10%) 7.8 b (79%) 4.2 b (42%)
Baseline uracil level (ng/
ml) c
1,920 28.7 35.6 ND 14.5 26.8
Baseline dihydrouracil 
level (ng/ml) c
<LLOQ 71.7 114 ND 104 164
Treated with 
fluoropyrimidines d
Yes: C1 6.5% 
of planned 
dose (severe 
toxicity), 
then 10-fold 
reduction 
to 0.65% of 
planned dose 
Yes: 17% of 
planned dose 
Yes: C1 51% of 
planned dose, 
C2 72%, C3 
57%
No: disease 
free after 
surgery
Yes: C1 75% 
of planned 
dose; C2 
100%
Yes: 50% of 
planned dose 
(5-FU)
a Measured according to method by Pluim et al.25 Reference DPD activity: 9.6 ± 2.2 nmol/(mg*h).25
b Measured according to method by Van Kuilenburg et al.26 Reference DPD activity: 9.9 ± 2.8 nmol/(mg*h).14
c Reference baseline uracil level: median 8.32 ng/ml, range 3.2 to 38.2 ng/ml, reference baseline dihydrouracil 
level: median 91.9 ng/ml, range 31.9 to 189.0 ng/ml. Both were determined in a cohort of 550 patients.27
d The amount of dose reduction and clinical course for patients 1, 2, and 3 are described in detail in the main 
article. Details for patients 4, 5, and 6 are described in the Supplementary Results. Abbreviations: C1: cycle 1; 
C2: cycle 2; C3: cycle 3; CRC: colorectal carcinoma; DPD: dihydropyrimidine dehydrogenase; LLOQ: lower 
limit of quantification; ND: not determined; PBMCs: peripheral blood mononuclear cells; 5-FU: 5-fluorouracil. 
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Table 2. Pharmacokinetic parameters of capecitabine and metabolites in plasma of patients 1 
through 3
Metabolite AUC
0-last time point
 (ng*h/ml) a     T
1/2
 (h) a
Patient 1 b Patient 1 normalized f Patient 2 c Patient 2 normalized f Patient 3 d Patient 3 normalized f Mean (CV%) control 
value e
Patient 1 b Patient 2 c Patient 3 d Mean (CV%) control 
value e
Capecitabine 296 (195 – 387) 3,871 1,186 3,626 3,357 7,134 4,281 (31%) 0.41 (0.24 – 0.61) 0.51 0.41 0.76 (55%)
5’-dFCR 1,310 (960 – 1,495) 17,131 2,445 7,476 3,198 6,796 8,192 (30%) 0.83 (0.70 – 1.04) 0.84 0.44 1.0 (35%)
5’-dFUR 1,257 (1,224 – 1,308) 16,438 4,139 12,655 2,912 6,188 7,673 (29%) 0.99 (0.76 – 1.26) 0.55 0.55 0.9 (34%)
5-FU 4,024 (3,795 – 4,351) 52,622 1,079 3,299 407 865 381 (40%) 5.31 (4.91 – 6.07) 0.39 0.57 1.0 (57%)
5-FU relative 
exposure g
1.1 - 1.4 - 1.1 - 1 (reference) - - - -
FUH
2
<LLOQ <LLOQ 1,112 3,303 1,318 2,718 ND <LLOQ 0.59 0.72 ND
FUPA <LLOQ <LLOQ 476 1,414 740 1,526 ND <LLOQ 2.01 1.84 ND
FBAL <LLOQ <LLOQ 4,106 12,195 6,979 14,394 14,177 (31%) <LLOQ 2.12 2.49 2.6 (33%)
a For patient 1, the mean values of three intakes (C1D1, C2D1, and C2D16) are reported, including range. The 
ingested dose was the same (150 mg) for all three days. For patients 2 and 3, the values of the first intake are 
reported. 
b Patient 1 was a homozygous DPYD*2A variant allele carrier. Results depicted are after an intake of 150 mg 
capecitabine (65 mg/m2). 
c Patient 2 was a homozygous c.2846A>T variant allele carrier. Results depicted are after an intake of 500 mg 
capecitabine (278 mg/m2). 
d Patient 3 was a heterozygous carrier of both c.2846A>T and c.1236G>A. Results depicted are after an intake 
of 800 mg (400 mg/m2). 
e Control values are derived from Deenen et al.6 and are the mean values and CV% for patients with advanced 
cancer of the stomach or gastresophageal junction (N=22), after administration of 850 mg/m2 capecitabine 
(dose level 2 of the study). Capecitabine and metabolite control values are measured using the same assay as 
for patients 1, 2, and 3.
f Normalized AUC values (normalized AUC = AUC * (850 mg/m2 / administered dose in mg/m2)
g For the 5-FU AUC, the relative exposure is depicted, corrected for the dosing interval. 5-FU relative exposure 
=5-FU AUC / (factor * 5-FU AUC from Deenen et al.6). Factor patient 1 = 10 (as dosing 1x in the 5 days), factor 
patient 2 = 2 (as dosing once daily), factor patient 3 = 1 (as dosing twice daily). 
Abbreviations: 5’-dFCR: 5’-deoxy-5-fluorocytidine; 5’-dFUR: 5’-deoxy-5-fluorouridine; AUC: area under the 
curve; CV%: coefficient of variation; C1D1: cycle 1 day 1; C2D1: cycle 2 day 1; C2D16: cycle 2 day 16; FBAL: 
fluoro-β-alanine; FUH
2
: dihydro-5-fluorouracil; FUPA: α-fluoro-ureidopropionic acid; LLOQ: lower limit of 
quantification; ND: not determined; T
1/2
: half-life; 5-FU: 5-fluorouracil.
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Table 2. Pharmacokinetic parameters of capecitabine and metabolites in plasma of patients 1 
through 3
Metabolite AUC
0-last time point
 (ng*h/ml) a     T
1/2
 (h) a
Patient 1 b Patient 1 normalized f Patient 2 c Patient 2 normalized f Patient 3 d Patient 3 normalized f Mean (CV%) control 
value e
Patient 1 b Patient 2 c Patient 3 d Mean (CV%) control 
value e
Capecitabine 296 (195 – 387) 3,871 1,186 3,626 3,357 7,134 4,281 (31%) 0.41 (0.24 – 0.61) 0.51 0.41 0.76 (55%)
5’-dFCR 1,310 (960 – 1,495) 17,131 2,445 7,476 3,198 6,796 8,192 (30%) 0.83 (0.70 – 1.04) 0.84 0.44 1.0 (35%)
5’-dFUR 1,257 (1,224 – 1,308) 16,438 4,139 12,655 2,912 6,188 7,673 (29%) 0.99 (0.76 – 1.26) 0.55 0.55 0.9 (34%)
5-FU 4,024 (3,795 – 4,351) 52,622 1,079 3,299 407 865 381 (40%) 5.31 (4.91 – 6.07) 0.39 0.57 1.0 (57%)
5-FU relative 
exposure g
1.1 - 1.4 - 1.1 - 1 (reference) - - - -
FUH
2
<LLOQ <LLOQ 1,112 3,303 1,318 2,718 ND <LLOQ 0.59 0.72 ND
FUPA <LLOQ <LLOQ 476 1,414 740 1,526 ND <LLOQ 2.01 1.84 ND
FBAL <LLOQ <LLOQ 4,106 12,195 6,979 14,394 14,177 (31%) <LLOQ 2.12 2.49 2.6 (33%)
a For patient 1, the mean values of three intakes (C1D1, C2D1, and C2D16) are reported, including range. The 
ingested dose was the same (150 mg) for all three days. For patients 2 and 3, the values of the first intake are 
reported. 
b Patient 1 was a homozygous DPYD*2A variant allele carrier. Results depicted are after an intake of 150 mg 
capecitabine (65 mg/m2). 
c Patient 2 was a homozygous c.2846A>T variant allele carrier. Results depicted are after an intake of 500 mg 
capecitabine (278 mg/m2). 
d Patient 3 was a heterozygous carrier of both c.2846A>T and c.1236G>A. Results depicted are after an intake 
of 800 mg (400 mg/m2). 
e Control values are derived from Deenen et al.6 and are the mean values and CV% for patients with advanced 
cancer of the stomach or gastresophageal junction (N=22), after administration of 850 mg/m2 capecitabine 
(dose level 2 of the study). Capecitabine and metabolite control values are measured using the same assay as 
for patients 1, 2, and 3.
f Normalized AUC values (normalized AUC = AUC * (850 mg/m2 / administered dose in mg/m2)
g For the 5-FU AUC, the relative exposure is depicted, corrected for the dosing interval. 5-FU relative exposure 
=5-FU AUC / (factor * 5-FU AUC from Deenen et al.6). Factor patient 1 = 10 (as dosing 1x in the 5 days), factor 
patient 2 = 2 (as dosing once daily), factor patient 3 = 1 (as dosing twice daily). 
Abbreviations: 5’-dFCR: 5’-deoxy-5-fluorocytidine; 5’-dFUR: 5’-deoxy-5-fluorouridine; AUC: area under the 
curve; CV%: coefficient of variation; C1D1: cycle 1 day 1; C2D1: cycle 2 day 1; C2D16: cycle 2 day 16; FBAL: 
fluoro-β-alanine; FUH
2
: dihydro-5-fluorouracil; FUPA: α-fluoro-ureidopropionic acid; LLOQ: lower limit of 
quantification; ND: not determined; T
1/2
: half-life; 5-FU: 5-fluorouracil.
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Figure 1. Pharmacokinetic results in plasma of patients 1, 2, and 3
Results of plasma levels of capecitabine (A) and the metabolites 5’-deoxy-5-fluorocytidine (5’-
dFCR, B), 5’-deoxy-5-fluorouridine (5’-dFUR, C), 5-fluorouracil (5-FU, D), dihydro-5-fluorouracil 
(FUH
2
, E), α-fluoro-ureidopropionic acid (FUPA, F) and fluoro-β-alanine (FBAL, G). For all three 
patients, the results after the first intake of capecitabine are depicted. 
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DISCUSSION
To our knowledge, this is the first report to describe prospectively identified patients, 
who are homozygous or compound heterozygous for DPYD variants, who could be 
treated safely with fluoropyrimidines. Multiple occurrences of fatal or life-threatening 
toxicity after fluoropyrimidine treatment have been described and, retrospectively, the 
patients who experienced these toxicities were identified as homozygous DPYD variant 
carriers who had complete DPD deficiency.10–15
Pretreatment identification of the patient homozygous for DPYD*2A with complete 
DPD deficiency saved this patient from receipt of a full fluoropyrimidine dose, which 
most likely would have been fatal. We hypothesized that a dose of 5 to 10% would be 
well tolerated by this patient, because this percentage is usually excreted unchanged 
in urine.16 However, this dose still resulted in severe toxicity. We showed, though, that 
treatment with an extremely low dose of capecitabine (0.65% of standard dose) was safe 
and feasible. Baseline uracil levels were extremely high, which confirmed the expected 
absent enzyme activity. Also, pharmacokinetic results showed that 5-FU could not be 
metabolized further, because the 5-FU half-life and exposure were highly increased. 
Urine results of this patient differed from results described elsewhere. In patients who 
are not DPD deficient, FBAL is the major urinary metabolite,9,17 whereas this metabolite 
was not present in the urine analyzed in this paper. Evidence about pharmacokinetic-
based dosing for capecitabine is limited. However, for 5-FU, dosing based on plasma 
levels is described more extensively.18,19
The two patients who had a homozygous c.2846A>T genotype and a c.2846A>T/
c.1236G>A genotype had a partial remaining DPD activity. Pharmacokinetic results 
showed that administration of a moderately reduced dose of capecitabine resulted in 
adequate exposure. 
A variation in retained DPD activity in the two carriers of the homozygous c.1236G>A 
variant was determined. This is in contrast to results by Meulendijks et al. in which DPD 
activity was reduced approximately 50% in two patients.20 The c.1236G>A variant is 
part of haplotype B3, of which the intronic variant c.1129-5923C>G is expected to be 
responsible for the effect on DPD activity.21 Nie et al. showed that this intronic variant 
resulted in a 35% reduction of DPD enzyme function.22 
Because patients only underwent genotyping for four DPYD variants, the effects of 
additional deleterious DPYD variants cannot be ruled out. For example, MIR27A 
polymorphisms could play a role in variation of DPD activity, because these 
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polymorphisms reduce DPD activity.23,24 
In conclusion, we showed that fluoropyrimidine treatment in homozygous or 
compound heterozygous DPYD variant allele carriers is feasible and that therapy does 
not have to be withheld. Additional DPD phenotyping tests, such as measurement of 
DPD activity in PBMCs, are recommended to compose an individualized treatment. 
After an initial dose reduction, tolerability in patients should be monitored closely, and 
the dose should be individually titrated according to tolerance. 
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SUPPLEMENTARY INFORMATION
SUPPLEMENTARY METHODS
PATIENTS
Patients were treated at three different institutes in the Netherlands (the Netherlands 
Cancer Institute, Amsterdam; Erasmus Medical Center, Rotterdam; Fransciscus Gasthuis 
& Vlietland, Rotterdam). Toxicity was scored according to the Common Terminology 
Criteria for Adverse Events (CTC-AE) version 4.03.
DPYD GENOTYPING
Genomic DNA was isolated from peripheral blood cells and screening for the DPYD 
variants DPYD*2A (IVS14+1G>A, rs3918290), c.2846A>T (rs67376798), c.1679T>G 
(DPYD*13, rs55886062), and c.1236G>A (rs56038477) was performed using standard 
operating procedures in two different institutes (the Netherlands Cancer Institute, 
Amsterdam and Erasmus Medical Center, Rotterdam). This screening was performed 
before treatment as part of routine clinical care. In the Netherlands Cancer Institute, 
screening for DPYD variants was performed with the Roche LightCycler® 480II 
platform (Roche Diagnostics, Almere, the Netherlands) by using commercially available 
probes and primers (TIB Molbiol, Berlin, Germany), and results were confirmed by 
direct sequencing. At the Erasmus Medical Center, each sample was genotyped on two 
different platforms  ̶ Taqman (with predefined Drug metabolizing Enzyme (DME) assays) 
and PCR-restriction fragment length polymorphism (RFLP) assays  ̶ to allow checks for 
potential wrong genotyping. Details about the assays are included in Supplementary 
Table 1. Wild type, heterozygous, and no template controls were included in each run. 
Both laboratories participated during the study in the Dutch national quality control 
program for DPYD proficiency testing (SKML), in which all four DPYD variants were 
included. 
DPD ACTIVITY IN PBMCs
Dihydropyrimidine dehydrogenase (DPD) activity was measured in peripheral blood 
mononuclear cells (PBMCs), isolated from a baseline (pretreatment) peripheral blood 
sample. One of two comparable validated methods by Van Kuilenburg et al. or Pluim 
et al. was used; both used radio-labeled thymine (14C-labeled thymine or 3H-labeled 
thymine) as a substrate and consisting of high performance liquid chromatography 
(HPLC) with online radioisotope detection and with liquid scintillation counting.1,2 
Reference values for both assays were highly comparable, respectively 9.9 ± 2.8 nmol/
(mg*h) for the method of Van Kuilenburg et al.2 and 9.6 ± 2.2 nmol/(mg*h) for the 
method of Pluim et al.1
133
6
TREATMENT ALGORITHM FOR HOMOZYGOUS OR COMPOUND HETEROZYGOUS  DPYD VARIANT CARRIERS
URACIL AND DIHYDROURACIL PLASMA LEVELS
Endogenous uracil and dihydrouracil levels were quantified in a baseline (pretreatment) 
plasma sample by using a validated ultra-performance liquid chromatography – 
tandem mass spectrometry (UPLC-MS/MS) method.3 Analytes were extracted by 
protein precipitation; chromatographic separation was performed on an Acquity UPLC 
HSS T3 column (Acquity Waters, Milford, MA) and were analyzed with MS/MS with 
an electrospray ionization source.3 All samples were measured at one institute (The 
Netherlands Cancer Institute).
PHARMACOKINETIC MEASUREMENTS
Peripheral blood samples for patient 1 were obtained for pharmacokinetic analysis on 
cycle 1, day 1 (C1D1); cycle 2, day 1 (C2D1); and cycle 2, day 16 (C2D16). Samples on 
those 3 days were collected at 10 time points up to 10 hours after capecitabine intake 
(at predose, and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 
8 hours, and 10 hours after capecitabine intake). For patients 2 and 3, samples were 
collected only on C1D1, on the same time points as for patient one, except for the 
latest time point (the sample 10 hours after capecitabine intake was not collected for 
patient 2 and the last sample was collected at 12 hours instead of 10 hours for patient 
3). For patient 1, pharmacokinetic results of the cycle one were known before the start 
of cycle two. For patients 2 and 3, pharmacokinetic results were not known during 
treatment, because samples were analyzed after treatment had finished.
Capecitabine and its metabolites 5’-deoxy-5-fluorocytidine (5’-dFCR), 5’-deoxy-5-
fluorouridine (5’-dFUR), 5-fluorouracil (5-FU), dihydro-5-fluorouracil (FUH
2
), α-fluoro-
ureidopropionic acid (FUPA) and fluoro-β-alanine (FBAL), were quantified by using 
HPLC coupled to electrospray MS/MS. Two individual validated assays were used, 
one for the simultaneous quantification of capecitabine, 5’-dFCR and 5’-dFUR, and 
another for 5-FU, FUH
2
, FUPA and FBAL.4 In addition, for patient 1, urine samples were 
collected for additional analysis on C2D1 and C2D16. Urine was collected per portion 
from predose up to 10 hours after capecitabine intake on both days. The same HPLC-
MS/MS method as for plasma samples was used. Urine samples were diluted 20 times 
in blank plasma before additional sample pretreatment. All pharmacokinetic samples 
were measured at the same institute (The Netherlands Cancer Institute).
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Supplementary Table 1. DPYD genotyping assays.
DPYD SNP Rs-number PCR-RFLP forward primer PCR-RFLP reverse 
primer
Enzyme Taqman DME 
assay 
*2A 
(IVS14+1G>A)
rs3918290
5’-CTTGTTTTAGATGTTAAAT-
CACACATA - 3’
5’- CTTGTTTTAGATGT-
TAAATCACACATA - 3’
NdeI C__30633851_20
c.1679T>G rs55886062
5’- 
CCAGCTTCAAAAGCTCTTC- 3’
5’- CTTCCGTTTCTGC-
CAAGC -3’
TFiI C_11985548
c.1236G>A rs56038477
5’- CACTGTACCTTTAGGAT-
CAC - 3’
5’- ATGCAGTTTGTTC-
GGACTGA -3’
Ddel C_25596099
c.2846 A>T rs67376798
5’- CATAGCATTCTAATTC-
CAGC - 3’
5’- CAAGTTGTGGC-
TATGATCG -3’
Taqa1 C_27530948
Abbreviations: DME: drug metabolizing enzyme; PCR-RFLP: polymerase chain reaction - restriction fragment 
length polymorphism; Rs: reference SNP number; SNP: single nucleotide polymorphism.
SUPPLEMENTARY RESULTS
DIHYDROURACIL-URACIL LEVELS
Together with the sample for DPD activity in PBMCs, a pretreatment plasma sample was 
taken to measure uracil and dihydrouracil levels (Table 1). For patient 1, the baseline 
uracil plasma level was extremely high (1,920 ng/ml) compared with reference levels 
(median 8.32 ng/ml; range 3.2 to 38.2 ng/ml, N = 550),5 and no dihydrouracil could be 
detected. For patients 2 and 3, uracil levels increased compared with reference levels (a 
value of 28.7 ng/ml for patient 2 and of 35.6 ng/ml for patient 3), and both values were 
within the top 1% of reference values. Dihydrouracil levels were in the normal range for 
patients 2 and 3, compared to reference levels. 
OTHER HOMOZYGOUS DPYD VARIANT ALLELE CARRIERS
Three additional patients with a homozygous DPYD variant genotype were identified 
during routine DPYD-screening (Table 1). In these patients, DPD activity in PBMCs was 
measured pretreatment also and was used to determine the level of dose reduction. 
Two out of three patients (patients 5 and 6) were homozygous for the c.1236G>A 
variant. DPD activity varied between these two patients, from approximately 42% to 
79% residual activity. The two patients both received reduced fluoropyrimidine doses 
without occurrence of severe toxicity. It is unclear why there is a relatively high variation 
of the effect of this genotype on DPD phenotype in patients, and more research on this 
variant is advised.
In addition, one patient with a homozygous c.2846A>T genotype (patient 4) was 
identified. The residual DPD activity in this patient was approximately 10%. This patient 
was disease free after surgery, so it was decided not to treat this patient with adjuvant 
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chemotherapy. The remaining activity of patient 4 was lower than of patient 2, who 
had the same DPYD genotype and who had a residual activity of 29%. According to the 
calculated DPD activity score, as described by Henricks et al.,6 it could be concluded 
that a 50% dose reduction would be appropriate for homozygous c.2846A>T carriers, 
because a 25% dose reduction is recommended for heterozygous carriers of this 
variant. However, on the basis of the DPD activity results in these two patients, this 
amount of dose reduction seems insufficient for homozygous c.2846A>T carriers. 
Pharmacokinetic results in patient 2 showed that the normalized area under the plasma 
concentration-time curve (AUC) of 5-FU was 3,299 ng*h/ml, which is nine-fold higher 
than the mean control value of Deenen et al.,7 which showed that 5-FU clearance 
might be impaired more than expected on the basis of the value of 29% remaining DPD 
activity in PBMCs. 
Supplementary Figure 1. Pharmacokinetic results in urine of patient 1 
Patient 1 was a homozygous DPYD*2A carrier. Results of urine excretion on cycle 2 day 1 (C2D1, 
A) and cycle 2 day 16 (C2D16, B) of capecitabine and the metabolites 5’-deoxy-5-fluorocytidine 
(5’-dFCR), 5’-deoxy-5-fluorouridine (5’-dFUR), 5-fluorouracil (5-FU) and of the total excretion, 
after intake of 150 mg capecitabine. Excretion was calculated as a percentage of the administered 
dose of capecitabine.
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ABSTRACT 
Since the clinical introduction in 1998, the topoisomerase I inhibitor irinotecan is 
widely used in the treatment of solid tumors including colorectal, pancreatic, and 
lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and 
by large inter-individual pharmacokinetic variability. Irinotecan has a highly complex 
metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-
38, which is 100-1,000 fold more active compared to irinotecan itself. Several phase 
I and phase II enzymes, including CYP3A4 and UGT1A, are involved in the formation 
of inactive metabolites, making its metabolism prone to environmental and genetic 
influences. Genetic variants in the DNA of these enzymes and transporters could predict 
a part of the drug related toxicity and efficacy of treatment. This has been shown in 
retrospective and prospective trials and meta-analyses. Patient characteristics, life-
style and co-medication also influence irinotecan pharmacokinetics. Other factors, 
including dietary restriction, are currently studied. Meanwhile, a more tailored 
approach to prevent excessive toxicity and optimize efficacy is warranted. This review 
provides an updated overview on today’s literature on irinotecan pharmacokinetics, 
pharmacodynamics, and pharmacogenetics.
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INTRODUCTION 
Irinotecan (CPT-11) is a camptothecin derivative that demonstrates anti-cancer activity 
in many solid tumors. Currently, it is widely used in the treatment of colorectal, 
pancreatic, and lung cancer. Irinotecan is the prodrug for SN-38, which inhibits 
topoisomerase-I, an enzyme involved in DNA replication.1, 2 SN-38 is 100-1,000 fold 
more cytotoxic than irinotecan, and its exposure is highly variable.3 SN-38 is inactivated 
by further enzymatic conversion into SN-38 glucuronide (SN-38G).
PHARMACOKINETICS 
DISTRIBUTION
Irinotecan is a hydrophilic compound with a large volume of distribution estimated at 
almost 400 L/m2 at steady state.4 At physiological pH, the lactone-ring of irinotecan 
and SN-38 can be hydrolyzed to a carboxylate isoform (Figure 1). Consequently, a 
pH-dependent equilibrium between these forms exists.5 As only the lactone form has 
antitumor activity, a small change in pH could alter the pharmacokinetics and efficacy 
of irinotecan.6 In plasma, however, the carboxylate form of irinotecan and the lactone 
form of SN-38 dominate.7, 8 This could be explained by a higher tissue distribution of 
irinotecan lactone and the preferential binding of SN-38 lactone to plasma proteins.4, 9 
Conversion of irinotecan lactone to carboxylate within the circulation is rapid with an 
initial half-life between 9-14 minutes, which results in a 50% reduction in irinotecan 
lactone concentration after 2.5 hours, compared to end of infusion (66% versus 35%).4, 7, 8
After end of drug infusion, a rapid decrease in irinotecan plasma concentrations is seen. 
Peak concentrations of SN-38 are reached within two hours after infusion.8 Irinotecan 
is assumed to exhibit linear pharmacokinetics because of the correlation between dose 
and systemic exposure, which is highly variable between patients.[8] In plasma, the 
majority of irinotecan and SN-38 is bound to albumin, which has a stronger binding 
capacity for the more hydrophobic active metabolite, and albumin also stabilizes the 
lactone forms of irinotecan and SN-38.10 In blood, SN-38 is almost completely bound 
and for two-third located in platelets and in – predominantly – red blood cells.11 The 
binding constant of SN-38 with erythrocytes is almost fifteen times higher than that of 
irinotecan.11 
Thus far, several population pharmacokinetic models of irinotecan have been developed. 
All models confirmed the large inter-individual variability in pharmacokinetic parameters 
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of around 30%. In general, a three-compartmental model for irinotecan and a two-
compartmental model for SN-38 is assumed.4, 12-16 A mean SN-38 distribution half-life 
was estimated to be very short (approximately 8 minutes).13 Several models showed 
a second peak in the SN-38 plasma AUC, which was explained by an enterohepatic 
re-circulation of SN-38. SN-38 is reabsorbed after intestinal deconjugation of SN-38G 
by (bacterial) β-glucuronidases.15 Alternatively, release of SN-38 from erythrocytes has 
also been proposed to cause this second plasma peak.17
Figure 1. pH-dependent equilibrium of irinotecan and SN-38 isoforms
METABOLISM
Metabolism by carboxylesterases and butyrylcholinesterase
The prodrug irinotecan is hydrolyzed into the active metabolite SN-38 by two 
isoforms of carboxylesterases (CES1 and 2) and butyrylcholinesterase in the human 
body (Figure 2).18, 19 CES1 and CES2 are localized in liver, colon, kidney and blood 
cells. Butyrylcholinesterase is mainly found in plasma.20 Conversion by these esterases 
mainly occurs intra-hepatically and is a relatively slow and inefficient process, as only 
2-5% of irinotecan is converted into SN-38.12, 18 CES2 has a 12.5-fold higher affinity for 
irinotecan than CES1 and is therefore the predominant enzyme in this conversion.21-23 
In addition, this process also occurs in blood, where butyrylcholinesterase has a six-
fold higher activity than CES.20 After conversion, SN-38 is actively transported into the 
liver by the OATP1B1 transporter (Figure 2).24
Many studies have investigated intratumoral CES activity, by which irinotecan can be 
activated at the site of action. Indeed, the amount of CES activity could be related 
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to irinotecan efficacy, although preclinical work showed conflicting results.25-30 Many 
preclinical studies have been performed to selectively increase the intratumoral CES 
activity with a virus or engineered stem cells, thereby aiming to increase irinotecan 
efficacy.31-38 Although a few studies could indeed reverse irinotecan resistance in vitro 
and in mice, this mechanism has not been investigated in a clinical setting (yet). 
To our knowledge, no clinically relevant drug-drug interactions (DDIs) involving CES 
have been reported for irinotecan, although both inhibitors and inducers of CES have 
been described, which could potentially influence the rate of irinotecan conversion to 
SN-38.39
Figure 2 Irinotecan metabolism and excretion
* = active metabolite. Abbreviations: CES = carboxylesterase; BES = butyrylcholinesterase; CYP = cytochrome 
P450 enzymes; UGT = uridine diphosphate glucronosyltransferase; β-gluc = beta-glucuronidase
Metabolism by uridine diphosphate glucuronosyltransferases
SN-38 is inactivated via glucuronidation to SN-38G by uridine diphosphate 
glucuronosyl-transferase (UGT) and excreted into the bile.40, 41 Several UGT subtypes 
are involved in the hepatic (UGT1A1, UGT1A9) and extrahepatic (UGT1A1, UGT1A7, 
UGT1A10) conversion of SN-38, of which UGT1A1, UGT1A7 and UGT1A9 are the major 
iso-enzymes.42-46 SN-38G is formed almost directly after SN-38 formation, explaining 
the short half-life of SN-38.47 Plasma concentrations of SN-38G are the highest 
amongst all irinotecan metabolites, suggesting a highly efficient glucuronidation rate 
of SN-38 into SN-38G.4 UGT1A1 also conjugates bilirubin, and a significant correlation 
between SN-38 and bilirubin glucuronidation has been observed.42 In addition, patients 
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genetically predisposed with decreased UGT1 activity, e.g. in Gilbert’s syndrome, are 
at higher risk for severe toxicity when treated with irinotecan.48 Also, many other UGT 
polymorphisms have been described and their influence on irinotecan pharmacokinetics 
and pharmacodynamics is summarized in section 4. 
Metabolism by cytochrome P450 enzymes
Irinotecan is also metabolized by intrahepatic cytochrome P450 (CYP) enzymes, i.e. 
CYP3A4 and CYP3A5, into inactive metabolites: APC and NPC.49 In contrast to APC, 
NPC can be converted to SN-38 by CES1 and CES2 in the liver but to a lesser amount 
than irinotecan.50 The importance of CYP3A4 and CYP3A5 in irinotecan metabolism 
is underlined by the strong correlation between irinotecan clearance and midazolam 
clearance.51 Midazolam is an important CYP3A probe drug, and we previously 
conducted a randomized clinical trial aiming to individualize irinotecan dosing by 
use of an CYP3A4 phenotype-based algorithm. By dosing on this algorithm the inter-
individual variability in irinotecan and SN-38 exposure dramatically reduced compared 
to conventional dosing.52 In addition, smoking, some herbal supplements, and co-
medication are known to induce or inhibit CYP3A enzymes, resulting in interactions 
with irinotecan, which are summarized in more detail in section 2.5.
Metabolism by β-glucuronidases
As mentioned before, SN-38G can be deconjugated into SN-38 by β-glucuronidases 
produced by intestinal bacteria, which could result in an enterohepatic circulation of 
SN-38.15, 53-55 In addition, β-glucuronidase activity has been correlated to intestinal 
damage and diarrhea in rats/mice, which could (potentially) be reduced by inhibiting 
β-glucuronidase with antibiotics (penicillin and streptomycin) or with amopaxine.56, 57 
Nonetheless, attempts to reduce β-glucuronidase activity by neomycin did not alter 
irinotecan pharmacokinetic profile in patients significantly.58
ELIMINATION
Clearance of irinotecan is mainly biliary (66%) and independent of dose, estimated at 
12-21 L/h/m2.59, 60 Irinotecan is transported into the bile by several ATP-binding cassette 
transporters (i.e. ABCB1, ABCC2, and ABCG2, see Figure 2).61-63 In addition, active efflux 
by ABCB1 has been shown to lead to low intracerebral irinotecan concentrations 
in mice.64 All metabolites except for SN-38G, are predominately excreted in feces, 
although they are also detectable in urine.4, 59 Terminal elimination half-lives (t
1/2
) 
between 5-18 hours for irinotecan and between 6-32 hours for SN-38 were reported.4, 
12-14, 59, 65-71 However, later it was shown that the t
1/2
 was initially underestimated, as up to 
500 hours after infusion SN-38 concentrations can be detected.72, 73
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The wide inter-individual variability in irinotecan clearance is still not completely 
understood. Primarily, a decreased clearance in patients with altered hepatic function 
has been described.12, 13 Additionally, increasing age may negatively influence irinotecan 
clearance, although this could not be confirmed in another analysis.13, 74 Conflicting 
effects of gender on irinotecan pharmacokinetics have also been proposed. Several 
studies reported higher irinotecan exposure in women, which – in part – could be 
explained by decreased SN-38 (metabolic) clearance 13, 59, 75, while others found no 
gender effect.4, 74, 76 Several factors such as dose, timing of administration, enzyme-
activity, and hematocrit levels might be responsible for these differences. In addition, 
firm conclusions can neither be drawn for weight.13, 77 Worse clinical performance 
has been demonstrated to decrease irinotecan clearance.13 However, inter-individual 
variability does not seem to be related to body size measures as body-surface area 
(BSA). Although irinotecan dose is generally based on BSA, it has been shown that BSA 
and other body size measures do not predict irinotecan pharmacokinetics, and that 
flat-fixed dosing could be a safe alternative.74, 78
OTHER FORMULATIONS AND ADMINISTRATIONS
Other formulations
Also, several other irinotecan formulations have been evaluated. Firstly, oral 
administration of several different formulations has been investigated and deemed 
feasible in phase-I trials 79-81, but its poor and highly variable bioavailability have limited 
its current clinical usability.82 
Secondly, irinotecan drug-eluting beads (DEBIRI) have been developed to control 
drug release and is mostly used as regional administration. DEBIRI administered 
into the hepatic artery resulted in higher and prolonged intratumoral irinotecan and 
SN-38 exposure in liver metastases, whereas systemic exposure was lower than 
after intravenous administration.83-85 Hepatic arterial infusion of DEBIRI has been 
demonstrated to be an effective treatment for unresectable liver metastases.86
Thirdly, liposomal irinotecan has been developed and is clinically used. Encapsulated 
into liposomes, irinotecan is stable for a longer period of time, resulting in increased 
accumulation in tumor tissue and thereby increasing its effect, as described further in 
section 3.2.87 
Other variations in administration
Irinotecan administration based on circadian timing improved clinical outcome in 
several clinical trials 88-90, probably due to circadian rhythm of enzymes and transporters 
involved in irinotecan pharmacokinetics and pharmacodynamics.91-93  However, 
pharmacokinetic consequences have only been investigated in a small randomized 
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study, in which an increased metabolic ratio (SN-38  / irinotecan AUC) and smaller 
interindividual variability were found after circadian-timed dosing.94 
Trials on two different – more regional infusion methods – have been conducted. 
Firstly, locoregional therapy with irinotecan infusion into the hepatic artery has been 
evaluated for the treatment of unresectable liver metastases: different irinotecan 
formulations have been demonstrated to be safe and effective.95, 96 This approach 
resulted in lower systemic exposure to irinotecan and an increased conversion of 
irinotecan into SN-38 compared to intravenously administered irinotecan.97  Secondly, 
use of irinotecan as hyperthermic intraperitoneal chemotherapy (HIPEC) has been 
investigated as treatment option for colorectal peritoneal metastases.98-103 A small 
fraction of irinotecan is rapidly converted intraperitoneally into SN-38: systemic C
max
 
of SN-38 has been observed 30 minutes after intraperitoneal administration.98, 100 
Although these different administration methods are investigated for several years, 
there is yet insufficient evidence that it could be beneficial to implement these 
strategies in daily care.
DRUG-DRUG INTERACTIONS (DDIs)
DDIs with anti-cancer drugs
Many anticancer agents have been investigated in combination with irinotecan, of 
which no significant pharmacokinetic interactions with irinotecan have been reported 
for oxaliplatin, 5-fluorouracil (5-FU) / leucovorin, capecitabine and monoclonal 
antibodies.66, 70, 104-123 In contrast, paclitaxel combined with irinotecan in a 3-weekly 
regimen caused a significant increase of irinotecan, SN-38 and SN-38G exposure, 
which was assumed to be caused by competitive inhibition of ABCB1 (Table 1).124 
Sequencing the administration of paclitaxel after  irinotecan seems to improve their 
synergistic anticancer effects125, but irinotecan pharmacokinetics is not significantly 
altered in either sequence. 125, 126 Systemic SN-38 exposure was found to be reduced in 
patients concomitantly treated with tegafur (S-1) or carboplatin127-129, of which the latter 
also reduced irinotecan exposure. Patients seemed to tolerate irinotecan better when 
thalidomide was co-administered in two phase II studies, in which SN-38G exposure 
was increased at the expense of SN-38 exposure.130 However, the pharmacokinetic 
differences could not be replicated131, 132 and might be caused by confounding, as half 
of the patients also used antiepileptic drugs (AEDs).130 
Tyrosine kinase inhibitors (TKIs) have become very popular in cancer treatment, but 
are also known for their modulating effects on drug metabolizing enzymes.133 Several 
TKIs, i.e. imatinib, pazopanib, sunitinib, lapatinib and gefitinib, have been investigated 
in combination with irinotecan containing regimens.134-141 All of these combinations, 
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except for pazopanib and lapatinib, led to excessive toxicity and have therefore not 
been evaluated further for clinical use. Increased exposure to irinotecan or SN-38, 
due to inhibition of CYP3A4, ABCB1 or ABCG2, has been suggested as a cause of the 
intolerance of irinotecan combined with TKIs, but a pharmacodynamic interaction 
cannot be ruled out.
DDIs with non-anticancer drugs
Concomitant treatment with non-anticancer drugs such as anti-epileptic agents, 
certain antidepressants, antiretroviral drugs, and NSAIDs have been shown to affect 
irinotecan pharmacokinetics or pharmacodynamics. The combination with the 
potent CYP3A4 inhibitor ketoconazole was one of the first significant DDIs described 
for irinotecan (Table 1).142 Anecdotally, severe rhabdomyolysis syndrome has been 
described in a patient using irinotecan and citalopram.143 Although pharmacokinetic 
data were not available, competitive metabolism by CYP3A4 was suspected as the 
underlying mechanism. Hypothetically, other strong CYP3A4 inhibiting antidepressants 
such as nefazodone could be suspected for an interaction with irinotecan.144  
AEDs are also known for inducing CYP3A, UGTs and CES.145 The influence of phenytoin, 
phenobarbital, and carbamazepine on irinotecan pharmacokinetics was evaluated 
in a population pharmacokinetic model, which suggested that patients using these 
AEDs should receive a 1.7 times higher irinotecan dose to reach the same exposure 
as in patients without AEDs.75 Individual patients may require an even higher dose, 
as indicated by a four-fold higher irinotecan clearance and ten-fold lower systemic 
SN-38 exposure in a patient receiving phenytoin.146 Therefore, the combination of 
phenytoin and irinotecan must be avoided (if possible) or dosing must be guided on 
irinotecan pharmacokinetics to ensure a sufficient exposure. In addition, Innocenti 
et al. found a decreased exposure to SN-38 when irinotecan was combined with 
cyclosporine and the AED phenobarbital (Table 1).147 In addition, an important DDI 
between irinotecan and the combination treatment with ritonavir and lopinavir, caused 
by CYP3A4, UGT1A1 and ABC-transporter inhibition, resulted in a more than two-fold 
increase in SN-38 AUC and a 36% decrease in the SN-38G / SN-38 AUC ratio (Table 
1).148 A similar effect could be expected of atazanavir, which also is a strong inhibitor of 
CYP3A4 and UGT1A1.149 In contrast, by UGT1A induction by methimazole an increase 
in SN-38 and SN-38G concentrations, as well as an almost 50% increased ratio of 
SN-38G / SN-38 was found by within patient comparison (Table 1).150 Concerning 
frequently used drugs such as NSAIDs and proton pump inhibitors, only a possible 
DDI with celecoxib and omeprazole have been evaluated so far. One of three studies 
investigating co-administration of irinotecan and celecoxib, described an increased 
clearance of irinotecan and a decreased AUC of SN-38, although the mechanism is 
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not clear (Table 1).151, 152, 153 . Although omeprazole influences UGT, CYP3A, ABCB1, and 
ABCG2, a clinically relevant pharmacokinetic interaction with irinotecan was ruled out 
in a small cross-over study.154
DDIs with herbal and dietary supplements, and lifestyle 
In general, herbal and dietary supplements are frequently used by cancer patients.155, 
156 Unfortunately, the potential for herb-drug interactions in oncology is not frequently 
investigated in clinical studies.157 Thus far, the effects of St. John’s wort (SJW), milk 
thistle, cigarette smoking, and cannabis tea on irinotecan pharmacokinetics have been 
investigated. Concomitant use of SJW resulted in a 42% reduction of SN-38 AUC, 
primarily caused by CYP3A4 induction (Table 1).158 Flavonoids are components of many 
herbs, such as milk thistle (Silybum marianum), and are able to inhibit CYP3A4, UGT1A1 
and ABC-transporters159-161, but an interaction has not been demonstrated in clinical 
trials (yet).161 Cigarette smoking resulted in a decrease in irinotecan and SN-38 exposure, 
possibly caused by CYP3A induction (Table 1).162 In addition, (medicinal) cannabis can 
induce CYP3A4 and inhibit ABCB1 and its use is becoming more popular in cancer 
patients. Although no interaction was demonstrated between irinotecan and medicinal 
cannabis tea163, other cannabis formulations contain different concentrations of the 
enzyme-modulating compounds (e.g. cannabidiol and delta-9-tetrahydrocannabinol 
(THC)). Therefore, it remains unclear if cannabinoid oils – the most popular formulation 
nowadays – is safe in combination with irinotecan.
Table 1. Drug-drug interactions with irinotecan
All PK alterations mentioned are significant with p<0.05. 
Drug/OTC/Lifestyle N Enzyme/
Transporter
Irinotecan Dose PK alterations Ref.
Anticancer drugs
Paclitaxel 
135-200 mg/m2
D8
31 ABCB1 40-60 mg/m2
D1 + 8, Q3W
Irinotecan 
SN-38
SN-38G 
AUC
24.5h
 32.7%↑
AUC
24.5h
 40.4%↑
AUC
24.5h
 46.2%↑
124
Thalidomide 400mg OD 
(for 14D)
16 350 mg/m2,
Q3W
SN-38 
SN-38G 
AUC
48h
 74%↓
AUC
48h
 28%↑  
130*
S-1 (tegafur)
100/120 mg/m2, 4-7D
4 ABCG2 100-200 mg/m2
Q2W
SN-38  
 
AUC
24h
 50%↓ 128
Imatinib 300-600mg OD
Cisplatin 30 mg/m2
D1 + 8  
6 CYP3A4,5 
CYP2C9
65 mg/m2 
D1 + 8, Q3W   
Irinotecan AUC
8h
 67%↑, CL 36%↓ 134
Lapatinib 1250mg/day
Leucovorin 200 mg/m2
5-FU 600 mg/m2 
12 CYP3A4
OATP1B1
ABCB1
ABCG2
108 mg/m2
Q2W
SN-38 AUC
24h
  41%↑, C
max 
32%↑
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Table 1 continued.
Drug/OTC/Lifestyle N Enzyme/
Transporter
Irinotecan Dose PK alterations Ref.
Non-anticancer drugs
Ketoconazole 200mg OD 
for 2D
7 CYP3A4 100 mg/m2 (with 
ketoconazole)
350 mg/m2 
(alone)
Q3W
SN-38 
APC
AUC
500h
 109% ↑
AUC
500h
 87% ↓
142
Lopinavir 400mg/ Ritonavir 
100mg combination drug 
(Kaletra) BID  
8 CYP3A4
UGT1A1
ABCB1
150 mg/m2 
D1 + 10,  Q3W
Irinotecan 
SN-38
SN-38G 
APC
AUC
inf
 89% ↑, CL 47% ↓
AUC
inf
 204% ↑
AUC
inf  
94% ↑
AUC
inf 
 81% ↓
148
Cyclosporine 
5-10mg/kg 
Cyclosporine + 
Phenobarbital 90mg for 
14D
43
39
ABCB1
ABCC2
ABCB1
ABCC2
UGT1A1
25-75 mg/m2 
Q1W
72-144 mg/m2 
Q1W
Irinotecan 
SN-38
Irinotecan 
SN-38 
SN-38G 
CL 39-64% ↓
AUC
24h
 23-630% ↑
AUC
24h
 27% ↓, CL 
43% ↑
AUC
24h 
75% ↓
AUC
24h
 50% ↓
147
Celecoxib 400mg BID 11 50-60 mg/m2 
D1 + 8,  Q3W
Irinotecan
SN-38 
CL 18% ↑
AUC
12.5h
 21,8% ↓
151*
Methimazole 14 UGT1A 660mg 
Q3W
SN-38 
SN-38G 
AUC
56h
 14% ↑
AUC
56h
 67% ↑
150
Herbal and dietary supplements, and lifestyle
Cigarette smoking 190 CYP3A
UGT1A1
350 mg/m2 or 
600mg fixed 
dose
Q3W
Irinotecan 
SN-38  
AUC
100h 
15% ↓, CL 
18% ↑
AUC
100h  
38% ↓
162 
St. John’s wort 300mg TID 5 CYP3A4 350 mg/m2 
Q3W
SN-38 AUC
24h
 42% ↓ 158
*For thalidomide and celecoxib conflicting data have been published between pharmacokinetic drug 
interactions with irinotecan. Studies that did not show a significant drug-drug interaction are illustrated in more 
detail in the text. 131, 132, 152, 153 
Abbreviations: N = sample size; D = day; OD = once daily; BID = twice daily; TID: three times daily; AUC = area 
under the curve; Inf = infinity; CL = clearance; Q1W = weekly cycle; Q2W = 2-weekly cycle; Q3W = 3-weekly 
cycle; Ref = reference
PHARMACODYNAMICS
TOXICITY
Irinotecan is known for its dose-limiting adverse events; primarily diarrhea, neutropenia, 
and asthenia. Of patients with irinotecan monotherapy, 16-31% experience severe 
diarrhea and a comparable percentage of patients suffer from severe neutropenia 
and severe asthenia, classified as Common Terminology Criteria for Adverse Events 
(CTCAE) grade 3 or worse.164-168 Patients treated with a 5-FU, leucovorin and irinotecan 
(FOLFIRI) regimen experience severe diarrhea (9-44%) and severe neutropenia (18-54%) 
to the same extent.168-173 In addition, neutropenia appears to occur more frequently in 
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females.174 Although irinotecan dose is lower in this regimen, also 5-FU could cause 
these adverse events.
Two types of diarrhea caused by irinotecan can be distinguished: early- and late-onset 
diarrhea. Early-onset diarrhea starts during, or immediately after drug infusion and is 
caused by increased cholinergic activity, which stimulates intestinal contractility and 
reduces the absorptive capacity of the mucosa.175 In addition, early-onset diarrhea is 
often part of an acute cholinergic syndrome with diaphoresis and abdominal pain. 
Overall incidence of this syndrome is approximately 70% without premedication and is 
reduced to 9% by administration of anticholinergic agents (i.e. atropine or hyoscyamine) 
before irinotecan infusion.176, 177 Late-onset diarrhea occurs approximately 8-10 days 
after irinotecan infusion and is characterized by a more severe course, which is probably 
caused by damage of the intestinal mucosa due to increased oxidative-stress by biliary 
secreted or intestinally deconjugated SN-38.76, 178-180 Several guidelines recommend to 
treat late-onset diarrhea with loperamide or alternatively octreotide.181, 182 Antibiotics 
have been used in clinical practice as well, despite sufficient evidence supporting this 
strategy.182 However, these interventions are not always sufficient, which could lead to 
dose reductions, treatment interruptions and hospitalization. 
Conflicting results have been reported regarding the relationship between irinotecan 
and SN-38 exposure and toxicity (Table 2).60 An initial study suggested the biliary index 
(i.e. the ratio of SN-38 to SN-38G AUCs multiplied by the AUC of irinotecan) as a better 
predictor for gastro-intestinal toxicity.178 Following studies on this subject have been 
contradictory: a higher biliary index was significantly correlated with higher incidence 
of severe diarrhea in several studies76, 178, 183, whereas no significant association was 
found by others (Table 2).16, 66, 68, 184 The duration of neutropenia has been found to be 
significantly correlated to a prolonged systemic SN-38 exposure.73
Several interventions to prevent diarrhea have been investigated, such as reducing the 
intestinal exposure of SN-38. In a phase I study, firstly SN-38 excretion in the bile 
was inhibited by combining irinotecan with cyclosporine (due to ABCC2 and ABCB1 
inhibition). Subsequently, phenobarbital (as a UGT1A1 inductor) was added and the 
combination of cyclosporine/phenobarbital/irinotecan resulted in a 75% reduction 
of SN-38 AUC.147 However, when studied in a large randomized phase-III trial, the 
combination of cyclosporine, irinotecan and panitumumab did not significantly reduce 
the incidence of severe diarrhea.185 In another  randomized trial, prophylactic use 
of racecadotril, an anti-secretory drug, also failed to reduce this adverse event.186. 
Alternatively, SN-38 can be bound to activated charcoal or calcium aluminosilicate 
clay in the intestine. Up till now, only the activated charcoal has been found to reduce 
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the incidence of diarrhea.187, 188 However, evidence from a phase-III study and additional 
pharmacokinetic analysis is warranted to understand the real effect of activated 
charcoal, which also exhibits a general anti-diarrhoeic effect, and therefore the use of 
charcoal is not common practice.
Another attempt to reduce toxicity was by inhibition of β-glucuronidase production 
by antibiotics (i.e. streptomycin, penicillin, and neomycin), amopaxine, and herbal 
medicines, all without a relevant reduction in diarrhea incidence.56-58, 189 When combined 
with cholestyramine to reduce reabsorption, however, β-glucuronidase inhibition 
by levofloxacine was found to reduce irinotecan-induced diarrhea.190 In addition, a 
randomized double blind placebo controlled trial showed a 20% reduction in diarrhea 
incidence when irinotecan was combined with probiotics. Unfortunately, this did not 
result in a significant difference between groups, probably due to a lack of statistical 
power.191 Lastly, altering the intestinal environment by alkalinization or by reduction of 
inflammation (by the use of budesonide) did not reduce intestinal toxicity either.192-197 
Currently, fasting before chemotherapy is investigated to reduce toxicity, which 
has been shown to be effective in mice without affecting the anti-cancer effects. 
Systemic and hepatic exposure to SN-38 was reduced in these mice, but intratumoral 
concentrations were unaltered.198, 199 A prospective trial is currently ongoing in order 
to assess the effects of fasting in irinotecan-treated patients and to elucidate the 
underlying biological mechanisms (www.trialregister.nl/; Trial ID: NTR5731).    
EFFICACY
Irinotecan is effective in a wide range of malignancies. In metastatic colorectal cancer 
(mCRC), irinotecan has its most prominent role as monotherapy or within combination 
therapy. As first line mCRC treatment, the FOLFIRI regimen proved to be superior to 5-FU 
with leucovorin and to irinotecan monotherapy: a response rate (RR) of 39% and median 
overall survival (OS) of 14.8-17.4 months has been reported.168, 169 However, addition of 
oxaliplatin to this regimen (i.e. FOLFOXIRI) substantially increased treatment efficacy as 
shown by a RR of 60% and median OS of around 23 months.204, 205 As second line treatment 
after 5-FU containing regimens, irinotecan leads to a significantly longer OS than 5-FU 
with leucovorin or best supportive care (BSC).166, 167 For patients with a KRAS wild-type 
tumor, efficacy of palliative treatment could be increased by combining irinotecan 
monotherapy, FOLFIRI or FOLFOXIRI with monoclonal antibodies (e.g. bevacizumab, 
cetuximab, panitumumab, ramucirumab).165, 170-172, 206, 207 In the adjuvant setting, the addition 
of irinotecan to 5-FU and leucovorin did not result in a survival benefit.208, 209 Patients 
with tumors characterized by high microsatellite instability (MSI) have been suggested to 
respond better to irinotecan based chemotherapy210, 211, but, a recent meta-analysis failed 
to show any predictive value of MSI-status in relation to treatment response.212
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Table 2. Irinotecan toxicity in relation to pharmacokinetics and biliary index
Study N Irinotecan Dose Irinotecan SN-38 SN-38G Biliary index
Diarrhea
Ohe, 1992 200 36 5-40 mg/m2 ,5D, cont. YES1 No ND ND
de Forni, 1994 201 59 50-145 mg/m2, Q1W YES1 YES1 ND ND
Rowinsky, 1994 65 32 100-345 mg/m2, Q3W No No ND ND
Gupta, 1994 178 21 100-175 mg/m2, Q1W No No No YES2
Abigerges, 1995 202 64 100-750 mg/m2, Q3W YES3 YES3 ND ND
Catimel, 1995 67 46 33-115 mg/m2, D1-D3, Q3W YES1 No ND ND
Gupta, 1997 76 40 145 mg/m2, Q1W No No No YES2
Canal, 1996 68 47 350 mg/m2, Q3W No No No No
Mick, 1996 183 36 145 mg/m2, Q1W ND ND ND YES1
Rothenberg, 1996 203 48 125-150 mg/m2, Q1W No YES1 ND ND
Herben, 1999 184 29 10-12.5 mg/m2, D14-21, cont. No No No No
de Jong, 2000 66 52 175-300 mg/m2, Q3W No No ND No
Xie, 2002 16 109 100-350 mg/m2, Q3W YES1 No YES1 No
Neutropenia
Ohe, 1992 200 36 5-40 mg/m2, 5D, cont. No YES4 ND ND
de Forni, 1994 201 59 50-145 mg/m2, Q1W YES5 YES5 ND ND
Rowinsky, 1994 65 32 100-345 mg/m2, Q3W No YES5 ND ND
Abigerges, 1995 202 64 100-750 mg/m2, Q3W YES4 YES4 ND ND
Catimel, 1995 67 46 33-115 mg/m2, D1-D3, Q3W No No ND ND
Canal, 1996 68 47 350 mg/m2, Q3W YES5 YES5 No No
Rothenberg, 1996 203 48 125-150 mg/m2, Q1W No No ND ND
Herben, 1999 184 29 10-12.5 mg/m2 D14-21, cont.  No No No No
de Jong, 2000 66 52 175-300 mg/m2, Q3W No No ND ND
Mathijssen, 2002 73 26 350 mg/m2, Q3W ND YES6 ND ND
All assumed relationships mentioned are significant with p<0.05. 1 = diarrhea frequency, all grades. 2 = diarrhea 
grade ≥3. 3 = diarrhea ≥2. 4 = absolute decrease in neutrophil count, all grades. 5 = % decrease in neutrophil 
count, all grades. 6 = entire time course of absolute neutrophil count decrease. 
Abbreviations: N = sample size; ND = not determined; D = day; Q1W = weekly cycle; Q3W = 3-weekly cycle; 
cont. = continuously
For advanced esophageal or junction tumors, irinotecan has proven to be effective as 
monotherapy and when combined with respectively cisplatin, mitomycin, capecitabine 
and oxaliplatin, 5-FU and leucovorin and docetaxel.213-219 Of these regimens, however, 
only irinotecan combined with 5-FU was evaluated in a phase-III trial, in which this 
combination was inferior to cisplatin/5-FU.220 In advanced HER2 negative gastric 
cancer, addition of irinotecan to different combination therapies gave an OS benefit in 
a pooled analysis of ten studies: median OS was 11.3 months and RR was approximately 
38%.221 
Irinotecan is also used in the treatment of small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC). For advanced NSCLC, irinotecan combined with respectively 
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taxanes, platinum, ifosfamide or gemcitabine demonstrated efficacy as first-line 
treatment in several trials.222 For advanced SCLC, irinotecan combined with cisplatin 
or carboplatin had similar RR and median OS as platinum compounds with etoposide 
(RR 39-84% and median OS  9-13 months) and is therefore used as first-line treatment 
in Japan, whereas the etoposide containing regimen is preferred elsewhere.223 
Furthermore, irinotecan has demonstrated anti-cancer activity in phase-II trials in 
a wide range of other solid tumors (i.e. mesothelioma, glioblastoma, gynecological 
cancers, head and neck cancer), although no phase-III data are available.224-231
Finally, in pancreatic cancer, the combination of 5-FU, leucovorin, irinotecan and 
oxaliplatin (FOLFIRINOX) is used for both first-line adjuvant and palliative treatment, 
in which it was shown to be superior to gemcitabine monotherapy (median OS 11.1 
months, RR 31.6%).232 Recently, liposomal irinotecan, has been approved as second-
line treatment for metastatic pancreatic cancer for patients with progression on 
gemcitabine-based therapies.87 Efficacy of this liposomal formulation needs to be 
explored further in other tumor types.
 
PHARMACOGENETICS
Expression and functionality of enzymes and drug transporters involved in the 
metabolism and elimination of irinotecan can be affected by genetic polymorphisms 
which could influence both irinotecan pharmacokinetics and pharmacodynamics. 
This section provides an overview of clinical correlations between polymorphisms and 
irinotecan pharmacokinetics and pharmacodynamics.
 
ASSOCIATIONS BETWEEN UGT1A1 POLYMORPHISMS AND IRINOTECAN 
PHARMACODYNAMICS
With more than one hundred reported genetic variants, UGT1A1 is a highly polymorphic 
enzyme.233 The most frequently studied UGT1A1 polymorphisms in relation to irinotecan 
pharmacokinetics and pharmacodynamics are UGT1A1*6 and UGT1A1*28. The majority 
of the genetic association studies have focused on neutropenia and diarrhea as clinical 
endpoints.169 
Wild-type UGT1A1 is characterized by six thymine-adenine (TA) repeats in the 
promotor region, whereas UGT1A1*28 (rs8175347) carriers have an extra TA repeat 
which impairs UGT1A1 transcription and thereby reduces expression by approximately 
70%.234 The incidence of this genetic variant is relatively high among Caucasians 
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(minor allele frequency, MAF: 26 – 39%) and Africans/African Americans (MAF: 30 – 
56%).235, 236 Among Asians, UGT1A1*28 is far less common as indicated by an MAF of 
9 – 20%.235, 236 With an reported MAF of up to 47%, another polymorphism – UGT1A1*6 
(rs4148323, 211G>A) – is more common in Asian populations and may therefore be a 
better predictor for irinotecan-related toxicities in that area of the world.237 UGT1A1*6 also 
results in a ~70% reduction of UGT1A1 activity in individuals carrying the UGT1A1*6/*6 
genotype.238 
Both UGT1A1*28 and *6 polymorphisms result in an increased systemic exposure to 
irinotecan and SN-38 in patients homozygous for these variants, thereby increasing 
the risk of irinotecan-associated adverse events.239, 240 This is also accompanied 
by increased financial costs of toxicity management.241 Due to the high number of 
genetic association studies on the clinical effects of UGT1A1*6 and *28 on irinotecan 
pharmacokinetics / pharmacodynamics and large differences between studies in terms 
of tumor type, dosing regimen, and genetic models, this review will mainly focus on 
meta-analyses for UGT1A1*28 and *6 to extract the most relevant information with the 
highest level of evidence (Table 3).
Initially, significant associations between UGT1A1*28 and hematologic toxicities were 
only reported for irinotecan doses higher than 180 mg/m2.242 More recent meta-
analyses, however, did not show a dose-dependent effect of UGT1A1*28: also *28 
carriers receiving lower irinotecan doses were at risk of neutropenia.243, 244 These meta-
analyses were carried out in a predominantly Caucasian population, thus regardless 
of scheduled starting dose, genotyping for UGT1A1*28 and dose reductions in all 
Caucasian patients homozygous for UGT1A1*28 may be considered to reduce the risk 
of severe neutropenia. 
Presumably due to the lower incidence of UGT1A1*28 in Asians, the effects of UGT1A1*28 
on toxicity endpoints are less straightforward in this population. Several meta-analyses 
in Asian patients with different tumor types and treatment schedules did not show any 
significant association between UGT1A1*28 and irinotecan-induced neutropenia.245, 246 
In contrast, UGT1A1*6 seems to be a more accurate predictor of irinotecan-induced 
toxicity: Asian patients with gastro-intestinal tumors or with NSCLC were more likely to 
suffer from neutropenia if they were carrying at least one UGT1A1*6 allele (Table 3).245, 
247 This association does not seem to be dose-dependent.248 
Both Caucasian and Asian patients homozygous or heterozygous for UGT1A1*28 have 
a greater risk of suffering from severe diarrhea compared to wild type patients after 
receiving irinotecan doses greater than 125 mg/m2.249 In another meta-analysis among 
156
PART II | CHAPTER 7
Caucasian *28/*28 carriers, this dose-dependent effect was also observed.244 In Asian 
patients, UGT1A1*6 not only correlates well with the risk for irinotecan-induced 
neutropenia, but is also significantly associated with severe diarrhea.245, 248 Whether this 
association is dose-dependent is currently unknown, since no dose subgroup analysis 
has been carried out.250
It seems that response or survival endpoints are not significantly affected by UGT1A1*6 
or *28. Both UGT1A1*6 and UGT1A1*28 genotypes did not have any significant 
association with tumor response in Asian NSCLC or SCLC patients receiving irinotecan 
as first- or second-line chemotherapy.245 Also in Caucasian patients with colorectal 
cancer, the presence of one or more UGT1A1*28 alleles did not significantly affect 
overall and progression-free survival (PFS).251 
Besides UGT1A1*6 and UGT1A1*28, other common UGT1A1 polymorphisms could 
theoretically also 
affect irinotecan-related toxicity (Table 3). For instance, UGT1A1*60 (rs4124874; 
3279T>G) is in linkage with UGT1A1*28 and is associated with a decrease in 
transcriptional activity.238 This genetic variant is common among Caucasians (MAF: 
47%) and African Americans (MAF: 85%).252 Two clinical studies did not report any 
significant associations between UGT1A1*60 status and irinotecan-related toxicities253, 
254, irinotecan pharmacokinetics, or tumor response.253 The only significant association 
including UGT1A1*60 was found in a haplotype analysis in which a haplotype consisting 
of UGT1A1*28, *93 and *60 variant alleles was significantly associated with grade 4 
neutropenia.255 
Similar to UGT1A1*60, also UGT1A1*93 (rs10929302; -3156G>A) is in linkage 
disequilibrium with UGT1A1*28.252 UGT1A1*93 results in reduced UGT1A1 expression 
and is associated with elevated bilirubin concentrations in patients homozygous for 
UGT1A1*93 255. With an MAF of approximately 30% this genetic variant is commonly 
detected in Caucasians and African Americans.252 Clinically, UGT1A1*93 is associated 
with increased SN-38 AUC, lower neutrophil count, increased incidence hematologic 
toxicities (including neutropenia), diarrhea, and grade 3 vomiting.256-261 Moreover, 
UGT1A1*93 was also part of a haplotype including variant alleles of UGT1A1*28, *60, 
*93, and UGT1A7*3, that was associated with increased response rate.262 A prospective 
trial on genotype-guided irinotecan dosing based on UGT1A1*28 and UGT1A1*93 
genotype status is currently ongoing (Trial ID: NTR6612).    
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ASSOCIATIONS BETWEEN OTHER UGT1A POLYMORPHISMS AND IRINOTECAN 
PHARMACODYNAMICS: UGT1A7 AND UGT1A9
Compared to patients with UGT1A9*1/*1, individuals carrying the UGT1A9*22 genotype 
(T9>T10; MAF: 45%) show higher enzyme expression, higher SN-38 glucuronidation and 
are therefore more at risk for diarrhea.263, 264 Other UGT1A9 variants, UGT1A9*3 (98T>C; 
MAF: 3%) and UGT1A9*5 (766G>A; MAF: 1%), are rare in Caucasians and are therefore not 
likely to significantly affect irinotecan pharmacokinetics and pharmacodynamics in this 
population.265 Lower enzyme activity and SN-38 conjugation is observed in UGT1A7*3 
and UGT1A7*4 polymorphisms.263, 266. In line with these findings, UGT1A7*3/*3 carriers 
are at greater risk of adverse events while receiving irinotecan chemotherapy.262, 263 A 
haplotype consisting of UGT1A7*3, UGT1A9*1, UGT1A1*28, UGT1A1*60 and UGT1A1*93 
alleles was associated with severe neutropenia in a cohort of 167 colorectal cancer 
patients treated with FOLFIRI.259 In the same cohort UGT1A7*3 was also part of two 
other haplotypes (including UGT1A9, UGT1A7, and UGT1A6 variants) associated with 
increased risk of grade 3-4 neutropenia (Table 3).
ASSOCIATIONS BETWEEN DRUG TRANSPORTER POLYMORPHISMS AND IRINOTECAN 
PHARMACOKINETICS AND PHARMACODYNAMICS 
Since both irinotecan and SN-38 are substrates of ABC transporters (Figure 2), ABC 
polymorphisms may also affect irinotecan pharmacokinetics 267, as well as irinotecan-
related toxicities.174 In a multivariate analysis including UGT1A1*93, ABCC1 SNPs 
rs6498588 and rs17501331, these variants were associated with increased SN-38 
plasma concentrations and/or decreased absolute neutrophil counts.256 Opposite 
effects were reported for the ABCB1 variant rs12720066 which was associated with 
decreased SN-38 exposure and increased neutrophils. Carriers of another ABCB1 SNP 
(rs1045642) had an increased risk for early toxicity and lower treatment response.268 
In patients with liver metastases treated with hepatic artery infusion of irinotecan, 
oxaliplatin and 5-fluorouracil and intravenous cetuximab, this SNP was also associated 
with toxicity (grade 3-4 neutropenia), increased systemic concentrations of oxaliplatin 
and cetuximab, and prolonged PFS.269 Furthermore, carriers of the ABCB1 haplotype 
(including rs1045642, rs1128503, rs2032582) responded less frequently and had shorter 
survival.268 In addition to ABCB1 and ABCC1, polymorphisms of ABCC2 (rs3740066) and 
ABCG2 (rs2231137) were reported to be independently predictive for toxicity (i.e. grade 
3 diarrhea).264 In contrast, the ABCG2 421C>A SNP seems to have a limited impact on 
irinotecan exposure.270 Polymorphisms in the gene for the hepatic efflux transporter 
ABCC2 may have a protective effect on diarrhea, which is presumably caused by 
decreased hepatobiliary transport of irinotecan and therefore reduced irinotecan 
exposure to the gut.271 This protective effect was observed in Caucasian patients with 
the ABCC2*2 haplotype (including six ABCC2 variants without any UGT1A1*28 alleles). 
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Although their role in irinotecan efflux has not yet been established, ABCC5 and ABCG1 
could also be involved in this process, since several SNPs in these transporters are 
correlated with severe diarrhea.272 
OATP1B1, encoded by the SLCO1B1 gene, is involved in the hepatic uptake of SN-
38 (Figure 2). In Caucasian patients carrying at least one SLCO1B1*1b variant allele 
(rs2306283; MAF: 38%), median neutrophil count was approximately two-fold increased, 
compared with wild-types, presumably by increased hepatic uptake of SN-38 thereby 
reducing SN-38 plasma concentrations (Table 3).273 This result confirms an earlier 
genetic association study on the effects of drug transporters on irinotecan neutropenia 
and pharmacokinetics.174 In addition, SLCO1B1*1b was also associated with increased 
PFS in patients with colorectal and pancreatic cancer.274 Thus, potentially SLCO1B1*1b 
could be a protective biomarker for neutropenia and may improve efficacy. In contrast, 
SLCO1B1*5 (rs4149056) leads to reduced transporter activity and was associated 
with increased SN-38 plasma concentrations and an increased risk of neutropenia (in 
combination with UGT1A1*28 variant alleles).274  
IMPLEMENTATION OF GENOTYPE-ADJUSTED IRINOTECAN DOSING GUIDELINES
Both the U.S. Food and Drug Administration (FDA) and Health Canada/Santé Canada 
(HCSC) recommend a reduction of the irinotecan starting dose in patients who are 
homozygous for UGT1A1*28  without specifying the extent of reduction (Table 4). 
275, 276 In contrast, the Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) Working Group did not find sufficient evidence that UGT1A1 genotyping 
should be used.277 Subsequent guidelines, however, do underline the importance of 
UGT1A1 genotyping, especially for UGT1A1*28 variant alleles in Western countries. For 
example, in France and The Netherlands a reduction of the starting dose of 25-30% 
is recommended in patients homozygous for UGT1A1*28 receiving higher doses of 
irinotecan (≥ 180 mg/m2).278, 279 Regarding liposomal irinotecan, the European Medicines 
Agency (EMA) recommends an initial dose reduction from 80 to 60 mg/m2 in patients 
homozygous for UGT1A1*28.280  
In line with the significant associations between UGT1A1*6 genotype and irinotecan-
induced toxicities in Asian populations, the Japanese Pharmaceuticals and Medical 
Devices Agency (PMDA) recommends screening patients for UGT1A1*6 and *28 
polymorphisms.281
Despite the establishment of these guidelines, UGT1A1 genotyping is currently not 
routinely performed.282 This could be explained by the fact that prospective studies 
evaluating the clinical effects of genotype-directed dosing are scarce. Most likely, 
159
7
INDIVIDUALIZATION OF IRINOTECAN TREATMENT: A REVIEW
reduction of the irinotecan dose to prevent toxicity in carriers of UGT1A1*1/*28 and 
UGT1A1*28/*28 is indeed useful, since the maximum-tolerated dose of irinotecan was 
lower in these patients relative to wild-type patients.283 Whether a dose reduction of 
irinotecan affects tumor response in UGT1A1*28 carriers is yet unknown. On the other 
hand, patients with the UGT1A1*1/*1 or UGT1A1*1/*28 genotype may tolerate higher 
irinotecan doses than the currently recommended doses and are therefore at risk of 
suboptimal treatment. Indeed, a phase I dose-finding study showed convincingly that, 
compared with the recommended irinotecan dose of 180 mg/m2 in the FOLFIRI regimen, 
substantial higher doses of irinotecan (up to 420 mg/m2) were tolerated in patients 
wild-type or heterozygous for UGT1A1*28.284 More recently, similar findings were 
observed in patients receiving FOLFIRI in combination with bevacizumab 282, implying 
that the therapeutic window of irinotecan may be increased for the UGT1A1*1/*1 and 
UGT1A1*1/*28 genotypes. 
In summary, particularly for Caucasians UGT1A1*28 seems to be a good predictor 
for neutropenia (all irinotecan doses) and diarrhea (doses > 125 mg/m2). UGT1A1*28 
is also significantly associated with an increased risk for diarrhea in Asian patients at 
irinotecan doses > 125 mg/m2. In Asian populations, however, the UGT1A1*6 variant 
is more common and appears to be a more accurate predictor for neutropenia (all 
irinotecan doses) and diarrhea. In addition to UGT1A1*6 and UGT1A1*28, UGT1A1*93 is 
also significantly associated with irinotecan-induced toxicity. Less extensively studied 
polymorphisms such as UGT1A7*3, UGT1A9*1, and drug transporter polymorphisms 
(ABCB1, ABCC5, ABCC2, ABCG1, SLCO1B1) may also be useful predictors for toxicity. 
Interestingly, CYP3A4*22 has not been studied thus far, while this SNP has shown 
relevance for many other CYP3A substrates 285-287.  In order to determine the true value 
of genotype-driven dosing of irinotecan, the efficacy of this dosing strategy should 
be evaluated prospectively. Inclusion of additional predictive genetic variants (e.g. 
UGT1A1*6, *93) in genotype-directed dosing schedules may improve its predictive 
value.  
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Table 3. Overview of pharmacogenetic studies on irinotecan toxicity and survival
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Table 3 continued.
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Table 4. Overview of guidelines on pharmacogenetic testing for irinotecan
Organization Country Year 
of last 
update
Genotype 
recommended 
for testing 
Dose reduction 
explicitly  
recommended?
Recommendation Ref.
U.S. Food and Drug 
Administration 
(FDA)
United States of 
America
2014 UGT1A1*28 Yes UGT1A1*28/*28: 
starting dose 
reduction by at 
least one dose level
275
Health Canada/
Santé Canada 
(HCSC)
Canada 2014 UGT1A1*28 Yes UGT1A1*28/*28: 
reduced starting 
dose 
276
National 
Pharmacogenetics 
Network (RNPGx) 
and the Group of 
Clinical Onco-
pharmacology 
(GPCO-Unicancer)
France 2015 UGT1A1*28 Yes UGT1A1*28/*28 
and dose 180 – 
230 mg/m2: 25-
30% reduction of 
starting dose.
UGT1A1*28/*28 
and dose ≥ 240 
mg/m2: irinotecan 
contra-indicated
278
Royal Dutch 
Association for the 
Advancement of 
Pharmacy (KNMP)
The Netherlands 2011 UGT1A1*28 Yes UGT1A1*28/*28 
and dose > 250 
mg/m2: 
30% reduction of 
starting dose. 
279
European 
Medicines Agency 
(EMA)
Europe 2017 UGT1A1*28 Yes UGT1A1*28/*28: 
reduce starting 
dose of liposomal 
irinotecan from 80 
to 60 mg/m2.
280
Pharmaceuticals 
and Medical 
Devices Agency 
(PMDA)
Japan 2014 UGT1A1*6 and 
*28
No Use irinotecan with 
caution in patients 
with the following 
genotypes: 
UGT1A1*6/*6, 
UGT1A1*28/*28 
and UGT1A1*6/*28. 
281
Abbreviations: Ref. = reference
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CONCLUSIONS AND FUTURE PERSPECTIVES
Irinotecan is a crucial anti-cancer drug in treatment regimens for several solid tumors. 
Many factors which contribute to the large inter-individual pharmacokinetic variability 
have been elucidated. The last decade, much progress has been made in unraveling 
the pharmacogenetics influence on systemic exposure, toxicity, and survival. However, 
this knowledge has not sufficiently been translated into general clinical practice yet.
Based on the pharmacokinetic and pharmacogenetic data discussed in this review 
article, we recommend dosing adjustments in the following situations: 
•	 Concomitant use of potent CYP3A4 inducers (e.g. rifampicin, phenytoin, 
phenobarbital, carbamazepine, St. John’s wort): avoid combination.  
•	 Concomitant use of potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole): 
avoid combination. 
•	 Caucasians: perform genotyping for UGT1A1*28. Consider at least a 25% reduction 
of starting dose in patients homozygous for UGT1A1*28.
•	 Asians: perform genotyping for UGT1A1*6. Consider dose reduction of starting 
dose in patients homozygous for UGT1A1*6. Exact dosing adjustments are yet 
unknown.
Future research should prospectively investigate the added value of individualized 
irinotecan treatment based on patient characteristics, pharmacogenetics and co-
medication. Furthermore, novel drug formulations such as liposomal forms of 
irinotecan could help to pharmacologically optimize irinotecan treatment.
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ABSTRACT 
BACKGROUND
Regorafenib exposure could potentially be influenced by an interaction with acid 
reducing drugs. 
METHODS
In this cross-over trial, patients were randomized into 2 sequence groups consisting 
of 3 phases: regorafenib intake alone, regorafenib with concomitant esomeprazole, 
and regorafenib with esomeprazole 3 hours prior. Primary endpoint was the relative 
difference (RD) in geometric means for regorafenib AUC
0-24h
, and was analyzed by a 
linear mixed model in 14 patients. 
RESULTS
AUC
0-24h
 for regorafenib alone was 55.9 μg*h/mL (CV: 40%), and for regorafenib 
with concomitant esomeprazole or with esomeprazole 3 hours prior AUC
0-24h
 was 
53.7 μg*h/mL (CV: 34%) and 53.6 μg*h/mL (CV: 43%), respectively. No significant 
differences were identified when regorafenib alone was compared to regorafenib with 
concomitant esomeprazole (RD: -3.9%, 95% CI: -20.5-16.1%, P=1.0) or regorafenib 
with esomeprazole 3 hours prior (RD: -4.1%, 95% CI: -22.8-19.2%, P=1.0). 
CONCLUSION
These findings indicate that regorafenib and  esomeprazole can be safely combined in 
clinical practice. 
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INTRODUCTION
Regorafenib is an oral multi-kinase inhibitor that targets angiogenic, stromal and 
oncogenic receptor tyrosine kinases (e.g. VEGFR, KIT, BRAF, PDGFR and FGFR).1 It is 
currently registered for metastatic colorectal cancer (mCRC), gastro-intestinal stromal 
tumor (GIST), and hepatocellular carcinoma (HCC).2-4 Regorafenib is the first and 
currently only tyrosine kinase inhibitor (TKI) registered for mCRC, although the median 
overall survival increase for an unselected group in the 3rd or 4th line of treatment is only 
1.4 months compared to placebo.2 For HCC and GIST, regorafenib provides a stronger 
survival benefit as second and third line TKI-based therapy.3,4 For several TKIs, systemic 
exposure has been demonstrated to influence toxicity and efficacy.5,6
After oral administration, regorafenib is rapidly absorbed, with a time of maximum 
concentration (T
max
) reached at 3-4 hours.6,7 Most TKIs exhibit pH-dependent 
solubility.8 For regorafenib a low basic predicted pK
a
 of around 2 suggests influence of 
the gastro-intestinal pH on the absorption, however this is not clearly demonstrated.9,10 
Although the physiochemical properties of regorafenib may not predict significant pH 
dependent solubility, regorafenib absorption is multifactorial and may be affected 
by the concomitant use of acid-reducing drugs.11 For many TKIs, a pharmacokinetic 
interaction with an acid-suppressive agent has already been demonstrated, for example, 
erlotinib combined with omeprazole resulted in 46% decrease in systemic exposure.8 
However, for some TKIs this interaction could be ruled out. To our knowledge, for 
regorafenib there is no study available yet on a possible drug-drug interaction with 
acid-reducing drugs. 
When the exposure is decreased, the efficacy of TKI treatment could potentially also 
decrease, as was demonstrated for sorafenib and pazopanib among other TKIs.6 As 
regorafenib resembles the structure and mechanism of action of sorafenib, an exposure-
response relationship could be suspected for regorafenib as well. In a secondary 
analysis of the phase-3, RESORCE trial in HCC patients, median overall survival and 
time-to-progression tended to be longer in patients with higher regorafenib exposure 
during the first treatment cycle, however after correction for several covariates it did 
not reach statistical significance.12 To our knowledge, this trial is the only available 
evidence on a possible exposure-response relationship for regorafenib; therefore, 
more research is necessary on this point.
Acid-suppressive therapy is frequently used by cancer patients, both as prophylaxis 
for gastro-intestinal bleeding due to drug-drug interactions (DDI) and as treatment 
for gastresophageal reflux disease (GERD).13 In 2013, Smelick et al reported that up 
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to 33% of all anticancer patients used any form of acid-suppressive therapy, most 
notably a proton pump inhibitor (PPI).14 TKIs often cause stomach complaints or GERD, 
which confronts clinicians with a challenge, as the general consensus is to avoid the 
combination of TKIs and acid-suppressive agents. Therefore,  registration authorities 
nowadays recommend investigating this DDI before registration of a new TKI. However, 
for regorafenib, this potential DDI has not been investigated. 
In this study we assessed the potential pharmacokinetic interaction between 
esomeprazole and regorafenib . Furthermore, we also assessed the potential influence 
of timing of esomeprazole intake relative to that of regorafenib (three hours before 
regorafenib ingestion or concomitantly).15 
METHODS
This study was a randomized, two-armed, three-phase, cross-over clinical trial in 
patients using regorafenib. Between May 2016 and February 2018, the study was 
performed at the Erasmus Medical Center, Rotterdam, The Netherlands. Approval of 
the Medical Ethics Committee and the board of directors from the Erasmus University 
Medical Center, and the competent authorities was obtained. The study was registered 
at the European Clinical Trials Database (EudraCT 2015-005784-17), and clinicaltrials.
gov (NCT02800330).
PATIENTS
Patients were included if they were 18 years or older, had a pathological confirmed 
diagnosis of mCRC or GIST, Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 1, with  adequate kidney and liver function. Patients were excluded if they 
could not abstain from dietary supplements or medication which could interact with 
regorafenib or esomeprazole, if they could not interrupt acid-suppressive therapy, or 
if they had a known impaired drug absorption or serious illness that could interfere 
with study conduct (e.g. infection, bleeding diathesis or hemorrhage, arterial or venous 
thrombotic or embolic events, uncontrolled hypertension despite optimal medical 
management, HIV, hepatitis, organ transplants, or kidney, cardiac and respiratory 
diseases). All patients provided written informed consent before any study related 
procedure was pursued.
STUDY DESIGN
The main objectives of this study were to compare the area under the curve (AUC) 
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of regorafenib alone to regorafenib concomitantly used with esomeprazole, and to 
regorafenib used with esomeprazole three hours prior in patients with mCRC or GIST. 
Patients started with regorafenib on 120 or 160 mg once daily during a loading phase 
of 14 consecutive days (Figure 1). Regorafenib dose adjustments were only allowed 
during these first two weeks of the trial. However, due to (reversible) toxicity, the study 
was allowed to be temporarily interrupted for a maximum of one full regorafenib dosing 
cycle (i.e. 28 days). After reaching steady-state, patients either used regorafenib alone 
(phase A), or with esomeprazole (40mg once daily) for five consecutive days (phase 
B and C). During phase B of the study regorafenib was administered concomitantly 
with esomeprazole, while during phase C regorafenib was administered three hours 
after esomeprazole intake, presuming a maximally elevated intragastric pH at the time 
of regorafenib ingesture.16 Subjects were randomized into two sequence groups (i.e. 
A-B-C or C-B-A) to rule out sequence and time effects (Figure 1).
Figure 1. Study procedures
PHARMACOKINETICS
Patients were admitted to the hospital on the 21st, the 49th and the 77th day of the trial 
for pharmacokinetic blood sampling. Blood samples were collected before regorafenib 
administration, and at the 0.5h; 1h; 1.5h; 2h, 2.5h; 3h; 3.5h; 4h; 6h; 8h; 12h and 24h time-
point after regorafenib administration (at 10:00 AM). Blood samples were collected in 
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4 mL lithium heparin (Li-He) blood collection tubes, and processed into plasma within 
10 minutes by centrifugation for 10 minutes at 2,500*g (at 4°C) and stored at T<-70°C 
until analysis. Regorafenib, M-2, and M-5 plasma concentrations were measured using 
a validated liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method 
(detailed description in Supplementary Methods). Pharmacokinetic parameters were 
calculated by using Phoenix WinNonlin version 7.0, and included exposure expressed 
as dose corrected area under the curve from pre-intake time point until 24 hours 
(AUC
0-24h
), maximum observed concentration (C
max
), and time until maximum observed 
concentration (T
max
).  
STATISTICAL ANALYSIS
A difference in systemic exposure to regorafenib of 30% was determined to be 
clinically relevant. Since two primary comparisons were to be made, i.e. regorafenib 
with esomeprazole concomitant or three hours prior compared to regorafenib alone, 
a Bonferroni correction was applied. The Bonferroni correction was implemented by 
multiplying the obtained p-values by two and calculation of 97.5% confidence intervals 
(CI) which correspond to the alpha of 0.025 with the interpretation of Bonferroni 
corrected 95% CIs. It was assumed that the within patient standard deviation in regorafenib 
pharmacokinetics was 30%. Given a power of 80%, the sample size calculation resulted 
in a required number of 14 evaluable patients 17. Patients were considered evaluable 
when they completed all three phases, including all required blood samples.
Analyses of the AUC
0-24h
 and C
max
 were performed on log-transformed observations 
since they were assumed to follow a lognormal distribution 18. Estimates for the mean 
differences in (log) AUCs and C
max
 of regorafenib, M-2 and M-5 were obtained for the 
two comparisons separately using a linear mixed effect model with treatment, sequence, 
and phase as fixed effects and subject within sequence as a random effect 19. Variance 
components were estimated based on restricted maximum likelihood (REML) methods 
and the Kenward-Roger method of computing the denominator degrees of freedom 
was used. The mean differences and CIs for the differences were exponentiated to 
provide point estimates of the ratio of geometric means and CIs for these ratios, which 
can be interpreted as relative differences in percentages. T
max
 was analyzed by means 
of the Wilcoxon signed rank test and described with medians and interquartile ranges. 
Toxicity was described as the incidence of toxicity per phase and was corrected for 
baseline toxicity by describing only new or worsened toxicity compared to baseline. 
This study was not powered to detect a difference in toxicity between treatment 
phases, therefore these results only have a descriptive character.
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RESULTS
PATIENT CHARACTERISTICS
A total of 31 patients were included, of which 14 patients were evaluable for the 
primary endpoint analysis. The evaluable patients were equally distributed over the 
two treatment sequence groups. Patients were not evaluable due to various reasons: 
screen failures (n=4); rapid disease progression during treatment (n=8); and premature 
treatment interruption (n=5). Patients who developed progressive disease during the 
study period were also equally distributed over the two treatment sequences. 
Patient characteristics are detailed in Table 1. All patients suffered from mCRC, were 
of Caucasian origin and predominantly male (71%). Median age was 69 years and most 
patients had an ECOG performance status of 1 (86%). All patients used regorafenib 
120 mg at steady-state on recommendation of the treating physician or due to dose-
reductions in the first two weeks of the trial. 
Table 1. Patient characteristics
Characteristic Total
Gender
  Male 
  Female
10 (71%)
  4 (29%)
Age (years)
  Median [IQR] 69 [61-73]
ECOG Performance Status
   0
   1
  2 (14%)
12 (86%)
Ethnic origin
   Caucasian 14 (100%)
BMI (kg/m2)
   Median [IQR] 28.6 [24.1-29.9]
eGFR (mL/min)a
   Median [IQR] 82 [77-91]
Liver function (median [IQR])
   AST
   ALT
   Bilirubin
39 [27-68]
33 [17-39]
  8 [6-13] 
Prior therapy
   Surgery
   Radiotherapy
   Chemotherapy
   Monoclonal antibodiesb    
12 (86%)
  4 (29%)
14 (100%)
  9 (64%)
a eGFR was calculated according to the CKD-EPI
b Treatment with monoclonal antibodies included bevacizumab, panitumumab, and cetuximab
Abbreviations: AST = aspartate aminotransferase; ALT = alanine aminotransferase; BMI = Body Mass Index; eGFR 
= estimated glomerular filtration rate; IQR = interquartile range
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PHARMACOKINETICS
All obtained pharmacokinetic results are depicted in Table 2. No statistical difference 
in geometric means for regorafenib AUC
0-24h
 was found when regorafenib alone 
was compared to regorafenib and esomeprazole concomitantly (relative difference 
[RD]: -3.9%, 95%CI: -20.5-16.1%, P = 1.0) or when compared to regorafenib and 
esomeprazole three hours before regorafenib intake (RD: -4.1%, 95%CI:      -22.8-
19.2%, P = 1.0) (Figure 2). Furthermore, no differences could be identified in C
max 
or T
max 
for regorafenib. For M-2 and M-5 no differences could be identified either, although 
the interindividual variability (expressed as coefficient of variation; CV) was much 
higher for all these pharmacokinetic parameters compared to regorafenib (Table 2, 
Supplementary Figure 1). No sequence nor period effects were seen for any of the 
comparisons of the AUC
0-24h
 and C
max 
(results not shown).
Figure 2. Regorafenib AUC
Regorafenib exposure compared between phase A (regorafenib alone) and phase B (regorafenib 
concomitantly with esomeprazole) (figure 2A), and between phase A and C (regorafenib with 
esomeprazole 3 hours prior) (figure 2B)
Abbreviations: AUC
0-24 
= Area under the curve, timepoint 0h to 24h
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Table 2. Regorafenib pharmacokinetics
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TOXICITY
Most common adverse events during the whole study period were hoarseness (79%), 
anorexia (71%), hypertension (71%), hand foot skin reaction (64%), fatigue (71%), 
stomatitis (57%), and nausea (50%). Also, most common blood value disorders included 
transaminase increase (79%), bilirubin increase (50%) and hypophosphatemia (29%). 
The majority of adverse events was of low grade, the incidence of toxicity ≥ grade 3 
occurred mainly as hypertension (64%), anorexia (14%) and hand foot skin reaction 
(14%). The incidence of adverse events seems comparable between different phases. 
Two patients developed major cardiac events, possibly related to regorafenib treatment: 
myocardial infarction and atrial fibrillation. One patient developed hypertrichosis, 
although this rare side effect is seen more often with other TKIs such as erlotinib 20, to 
our knowledge it has not been described for regorafenib. All observed adverse events 
are described in Supplementary Table 1. 
DISCUSSION
This randomized, three-phase, cross-over clinical trial did not reveal a significant 
pharmacokinetic interaction between esomeprazole and regorafenib at the two time-
points studied. Therefore we can conclude that esomeprazole  can be combined with 
regorafenib safely, in contrast to other TKIs. 
In this study, esomeprazole was used because it exhibits the strongest pH-reducing 
effect of all acid-reducing drugs currently available.8,16 Also, esomeprazole does 
not influence other enzymes or transporters, such as P-glycoprotein (ABCB1), that 
could potentially influence the pharmacokinetics of regorafenib’s active metabolites 
M-2 and M-5.21 Therefore, our findings cannot be extrapolated to other PPIs -- such 
as pantoprazole -- which is known to influence P-glycoprotein. We examined two 
time-points regarding the intake time of esomeprazole (i.e. concomitantly or three 
hours prior regorafenib intake), because PPIs are assumed to have their maximum 
acid-reducing effect three hours after intake and a possible interaction would be the 
strongest at this time-point.15 However, even at this time-point we did not demonstrate 
an influence of esomeprazole on the pharmacokinetics of regorafenib, M-2 and M-5.
Regorafenib exhibits low solubility, which is mainly caused by its chemical structure 
as no strong basic or acidic group is attached (regorafenib: 4-[4-({[4-chloro-3-
(trifluoromethyl)phenyl]carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-
carboxamide).22 Furthermore, to improve the solubility, regorafenib is formulated as a 
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solid dispersion consisting of small powder particles in which the drug and excipient are 
integrated.23 Despite this formulation, regorafenib exhibits low solubility compared to 
other TKIs. As a result regorafenib absorption is, in theory, less affected by intragastric 
pH-alterations and the results of this study were not totally unexpected. However, 
since TKI absorption is multifactorial a drug-drug interaction with PPIs cannot always 
be fully ruled out based on modeling and physiochemical properties alone.11 Therefore, 
a drug interaction should always be verified in an in vivo setting as was done in this 
study for regorafenib.
In order to reach the required sample size of 14 evaluable patients a total of 31 patients 
had to be included in the study, due to the fact that many patients were not able 
to complete three cycles of regorafenib at 160 or 120 mg due to treatment-related 
adverse events or progression of disease. In addition, we aimed to include both mCRC 
and GIST patients, but mainly mCRC patients were included, which resulted in a 
possible selection bias. In general, mCRC patients are in a worse condition and more 
heavily pre-treated compared to GIST patients, which could have resulted in more 
adverse events and a higher drop-out rate. However, we do not think it influenced the 
pharmacokinetic end points. In addition, the CORRECT trial demonstrated a median 
overall survival increase of 1.4 months compared to placebo in mCRC patients.2 
Therefore, it was not completely surprising that quite some patients developed early 
disease progression during study treatment hampering prolonged study participation. 
In addition, all patients eventually used 120 mg at steady-state instead of 160 mg, 
due to known severe treatment-related adverse events (e.g. hypertension), which also 
occurred in up to 50% of patients in the registration studies.2-4 Furthermore, because 
this study was designed as a pharmacokinetic cross-over study, we could not compare 
toxicity between different cycles. However, because we found no differences in 
regorafenib pharmacokinetics, a difference in exposure-related toxicity seems unlikely.
This study was designed to demonstrate a difference based on two primary comparisons 
on regorafenib exposure depending on esomeprazole intake time (concomitantly or 
three hours prior). Because of the assumption of a difference between those cycles, 
we did not include a bioequivalence analysis. However, the boundaries of the adjusted 
90%-confidence interval of the relative differences of the regorafenib AUC found in 
this study almost fit the limits for bioequivalence (B vs A, RD: -3.9%, 90% CI: -18.2-
12.9%, and C vs A, RD: -4.1%, 90%CI: -20.3-15.4%)18, which supports the interpretation 
of our results.
In conclusion, we have shown that esomeprazole did not influence regorafenib 
exposure on two different intake time-points, and that these drugs can be combined in 
clinical practice, without the appearance of a significant pharmacokinetic interaction.
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SUPPLEMENTARY INFORMATION 
SUPPLEMENTARY METHODS 
DETAILED DESCRIPTION ASSAY REGORAFENIB, M-2 AND M-5
Regorafenib and the metabolites M-2- and M-5 were simultaneously quantitated 
by a validated liquid chromatography tandem triple quadrupole mass spectrometry 
(UPLC-MS/MS) assay. Aliquots of 25 μL of human lithium heparinized plasma samples 
for the quantitation of regorafenib and its metabolites were deproteinized, after the 
addition of 100 μL of Internal Standard (sunitinib-d10). After vigorously mixing for 5 
seconds and centrifugation for 10 min at 18,000*g, aliquots of 1 μL were injected into 
the UPLC-MS/MS-system. Peak area ratios of analytes versus the Internal Standard 
were a function of the concentration from 20.0 to 5,000 ng/mL. For regorafenib, the 
within and between-run precisions at five tested concentrations, including the LLQ, 
were ≤ 5.94 and ≤ 9.99%, respectively, while the average accuracy ranged from 101.4 
to 112.5%. For regorafenib-M2, the within and between-run precisions at five tested 
concentrations, including the LLQ, were ≤ 5.18 and ≤ 11.4%, respectively, while the 
average accuracy ranged from 91.0 to 96.7% and for regorafenib-M5, the within and 
between-run precisions at five tested concentrations, including the LLQ, were ≤ 6.47 
and ≤ 11.2%, respectively, while the average accuracy ranged from 92.8 to 99.4%.
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SUPPLEMENTARY RESULTS
Supplementary Figure 1. M-2 and M-5 AUC
M-2 and M-5 exposure compared between phase A (regorafenib alone) and phase B (regorafenib 
concomitantly with esomeprazole) (figure 1A, 1C), and between phase A and C (regorafenib 
with esomeprazole 3 hours prior) (figure 1B, 1D). Abbreviations: AUC
0-24 
= Area under the curve, 
timepoint 0h to 24h
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Supplementary Table 1. Toxicity 
Toxicitya Regorafenib
N (%)
Regorafenib + Esomeprazole
Concomitant
N (%)
Regorafenib + 
Esomeprazole 3h prior
N (%)
Overallb
N (%)
Gastrointestinal 
Anorexia
  All grades
  Grade ≥3 
6 (43)
1 (7)
5 (36)
1 (7)
5 (36)
1 (7)
10 (71)
2 (14)
Constipation
  All grades
  Grade ≥3
2 (14)
0
2 (14)
0
1 (7)
0
4 (29)
0
Diarrhea
  All grades
  Grade ≥3
0 1 (7)
0
2 (14)
0
2 (14)
0
Nausea
  All grades
  Grade ≥3
2 (14)
0
5 (36)
0
3 (21)
0
7 (50)
0
Reflux
  All grades
  Grade ≥3
1 (7)
0
0
0
1 (7)
0
2 (14)
0
Stomatitis
  All grades
  Grade ≥3
5 (36)
0
6 (43)
0
5 (36)
0
8 (57)
0
Vomiting
  All grades
  Grade ≥3
2 (14)
0
2 (14)
0
3 (21)
0
5 (36)
0
Respiratory
Cough
  All grades
  Grade ≥3
0 2 (14)
0
1 (7)
0
2 (14)
0
Dry mouth
  All grades
  Grade ≥3
0 1 (7)
0
3 (21)
0
3 (21)
0
Dyspnea
  All grades
  Grade ≥3
3 (21)
0
3 (21)
0
4 (29)
1 (7)
6 (43)
1 (7)
Ear pain
  All grades
  Grade ≥3
1 (7)
0
2 (14)
0
1 (7)
0
3 (21)
0
Hoarseness
  All grades
  Grade ≥3
8 (57)
0
11 (79)
0
9 (64)
0
11 (79)
0
Vascular 
Cardiac eventsc
  All grades
  Grade ≥3
0 2 (14)
0
0 2 (14)
0
Hypertension
  All grades
  Grade ≥3
4 (29)
3 (21)
4 (29)
3 (21)
5 (36)
5 (36)
10 (71)
9 (64)
Skin & Hair
Erythema
  All grades
  Grade ≥3
1 (7)
0
2 (14)
0
1 (7)
0
4 (29)
0
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Supplementary Table 1 continued.
Toxicitya Regorafenib
N (%)
Regorafenib + Esomeprazole
Concomitant
N (%)
Regorafenib + 
Esomeprazole 3h prior
N (%)
Overallb
N (%)
Skin & Hair
Hand foot skin reaction
  All grades
  Grade ≥3
6 (43)
0
9 (64)
1 (7)
7 (50)
1 (7)
9 (64)
2 (14)
Hypertrichosis
  All grades
  Grade ≥3
0 1 (7)
0
1 (7)
0
1 (7)
0
General disorders
Fatigue
  All grades
  Grade ≥3
6 (43)
1 (7)
7 (50)
0
7 (50)
1 (7)
10 (71)
1 (7)
Blood value disorders
AST/ALT increase
  All grades
  Grade ≥3
7 (50)
0
6 (43)
1 (7)
5 (36)
0
11 (79)
1 (7)
Bilirubin increase
  All grades
  Grade ≥3
4 (29)
0
3 (21)
0
2 (14)
0
7 (50)
0
Hypophosphatemia
  All grades
  Grade ≥3
2 (14)
0
1 (7)
0
1 (7)
1 (7)
4 (29)
1 (7)
Platelet count 
decreased
  All grades
  Grade ≥3
0 1 (7)
0
0 1 (7)
0
Number of patients is scored as individual patients per phase.
a Toxicity was graded according to the NCI CTC-AE classification (version 4.03)
b Overall toxicity was defined as the number of patients during the whole study period (i.e. all three phases) 
c Cardiac events included atrial fibrillation and myocardial infarction
Abbreviations: AST = aspartate aminotransferase; ALT = alanine aminotransferase; N = number of patients
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CARBOPLATIN / PACLITAXEL
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EFFICACY AND TOXICITY OF 
WEEKLY CARBOPLATIN AND
PACLITAXEL AS INDUCTION 
OR PALLIATIVE TREATMENT 
IN ADVANCED ESOPHAGEAL 
CANCER PATIENTS
11
ABSTRACT 
BACKGROUND
Unfortunately, many patients with esophageal cancer have advanced disease at 
diagnosis, hence many treatment regimens with induction or palliative intent have been 
described. However, the most optimal treatment has not been identified. Therefore, we 
evaluated a weekly regimen of carboplatin (targeted at an area under the curve (AUC) 
of 4) and paclitaxel 100mg/m2 as induction or palliative treatment. 
METHODS
All patients with advanced (gastro)esophageal cancer treated with this regimen at 
Erasmus MC between 2002-2018 were included. Exclusion criteria were previous or 
concurrent radiotherapy on the esophagus, limited data, or treatment elsewhere. Data 
on toxicity, treatment response and survival were collected. Analyses were performed 
in two separate groups: induction (iCT) or palliative chemotherapy (pCT). Progression 
free survival (PFS) and overall survival (OS) were estimated with the Kaplan-Meier 
method. 
RESULTS
A total of 291 patients was included; iCT: 122 and pCT: 169. Most patients had a T3 
carcinoma (iCT:54%; pCT:66%), and stage IV disease (iCT:42%; pCT:91%). Toxicity grade 
≥3 occurred mainly as hematological toxicity (iCT:71%; pCT:73%), and sometimes as 
gastrointestinal toxicity (iCT:3%; pCT:5%). Response rates after six cycles were 48% (iCT) 
and 44% (pCT). For 42% of iCT patients esophagectomy or definitive chemoradiotherapy 
followed, resulting in a median PFS of 22.1 months (interquartile range (IQR):12.4-114.2) 
and median OS of 26.8 months (IQR:15.4-91.7). For pCT, median PFS was 8.2 months 
(IQR:5.1-14.5) and median OS 10.9 months (IQR:6.5-18.3). 
CONCLUSION
Weekly carboplatin (AUC4) and paclitaxel (100mg/m2) is a well-tolerable and effective 
induction or palliative treatment regimen, and therefore an option for patients with 
locally advanced or metastatic disease.
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INTRODUCTION
Esophageal cancer is currently the 8th most common cancer type worldwide, the 
incidence is still rising, and its mortality is high.1-3 Squamous cell carcinoma (SCC) is the 
most common histology for esophageal cancer worldwide, though adenocarcinomas 
(AC) are more dominant in the Western world due to typical welfare risk factors including 
obesity, smoking, and chronic gastresophageal reflex resulting in Barrett’s esophagus.1, 
3, 4 Esophageal cancer occurs three to four times more often in male than in female 
patients in both histological subtypes.1, 3, 4 However, the reason for the lower incidence 
in women is not completely understood; it has been suggested that female hormones 
or the different body fat distribution may protect women against this type of tumor.5-7 
Furthermore, Bohanes et al. demonstrated that male sex is an independent adverse 
prognostic factor for esophageal cancer-specific survival with a shorter survival for men 
compared to women in both locally advanced and metastatic disease.8 Other adverse 
prognostic factors are performance status of 2 or higher, significant weight loss before 
diagnosis (i.e. ≥ 10%), adenocarcinoma as histological subtype, liver or peritoneal 
metastases, extensively disseminated disease, and an elevated alkaline phosphatase 
or lactate dehydrogenase.9-12 Anatomic origin (i.e. esophageal, esophageal-gastric 
junction or gastric) was not identified as a significant prognostic factor in two studies9, 
13, while another study demonstrated that tumors arising in the lower one-third of the 
esophagus did have a worse survival compared to tumors located in the cervical and 
upper esophagus.12 
Although the prognosis of esophageal cancer has improved over the last decades, the 
outcome still remains poor with an overall 5-year survival of 20%.2, 4 Improvement in 
prognosis might be caused by recent advances in the treatment of patients with resectable 
(gastro)esophageal cancer by introduction of neoadjuvant chemoradiotherapy such 
as the CROSS-regimen.14, 15 However, almost half of all patients already have non-
resectable (gastro)esophageal cancer at diagnosis (i.e. locally advanced tumors or 
distant metastasis).16 For patients with locally advanced disease, systemic treatment 
can be considered in an attempt to downstage the tumor (i.e. induction treatment), 
which can be followed by surgery or chemoradiotherapy in case of good response. 
For induction chemotherapy several treatment regimens are described; most of them 
platinum- or fluoropyrimidine-based.17-19 
For patients with distant metastases palliative chemotherapy can be considered.20, 21 
Palliative systemic treatment improves survival compared to best supportive care, yet 
survival benefit is limited and toxicity should be taken into account.4, 20-22 Many different 
palliative treatment regimens are described which are often fluoropyrimidine- or 
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platinum-based doublet or triplet combination regimens. 4, 20, 21 Triplet regimens might 
be more effective than doublet regimens, however the incidence of severe toxicity 
increases significantly in triplet regimens compared to doublets.21, 23 International 
guidelines often recommend the combination of a fluoropyrimidine and platinum 
compound as first-line treatment in metastatic (gastro)esophageal cancer but it should 
be noted that these guideline are sometimes consensus based. The Dutch Esophagus 
Cancer Guideline describes that chemotherapy can be considered in metastatic 
esophageal cancer, but does not recommend one specific treatment regimen.24 A 
study of the Netherlands Cancer Registry demonstrated that in the Netherlands only, 
up to 69 different palliative treatment regimens are administered in metastatic (gastro)
esophageal cancer patients.25 This clearly demonstrates that the most optimal palliative 
treatment in esophageal cancer is not well defined.
Fifteen years ago, our research group performed a phase-1 study of weekly paclitaxel 
and carboplatin as palliative treatment for patients with metastatic esophageal cancer.26 
This regimen uses the same chemotherapeutic backbone as the CROSS-regimen but 
is not combined with radiotherapy. As a result, higher dosages are possible with a 
recommended dose for paclitaxel of 100 mg/m2 and carboplatin targeted at an area 
under the curve (AUC) of 4 mg x min/mL.26 This weekly regimen appeared to be very 
tolerable and effective with an overall response rate of 54%. Therefore, this regimen 
was utilized for most patients with advanced or metastatic (gastro)esophageal cancer 
at the Erasmus University Medical Center, Rotterdam, The Netherlands. The current 
analysis describes the efficacy and toxicity of this weekly carboplatin and paclitaxel 
regimen as induction or palliative treatment option in a real-world treatment setting. 
Furthermore, predictive factors for treatment outcome and prognostic factors for 
survival will be analyzed. 
METHODS
The patient cohort for this analysis was obtained from the Erasmus University Medical 
Center, Rotterdam, The Netherlands. The primary end point was treatment response in 
patients with (gastro)esophageal cancer treated with a weekly regimen of carboplatin 
(AUC 4) and paclitaxel (100 mg/m2) with induction or palliative treatment intent, 
respectively. Secondary end points included progression free survival (PFS), OS, the 
identification of predictive or prognostic factors, and the evaluation of toxicity. As 
this treatment regimen was considered routine clinical care at the Erasmus University 
Medical Center, no specific ethics approval or informed consent was required to 
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retrospectively collect and analyze these data for research purposes.
PATIENTS
All patients with (gastro)esophageal cancer treated with a weekly regimen of 
carboplatin (AUC 4) and paclitaxel (100 mg/m2) between October 2002 and May 2018 
at the Erasmus University Medical Center, Rotterdam, The Netherlands, were identified 
by the hospital pharmacy based on drug-dispensing data and evaluated for inclusion. 
Patients were excluded if radiotherapy on the esophagus was given concurrent or prior 
to start of treatment with weekly carboplatin and paclitaxel, if one or more cycles 
were given outside the Erasmus University Medical Center, or if there was limited data 
on investigated cycles was recorded in the electronic patient file (e.g. due to missing 
paper files uploaded in the electronic patient file). A multidisciplinary team consisting of 
a medical oncologist, upper gastro-intestinal surgeon, gastroenterologist, radiologist, 
and a radiotherapist, decided upon the treatment intent (induction or palliative 
treatment). Patients with non-resectable disease due to advanced locoregional 
bulky disease and/or suspected lymph nodes outside the field of possible radiation 
therapy (i.e. around the common hepatic artery, splenic hilum, or caudal to the celiac 
artery) were considered for induction treatment. All patients with distant metastasis 
were considered for palliative treatment. The treatment intent as decided by the 
multidisciplinary team was used for all further analyses and not retrospectively altered. 
TREATMENT
Treatment consisted of a weekly regimen of carboplatin (AUC 4) and paclitaxel (100 
mg/m2) for three weeks, then one week rest, followed by another three weekly cycles. 
After these six cycles, response-evaluation with CT-scan followed. For patients with 
regression of the primary tumor or disappearance of distant metastases while not 
developing new distant metastases after these first six weekly cycles another treatment 
option could follow (i.e. esophagectomy or definitive chemoradiotherapy 27). Selection 
criteria for esophagectomy were: a radical and curative resection was deemed possible, 
no distant metastases, sufficient clinical condition for surgery, and patient’s consent for 
surgery. Definitive chemoradiotherapy was proposed to all other patients with a good 
response after the first six weekly cycles. 
For patients without other treatment options (e.g. due to distant metastasis) with a 
good response on these first six weekly cycles, treatment was continued with three 
3-weekly cycles of carboplatin (AUC 6) and paclitaxel (175 mg/m2). All patients and 
treatment intent were discussed in a multidisciplinary team both before start and after 
end of treatment. 
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Paclitaxel and carboplatin were diluted in 500 mL of sodium chloride solution (0.9%), 
and both administered in a 1h-infusion. All patients received intravenous premedication 
consisting of dexamethasone 10 mg, ranitidine 50 mg, clemastine 2 mg within 30 
minutes before paclitaxel infusion, and granisetron 1 mg administered within 30 minutes 
before carboplatin infusion 26. Before start of a new cycle, hematological laboratory 
values had to fulfill the following requirements; for the first and fourth cycle (day 0 and 
28): leukocytes > 3.0 x 109/L, thrombocytes > 100 x 109/L, and for the second, third, 
fifth and sixth cycle (day 7, 14, 35 and 42): leukocytes > 1.0 x 109/L, thrombocytes > 50 x 
109/L. There were no restrictions on the absolute neutrophil count. Furthermore, for a 
full paclitaxel dose, adequate transaminases and bilirubin were required (bilirubin ≤ 1.5 
x upper limit of normal (ULN), and AST / ALT ≤ 2.5 x ULN (in case of liver metastases: 
AST / ALT ≤ 5 x ULN)). 
DATA
Data related to patient demographics, tumor characteristics, laboratory results, adverse 
events, treatment, response and survival were collected. Tumors were (re)staged 
according to the 7th edition of UICC-AJCC TNM staging manual 28. Laboratory results and 
adverse events were scored according to the Common Terminology Criteria for Adverse 
Events (CTC-AE) version 4.03 29. All adverse events occurring during the six weekly cycles 
and up to one week after treatment were collected and the highest grade per item was 
used in the analysis. Severe toxicity was defined as adverse events with a CTC-AE grade 
3 or higher. Gastro-intestinal toxicity was defined as the occurrence of anorexia, nausea, 
vomiting, diarrhea, constipation and mucositis. Hematological toxicity was defined as the 
occurrence of anemia, thrombocytopenia, leukocytopenia and neutropenia. 
Response was determined after six cycles on radiological evaluation by CT-scan 
according to the radiologist (and if possible) by the RECIST criteria 30. If there was no 
radiological evaluation possible due to clinical deterioration or death, this was counted 
as progressive disease (PD) on date of whatever came first. PFS and OS were defined 
as time from start of chemotherapy till date of radiological or clinical progression or 
death, respectively.
STATISTICAL ANALYSIS
For all analyses, the patient cohort was divided in patients treated with induction or 
palliative treatment intent. These groups were analysed separately to prevent bias 
induced by baseline patient and tumor characteristics. Demographic characteristics 
and toxicity were described per group. Survival time (i.e. PFS and OS) was estimated 
according to the Kaplan-Meier method. Predictive factors for treatment response 
were analysed with logistic regression analysis, where good response was defined 
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as complete or partial response (CR or PR). Good response was compared to stable 
disease (SD) and progressive disease (PD) together. Prognostic factors for survival (PFS 
and OS) were identified by univariate and multivariate Cox regression analyses. All 
factors with a P-value <0.1 detected in univariate analyses were included in multivariate 
analyses. A backward selection method was used for the multivariate model where 
a threshold of P < 0.05 was applied. In general, P-values <0.05 were considered 
statistically significant. All statistical analyses were performed using Stata version 15.1 
(StataCorp. 2017. Statistical Software, College Station, TX: StataCorp LP). 
RESULTS
PATIENT, TUMOR AND TREATMENT CHARACTERISTICS
A total of 420 patients with (gastro)esophageal cancer who were treated with 
carboplatin (AUC 4) and paclitaxel (100 mg/m2) were screened for inclusion of whom 
129 patients were excluded, mainly because of concurrent radiotherapy or referral for 
chemotherapy in another hospital (Figure 1). This resulted in a total of 291 patients 
evaluable for the analysis of whom 122 patients were included in the induction 
chemotherapy (iCT) group and 169 patients in the palliative chemotherapy (pCT) 
group. For 8 patients (iCT: 3 and pCT: 5), date of death was unknown and they were 
excluded from the overall survival analysis. 
The majority of patients in both groups were male (76% and 82%, respectively) and 
had a good WHO performance status (i.e WHO 0 or 1). Median age was 64 years (IQR: 
58-69) in the iCT group and 61 years (IQR: 55-68) in the pCT group. Most patients still 
smoked tobacco and used alcohol before diagnosis or currently on a regular base. All 
patient and treatment characteristics are described in Table 1. In the iCT group the 
incidence of the adenocarcinoma was almost equal to squamous cell carcinoma (50% 
versus 48%) in contrast to the pCT group where the incidence of adenocarcinoma was 
higher (70% versus 28%). In the iCT group, tumors were most often located in the distal 
esophagus (47%), but also in the proximal (19%), middle esophagus (24%) and gastro-
esophageal junction (11%). In the pCT group, the majority of all tumors were located 
at the distal esophagus (73%). TNM-stage was also different between the iCT and pCT 
patients, which resembles the intent of treatment per group, with more M1-disease 
and higher variety of metastases locations in the pCT group (Table 1). The administered 
mean carboplatin and paclitaxel dose were comparable in both groups, and median 
number of treatment cycles was 7 in the iCT group and 8 in the pCT group (i.e. six 
weekly cycles, followed by 3-weekly cycles).
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Figure 1. STROBE diagram of included patients
Treatment elsewhere included patients who were referred for one or more cycles of chemotherapy 
in another hospital. 
Abbreviations: iCT = induction chemotherapy; N = number; pCT = palliative chemotherapy
Table 1. Patient, tumor and treatment characteristics
Characteristic iCT (N=122) pCT (N=169)
Sex
   Male 
   Female
93 (76%)
29 (24%)
138 (82%)
 31 (18%)
Age (years)
   Median [IQR] 64 [58-69]  61 [55-68]
Performance Status
   WHO 0
   WHO 1
   WHO 2
   Unknown
28 (23%)
73 (60%)
 7 (6%)
14 (12%)
 49 (29%)
 90 (53%)
  5 (3%)
 25 (13%)
Ethnic Origin
   Caucasian
   African 
   Asian
   Unknown
93 (76%)
 1 (0,8%)
 0
28 (23%)
120 (71%)
  3 (2%)
  4 (2%)
 42 (25%)
BSA (m2) a
   Mean [SD] 1.91 [0.22] 1.89 [0.21]
eGFR (mL/min)b
   Median [IQR]
   Unknown
93 [84-99]
21 (17%)
 92 [78-100]
 45 (27%)
Smoking   
   Never
   Before diagnosis
   Current
   Unknown
15 (12%)
22 (18%)
80 (66%)
 5 (4%)
 31 (18%)
 36 (21%)
 91 (54%)
 11 (7%)
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Table 1 continued.
Characteristic iCT (N=122) pCT (N=169)
Alcohol
   Never
   Before diagnosis
   Current
   Unknown
24 (20%)
54 (44%)
37 (30%)
 7 (6%)
 29 (17%)
 81 (48%)
 48 (28%)
 11 (7%)
Tumor Location
   Proximal 
   Middle
   Distal
   GE-junction
   Multiple locations
23 (19%)
29 (24%)
57 (47%)
13 (11%)
 0
  8 (5%)
 26 (15%)
123 (73%)
 10 (6%)
  2 (1%)
Tumor Type
   Adenocarcinoma
   Squamous cell carcinoma
   Other c
   Unknown
61 (50%)
59 (48%)
 2 (2%)
 0
117 (70%)
 48 (28%)
  3 (2%)
  1 (1%)
Tumor Differentiation
   Good
   Moderate
   Poor
   Unknown
 7 (6%)
38 (31%)
48 (39%)
29 (24%)
  3 (2%)
 50 (30%)
 74 (44%)
 42 (25%)
T-stage
   T1b
   T2
   T3
   T4a
   T4b
 0 
 5 (4%)
66 (54%)
27 (22%)
24 (20%)
  3 (2%)
 12 (7%)
112 (66%)
 23 (14%)
 13 (8%)
N-stage
   N0
   N1
   N2
   N3
12 (10%)
49 (40%)
48 (39%)
13 (11%)
 21 (12%)
 69 (41%)
 56 (33%)
 23 (14%)
M-stage
   M0
   M1
71 (58%)
51 (42%)
 15 (9%)
155 (91%)
Metastases Location
   Lymph nodes
   Liver
   Lungs
   Other
   Multiple locations
   Not applicable
50 (41%)
 0
 0
 0
 1 (1%)*
71 (58%)
 72 (43%)
 19 (11%)
  3 (2%)
 18 (11%)
  42 (25%)
  15 (9%)
Disease Stage
   IB
   IIA
   IIB
   IIIA
   IIIB
   IIIC
   IV
 1 (1%)
 5 (4%)
 1 (1%)
17 (14%)
13 (11%)
34 (28%)
51 (42%)
  0
  2 (1%)
  2 (1%)
  4 (2%)
  2 (1%)
  5 (3%)
154 (91%)
Carboplatin dose (mg)
   Mean [SD] 477 [90] 486 [95]
275
11
WEEKLY CARBOPLATIN AND PACLITAXEL IN ADVANCED ESOPHAGEAL CANCER PATIENTS
Table 1 continued.
Characteristic iCT (N=122) pCT (N=169)
Paclitaxel dose (mg)
   Mean [SD] 191 [22] 187 [22]
Number of treatment cycles d
   Median [IQR]   7 [6-9]   8 [6-9]
a BSA was calculated according to the Mosteller formula 31
b eGFR was calculated according to the CKD-EPI formula 32
c Tumor Type Other included undifferentiated large cell carcinomas and neuroendocrine carcinomas
d Six weekly cycles, followed by 3-weekly cycles
Abbreviations: BSA = body surface area; GE = gastro-esophageal; iCT = induction chemotherapy; IQR = inter-
quartile range; mg = milligram; N = number; pCT = palliative chemotherapy; SD = standard deviation; 
WHO = World Health Organization
TOXICITY
Overall, this treatment regimen was relatively well tolerated. However, the incidence 
of overall grade ≥ 3 toxicity was 71% in the iCT group and 78% in the pCT group, 
respectively. These grade 3 or 4 toxicities occurred mainly as hematological toxicity; 
especially neutropenia with grade 3 in 43% and grade 4 in 25% of patients in both 
groups. However, febrile neutropenia occurred in ten patients only, resulting in a low 
incidence of 3% complicated neutropenia (Table 2). Gastro-intestinal toxicity was 
mostly low-graded, gastro-intestinal toxicity grade ≤ 2 occurred mainly as nausea (iCT: 
39%, pCT: 46%), constipation (iCT: 34%, pCT: 42%) and anorexia (iCT: 21%, pCT: 26%). 
Severe gastro-intestinal toxicity (i.e. grade ≥ 3) occurred in 3% of the iCT and 5% of the 
pCT patients (Table 2). Fatigue grade ≤ 2 occurred in 70% of patients of both groups, 
but severe fatigue in only six patients. Neuropathy was mostly seen as low-graded 
sensory neuropathy in a quarter of patients in both groups, and motoric neuropathy 
grade 2 in six patients. Adverse events rarely resulted in a dose reduction of carboplatin 
or paclitaxel as dose reductions were applied in only 2 patients due to severe nausea 
in one patient and febrile neutropenia in the other. Transfusion related reactions were 
more frequent and occurred mainly as reaction to paclitaxel (instead of carboplatin) in 
around one fifth of the patients. 
During the six weekly cycles, cycle delay due to toxicity occurred in 42% and 43% of 
the patients treated with iCT and pCT, respectively. This delay was mainly caused by 
thrombocytopenia in 46% of these patients, leukocytopenia (20%) or a combination of 
both (11%), other reasons included non-neutropenic fever (6%) and gastro-intestinal 
toxicity (5%). Cycle delay consisted of one week in 70% of patients with delay, and two 
weeks in 19% of patients, and occurred mostly at cycle 4 (70%). For patients with a cycle 
delay due to toxicity, this was often one cycle (85%), however, in 18 patients (15%) two 
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separate cycles were delayed due to hematological toxicity. Premature termination of 
the planned six weekly cycles due to toxicity occurred in 14 iCT patients (12%) and 28 
pCT patients (17%) mostly due to general malaise (43%), or thrombocytopenia (14%) 
and leukocytopenia (10%) or both (7%). Hospitalization due to toxicity occurred in 18 
iCT patients (15%) and 17 pCT patients (10%), which was caused by gastro-intestinal 
toxicity in 11 patients, febrile neutropenia in 10 patients, non-neutropenic fever in 13 
patients, and malaise in one patient. There were no toxic deaths in our cohort. 
EFFICACY
After six weekly cycles, overall response rate was 48% for iCT and 44% pCT, with a 
complete response in 1% of both groups (Table 3). For many iCT patients additional 
treatment was given: definitive chemoradiotherapy (7%), esophagectomy (35%), 
exploratory laparotomy (4%), or second line chemotherapy (17%) (Table 3). In the pCT 
group some patients received another treatment also: definitive chemoradiotherapy 
(1%), esophagectomy (4%), exploratory laparotomy (5%), or second line chemotherapy 
(19%). 
Median follow-up for the 27 iCT patients still alive was 43.7 months (range 2-117 months), 
and 18.4 months in 21 patients for pCT (range 6-124 months). For the whole group of 
iCT patients, median PFS was 12.4 months (IQR: 7.1-45.3 months) and median OS was 
15.6 months (IQR: 9.7-36.3). However, in the 42% of patients who underwent subsequent 
resection or radiotherapy median PFS was 22.1 months (IQR: 12.4-114.2) and median OS 
was 26.8 months (IQR: 15.4-91.7). For patients treated with pCT, median PFS was 8.2 
months (IQR: 5.1-14.5) and median OS 10.9 months (IQR: 6.5-18.3). The median PFS and 
OS for patients treated with pCT are comparable to iCT patients who did not receive an 
esophagectomy or definitive chemoradiotherapy afterwards (Table 3). 
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Table 2. Toxicity and clinical consequences
ADVERSE EVENTS
iCT
N=122
pCT
N=169
Grade 1 Grade 2 Grade ≥3 Grade 1 Grade 2 Grade ≥3
Overall Toxicity 114 (93%) 111 (91%) 86 (71%) 167 (99%) 154 (91%) 131 (78%)
Gastrointestinal Toxicity
    Anorexia
    Nausea 
    Vomiting
    Diarrhea
    Constipation
    Mucositis
21 (17%)
39 (32%)
19 (16%)
20 (16%)
31 (25%)
4 (3%)
5 (4%)
8 (7%)
4 (3%)
1 (1%)
10 (8%)
2 (2%)
1 (1%)
1 (1%)
0
2 (2%)
0
0
35 (21%)
68 (40%)
27 (16%)
21 (12%)
57 (34%)
17 (10%)
9 (5%)
10 (6%)
5 (3%)
10 (6%)
15 (9%)
0
3 (2%)
3 (2%)
3 (2%)
2 (1%)
0
1 (1%)
Other Toxicity
    Alopecia
    Dermatitis
    Fatigue
    Sensory Neuropathy
    Motoric Neuropathy
32 (26%)
9 (7%)
59 (48%)
27 (22%)
1 (2%)
40 (33%)
2 (2%)
25 (21%)
3 (3%)
0
NA
0
1 (1%)
0
0
50 (30%)
10 (6%)
82 (49%)
40 (24%)
3 (2%)
65 (39%)
4 (2%)
36 (21%)
4 (2%)
6 (4%)
NA
0
5 (3%)
0
0
Hematological Toxicity
    Anemia
    Thrombocytopenia
    Leukocytopenia
    Neutropenia
57 (47%)
67 (55%)
7 (6%)
0
58 (48%)
22 (18%)
56 (46%)
21 (17%)
6 (5%)
13 (11%)
43 (35%)
82 (67%)
86 (51%)
83 (49%)
18 (11%)
0
64 (38%)
27 (16%)
74 (44%)
24 (14%)
17 (10%)
22 (13%)
52 (31%)
113 (67%)
Other blood value alterations
   Creatinine Increase
   AST Increase
   ALT Increase
   GGT Increase
   AF Increase
   Bilirubin Increase
6 (5%)
21 (17%)
20 (16%)
20 (16%)
19 (16%)
12 (10%)
0
0
3 (3%)
4 (3%)
0
5 (4%)
0
1 (1%)
0
1 (1%)
0
0
6 (4%)
29 (17%)
20 (12%)
25 (15%)
25 (15%)
7 (4%)
0
2 (1%)
3 (2%)
14 (8%)
1 (1%)
7 (4%)
0
4 (2%)
2 (1%)
12 (7%)
6 (4%)
3 (2%)
CLINICAL CONSEQUENCES
iCT
N=122
pCT
N=169
No Yes: toxicity Yes: other No Yes: toxicity Yes: other
Febrile Neutropenia 118 (97%) 4 (3%) NA 163 (96%) 6 (4%) NA
Dose reduction Carboplatin 117 (96%) 1 (1%) 3 (3%) a 126 (75%) 1 (1%) 4 (2%) a
Dose reduction Paclitaxel 97 (79%) 1 (1%) 24 (20%) a 126 (75%) 1 (1%) 40 (24%) a
Treatment delay 64 (53%) 51 (42%) 7 (6%) 84 (50%) 72 (43%) 11 (7%)
Premature end of treatment* 95 (78%) 14 (12%) 13 (11%) b 109 (64%) 29 (17%) 31 (19%) b
Hospitalization 96 (79%) 18 (15%) 8 (7%) 140 (83%) 17 (10%) 12 (7%)
* Premature end of treatment was defined as end of treatment before the planned six weekly cycles.
a Dose reduction other was defined as a transfusion related reaction to paclitaxel or carboplatin, in these cases 
dose was not reduced but infusion time was prolonged. 
b Premature end of treatment other included disease progression in 7 (iCT) and 16 (pCT) patients.
Abbreviations: ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; 
GGT = gamma-glutamyltransferase; iCT = induction chemotherapy; N = number; NA = not applicable, pCT = 
palliative chemotherapy
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Table 3. Treatment response
iCT
N=122
pCT
N=169
Response after 6 cycles
    Complete Response
    Partial Response
    Stable Disease
    Progressive Disease
    Unknown
 1 (1%)
57 (47%)
46 (38%)
11 (9%)
 7 (6%)
 2 (1%)
72 (43%)
56 (33%)
23 (14%)
16 (10%)
Treatment afterwards a
    Carboplatin-Paclitaxel b
    Chemotherapy Other c
    Definitive Chemoradiotherapy d
    Esophagectomy
 13 (11%)
  8 (7%)
  9 (7%)
 43 (35%)
 14 (8%)
 18 (11%)
  1 (1%)
  7 (4%)
PFS (months; median [IQR])
    All patients
    No CRT or esophagectomy afterwards 
    CRT or esophagectomy afterwards
12.4 [7.1-45.3]
 9.0 [4.3-13.4]
22.1 [12.4-114.2]
 8.2 [5.1-14.5]
 8.0 [5.0-13.2]
18.1 [14.8-122.2]
OS (months; median [IQR])
    All patients
    No CRT or esophagectomy afterwards 
    CRT or esophagectomy afterwards
15.6 [9.7-36.3]
11.8 [7.3-18.6]
26.8 [15.4-91.7]
10.9 [6.5-18.3]
10.6 [6.4-17.2]
23.1 [14.8-28.0]
a Intervention after last administration of carboplatin (AUC 4) and paclitaxel (100 mg/m2)
b Second period of treatment with carboplatin (AUC 4) and paclitaxel (100 mg/m2)
c Chemotherapy other than carboplatin and paclitaxel; including EOX (epirubicin, oxaliplatin and capecitabine), 
5-fluorouracil combined with cisplatin, or phase-1 trial medication combined with docetaxel, irinotecan, or 
capecitabine
d Definitive chemoradiotherapy included six weekly cycles of carboplatin (targeted at AUC 2) and paclitaxel (50 
mg/m2) combined with radiotherapy on the esophagus 27
Abbreviations: AUC = area under the curve; CRT = definitive chemoradiotherapy; iCT = induction chemotherapy; 
IQR = inter-quartile range; N = number; pCT = palliative chemotherapy
PREDICTIVE AND PROGNOSTIC FACTORS
In the iCT group, smoking was identified as a predictive factor for poor response (SD/
PD) with an odds ratio of 2.30 (95% confidence interval (CI): 1.02-2.21, P = 0.045) 
for current smokers compared to former and non-smokers. Unfortunately, no other 
predictive factors for treatment response could be identified in the iCT group, nor in 
the pCT group, for these results see Supplementary Table 1. 
For iCT patients smoking was also an adverse prognostic factor for PFS and OS 
univariately, but only remained significant in the multivariate analysis of PFS with an 
hazard ratio (HR) of 2.61 (95% CI: 1.17-5.85, P = 0.020) for current smokers versus non-
smokers. In addition, elevated thrombocyte number and alkaline phosphatase levels 
were also adverse prognostic factors for PFS in the multivariate model (HR: 1.00, 95% 
CI: 1.00-1.01, P = 0.001 and HR: 1.02, 95% CI: 1.00-1.03, P=0.023, respectively). For 
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OS, higher WHO performance status (HR: 1.87, 95% CI: 1.06-3.29, P = 0.031), higher 
T-stage (T4B; HR: 1.82, 95% CI: 1.02-3.25, P = 0.044) and thrombocyte number (HR: 
1.00, 95% CI: 1.00-1.00, P = 0.025) were adverse prognostic factors in the multivariate 
model, see Table 4. 
For pCT patients tumor location and year of diagnosis remained prognostic factors in 
the multivariate analysis for PFS with patients with a mid-esophageal tumor having a 
better PFS compared to proximal tumors (HR: 0.29, 95% CI: 0.10-0.80, P = 0.017). For 
OS, mid-esophageal tumor location was also found to be significant with a comparable 
HR as for PFS. Other variables included in the multivariate model for OS were body 
surface area (BSA; HR: 0.34, 95% CI: 0.12-0.91, P = 0.032) and WHO 1/2 versus 0 (HR: 
1.69, 95% CI: 1.13-2.52, P = 0.011). For all results, see Table 4.
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Table 4. Prognostic factors for PFS and OS in patients treated with induction or palliative 
chemotherapy
BASELINE FACTOR
INDUCTION CHEMOTHERAPY (iCT) PALLIATIVE CHEMOTHERAPY (pCT)
Progression Free Survival Overall Survival Progression Free Survival Overall Survival
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
SEX(M vs F) 0.77 0.45-1.29 0.319 0.83 0.51-1.34 0.443 1.00 0.63-1.59 0.989 0.90 0.58-1.39 0.623
AGE 1.01 0.98-1.03 0.600 1.01 0.99-1.03 0.496 1.00 0.98-1.03 0.738 1.00 0.98-1.02 0.892
BSA 0.89 0.30-2.62 0.835 0.63 0.24-1.64 0.341 0.80 0.33-1.94 0.618 0.30 0.13-0.69 0.005 0.34 0.12-0.91 0.032
WHO (1 vs 0) 1.31 0.77-2.23 0.322 2.20 1.30-3.72 0.003 1.87 1.06-3.29 0.031 1.34 0.90-2.01 0.154 1.70 1.16-2.48 0.006 1.69 1.13-2.52 0.011
ALCOHOL (vs never)
   History
   Current 
1.03
1.50
0.44-2.43
0.76-2.96
0.311
1.49
1.98
0.64-3.49
0.95-4.14
0.114
0.71
0.90
0.40-1.29
0.57-1.44
0.498
0.83
0.87
0.50-1.40
0.56-1.34
0.767
SMOKING (vs never)
   History 
   Current 
1.17
2.22
0.63-2.18
1.14-4.33
0.032
0.619
0.019
1.28
2.61
0.60-2.75
1.17-5.85
0.522
0.020
1.40
2.42
0.76-2.60
1.26-4.63
0.015
0.281
0.008
0.92
1.02
0.55-1.53
0.58-1.78
0.883
0.92
0.98
0.57-1.47
0.59-1.63
0.915
TUMOR LOCATION (vs 
proximal)
   Middle
   Distal
   Junction/Cardia
   Multiple locations
1.17
0.99
0.94
NA
0.57-2.43
0.52-1.91
0.37-2.41
NA
0.937
0.79
0.67
0.55
0.43-1.45
0.39-1.16
0.24-1.26
0.429
0.32
0.59
0.69
0.85
0.12-0.89
0.24-1.45
0.22-2.11
0.16-4.42
0.100
0.029
0.246
0.513
0.849
0.29
0.55
0.68
0.73
0.10-0.80
0.22-1.36
0.22-2.08
0.14-3.80
0.017
0.193
0.498
0.705
0.27
0.45
0.46
0.87
0.12-0.63
0.22-0.94
0.18-1.17
0.18-4.13
0.045
0.002
0.033
0.103
0.859
0.27
0.54
0.49
0.11-0.65
0.26-1.15
0.18-1.33
0.004
0.110
0.160
YEAR OF DIAGNOSIS 1.03 0.96-1.10 0.381 1.01 0.95-1.08 0.689 1.06 1.01-1.12 0.016 1.06 1.01-1.12 0.028 1.01 0.96-1.05 0.833
HISTOLOGY (SCC vs AC) 1.06 0.66-1.68 0.816 1.22 0.80-1.86 0.354 0.56 0.36-0.86 0.008 0.76 0.52-1.10 0.146
DIFFERENTIATION 
(poor vs good/moderate) 1.40 0.83-2.37 0.206 1.15 0.71-1.86 0.572 1.06 0.70-1.63 0.776 1.06 0.72-1.56 0.761
T-STAGE 
(iCT: vs T2/T3, pCT: vsT1b/
T2)
   T3
   T4A
   T4B
NA
1.28
1.61
NA
0.74-2.22
0.86-3.00
0.305
NA
0.98
2.20
NA
0.57-1.68
1.32-3.66
0.014
NA
0.948
0.003
NA
1.01
1.82
NA
0.56-1.81
1.02-3.25
NA
0.984
0.044
1.85
1.68
1.36
0.98-3.48
0.76-3.71
0.56-3.28
0.204 2.03
2.13
1.59
1.11-3.71
1.03-4.41
0.71-3.55
0.076
N-STAGE (vs N0)
   N1
   N2
   N3
0.72
0.83
0.79
0.29-1.75
0.35-2.00
0.28-2.25
0.888
0.93
0.94
0.77
0.47-1.83
0.48-1.86
0.33-1.82
0.935
0.92
1.17
1.15
0.51-1.65
0.65-2.12
0.59-2.24
0.704
1.03
1.14
1.23
0.60-1.76
0.65-1.98
0.65-2.33
0.867
M-STAGE (vs M0) 0.97 0.61-1.53 0.880 0.90 0.59-1.38 0.634 2.72 1.00-7.38 0.050 1.05 0.58-1.90 0.877
METASTASES LOCATION
(vs no metastases)
   Nodal
   Liver
   Other
   Multiple locations
NA NA NA NA NA NA
1.78
3.43
2.36
2.51
0.71-4.48
1.26-9.33
0.85-6.57
0.98-6.44
0.048
0.219
0.016
0.099
0.055
1.00
1.26
1.14
1.16
0.54-1.86
0.57-2.77
0.54-2.42
0.60-2.23
0.916
LIVER METASTASES (Y vs No) NA NA NA NA NA NA 1.47 1.02-2.13 0.040 1.12 0.78-1.60 0.534
HEMOGLOBIN (mmol/L) 0.99 0.79-1.26 0.961 0.83 0.67-1.03 0.087 0.95 0.80-1.12 0.520 0.86 0.74-1.00 0.052
THROMBOCYTES (109/L) 1.00 1.00-1.00 0.010 1.00 1.00-1.01 0.001 1.00 1.00-1.00 0.020 1.00 1.00-1.00 0.025 1.00 1.00-1.00 0.695 1.00 1.00-1.00 0.684
LEUKOCYTES (109/L) 1.05 0.97-1.13 0.206 1.04 0.97-1.11 0.270 1.01 0.99-1.03 0.478 1.00 0.99-1.02 0.735
NEUTROPHILS (109/L) 1.05 0.96-1.14 0.310 1.04 0.96-1.12 0.312 1.01 0.97-1.05 0.696 1.01 0.95-1.08 0.660
AST (U/L) 1.00 0.97-1.03 0.958 0.99 0.97-1.02 0.599 1.00 1.00-1.01 0.145 1.00 1.00-1.01 0.883
ALT (U/L) 1.00 0.99-1.01 0.880 1.00 0.99-1.01 0.633 1.00 1.00-1.00 0.767 1.00 0.99-1.00 0.475
LD (U/L) 1.00 1.00-1.00 0.396 1.00 1.00-1.00 0.716 1.00 1.00-1.00 0.908 1.00 1.00-1.00 0.414
GGT (U/L) 1.00 1.00-1.01 0.301 1.00 1.00-1.01 0.193 1.00 1.00-1.00 0.608 1.00 1.00-1.00 0.973
AP (U/L) 1.01 1.00-1.01 0.056 1.02 1.00-1.03 0.023 1.00 1.00-1.01 0.183 1.00 1.00-1.00 0.948 1.00 1.00-1.00 0.943
BILIRUBIN (μmol/L) 1.01 0.95-1.07 0.836 1.02 0.96-1.08 0.596 1.00 0.96-1.03 0.953 1.01 0.97-1.04 0.722
KREATININ (μmol/L) 0.99 0.97-1.00 0.114 1.00 0.98-1.01 0.665 1.00 0.99-1.02 0.552 0.99 0.98-1.01 0.356
P-values < 0.05 are considered statistically significant and are depicted in bold. 
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Table 4. Prognostic factors for PFS and OS in patients treated with induction or palliative 
chemotherapy
BASELINE FACTOR
INDUCTION CHEMOTHERAPY (iCT) PALLIATIVE CHEMOTHERAPY (pCT)
Progression Free Survival Overall Survival Progression Free Survival Overall Survival
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
SEX(M vs F) 0.77 0.45-1.29 0.319 0.83 0.51-1.34 0.443 1.00 0.63-1.59 0.989 0.90 0.58-1.39 0.623
AGE 1.01 0.98-1.03 0.600 1.01 0.99-1.03 0.496 1.00 0.98-1.03 0.738 1.00 0.98-1.02 0.892
BSA 0.89 0.30-2.62 0.835 0.63 0.24-1.64 0.341 0.80 0.33-1.94 0.618 0.30 0.13-0.69 0.005 0.34 0.12-0.91 0.032
WHO (1 vs 0) 1.31 0.77-2.23 0.322 2.20 1.30-3.72 0.003 1.87 1.06-3.29 0.031 1.34 0.90-2.01 0.154 1.70 1.16-2.48 0.006 1.69 1.13-2.52 0.011
ALCOHOL (vs never)
   History
   Current 
1.03
1.50
0.44-2.43
0.76-2.96
0.311
1.49
1.98
0.64-3.49
0.95-4.14
0.114
0.71
0.90
0.40-1.29
0.57-1.44
0.498
0.83
0.87
0.50-1.40
0.56-1.34
0.767
SMOKING (vs never)
   History 
   Current 
1.17
2.22
0.63-2.18
1.14-4.33
0.032
0.619
0.019
1.28
2.61
0.60-2.75
1.17-5.85
0.522
0.020
1.40
2.42
0.76-2.60
1.26-4.63
0.015
0.281
0.008
0.92
1.02
0.55-1.53
0.58-1.78
0.883
0.92
0.98
0.57-1.47
0.59-1.63
0.915
TUMOR LOCATION (vs 
proximal)
   Middle
   Distal
   Junction/Cardia
   Multiple locations
1.17
0.99
0.94
NA
0.57-2.43
0.52-1.91
0.37-2.41
NA
0.937
0.79
0.67
0.55
0.43-1.45
0.39-1.16
0.24-1.26
0.429
0.32
0.59
0.69
0.85
0.12-0.89
0.24-1.45
0.22-2.11
0.16-4.42
0.100
0.029
0.246
0.513
0.849
0.29
0.55
0.68
0.73
0.10-0.80
0.22-1.36
0.22-2.08
0.14-3.80
0.017
0.193
0.498
0.705
0.27
0.45
0.46
0.87
0.12-0.63
0.22-0.94
0.18-1.17
0.18-4.13
0.045
0.002
0.033
0.103
0.859
0.27
0.54
0.49
0.11-0.65
0.26-1.15
0.18-1.33
0.004
0.110
0.160
YEAR OF DIAGNOSIS 1.03 0.96-1.10 0.381 1.01 0.95-1.08 0.689 1.06 1.01-1.12 0.016 1.06 1.01-1.12 0.028 1.01 0.96-1.05 0.833
HISTOLOGY (SCC vs AC) 1.06 0.66-1.68 0.816 1.22 0.80-1.86 0.354 0.56 0.36-0.86 0.008 0.76 0.52-1.10 0.146
DIFFERENTIATION 
(poor vs good/moderate) 1.40 0.83-2.37 0.206 1.15 0.71-1.86 0.572 1.06 0.70-1.63 0.776 1.06 0.72-1.56 0.761
T-STAGE 
(iCT: vs T2/T3, pCT: vsT1b/
T2)
   T3
   T4A
   T4B
NA
1.28
1.61
NA
0.74-2.22
0.86-3.00
0.305
NA
0.98
2.20
NA
0.57-1.68
1.32-3.66
0.014
NA
0.948
0.003
NA
1.01
1.82
NA
0.56-1.81
1.02-3.25
NA
0.984
0.044
1.85
1.68
1.36
0.98-3.48
0.76-3.71
0.56-3.28
0.204 2.03
2.13
1.59
1.11-3.71
1.03-4.41
0.71-3.55
0.076
N-STAGE (vs N0)
   N1
   N2
   N3
0.72
0.83
0.79
0.29-1.75
0.35-2.00
0.28-2.25
0.888
0.93
0.94
0.77
0.47-1.83
0.48-1.86
0.33-1.82
0.935
0.92
1.17
1.15
0.51-1.65
0.65-2.12
0.59-2.24
0.704
1.03
1.14
1.23
0.60-1.76
0.65-1.98
0.65-2.33
0.867
M-STAGE (vs M0) 0.97 0.61-1.53 0.880 0.90 0.59-1.38 0.634 2.72 1.00-7.38 0.050 1.05 0.58-1.90 0.877
METASTASES LOCATION
(vs no metastases)
   Nodal
   Liver
   Other
   Multiple locations
NA NA NA NA NA NA
1.78
3.43
2.36
2.51
0.71-4.48
1.26-9.33
0.85-6.57
0.98-6.44
0.048
0.219
0.016
0.099
0.055
1.00
1.26
1.14
1.16
0.54-1.86
0.57-2.77
0.54-2.42
0.60-2.23
0.916
LIVER METASTASES (Y vs No) NA NA NA NA NA NA 1.47 1.02-2.13 0.040 1.12 0.78-1.60 0.534
HEMOGLOBIN (mmol/L) 0.99 0.79-1.26 0.961 0.83 0.67-1.03 0.087 0.95 0.80-1.12 0.520 0.86 0.74-1.00 0.052
THROMBOCYTES (109/L) 1.00 1.00-1.00 0.010 1.00 1.00-1.01 0.001 1.00 1.00-1.00 0.020 1.00 1.00-1.00 0.025 1.00 1.00-1.00 0.695 1.00 1.00-1.00 0.684
LEUKOCYTES (109/L) 1.05 0.97-1.13 0.206 1.04 0.97-1.11 0.270 1.01 0.99-1.03 0.478 1.00 0.99-1.02 0.735
NEUTROPHILS (109/L) 1.05 0.96-1.14 0.310 1.04 0.96-1.12 0.312 1.01 0.97-1.05 0.696 1.01 0.95-1.08 0.660
AST (U/L) 1.00 0.97-1.03 0.958 0.99 0.97-1.02 0.599 1.00 1.00-1.01 0.145 1.00 1.00-1.01 0.883
ALT (U/L) 1.00 0.99-1.01 0.880 1.00 0.99-1.01 0.633 1.00 1.00-1.00 0.767 1.00 0.99-1.00 0.475
LD (U/L) 1.00 1.00-1.00 0.396 1.00 1.00-1.00 0.716 1.00 1.00-1.00 0.908 1.00 1.00-1.00 0.414
GGT (U/L) 1.00 1.00-1.01 0.301 1.00 1.00-1.01 0.193 1.00 1.00-1.00 0.608 1.00 1.00-1.00 0.973
AP (U/L) 1.01 1.00-1.01 0.056 1.02 1.00-1.03 0.023 1.00 1.00-1.01 0.183 1.00 1.00-1.00 0.948 1.00 1.00-1.00 0.943
BILIRUBIN (μmol/L) 1.01 0.95-1.07 0.836 1.02 0.96-1.08 0.596 1.00 0.96-1.03 0.953 1.01 0.97-1.04 0.722
KREATININ (μmol/L) 0.99 0.97-1.00 0.114 1.00 0.98-1.01 0.665 1.00 0.99-1.02 0.552 0.99 0.98-1.01 0.356
P-values < 0.05 are considered statistically significant and are depicted in bold. 
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DISCUSSION
This retrospective analysis demonstrated that a weekly regimen of six cycles carboplatin 
(AUC 4) and paclitaxel (100 mg/m2) can be used as induction or palliative treatment 
for patients with advanced or metastatic (gastro-)esophageal cancer. The treatment 
regimen investigated was well-tolerated as demonstrated by the low incidence of 
toxicity grade ≥ 3 (except for grade ≥ 3 hematological toxicity). 
Almost two third of patients experienced severe neutropenia, which is higher than 
described for other frequently used regimens.22 However, the incidence of severe 
leukocytopenia (i.e. leukocytes lower than 2.0 x 109/L) was much lower than of 
neutropenia observed, and comparable with other frequently used regimens.22 
According to our treatment protocol, this regimen could be safely administered on 
an outpatient basis at any grade of neutropenia as long as leukocyte number was 
sufficient (i.e. day 0 and 28: > 3.0 x 109/L; day 7, 14, 35 and 42: > 1.0 x 109/L), which was 
also reflected by the low incidence of febrile neutropenia we observed. 
Furthermore, the incidence of severe nausea or diarrhea of only one to two percent of 
patients was much lower than in most other regimens described using combinations 
with 5-fluorouracil or capecitabine.22 In patients treated with fluorupyrimidine- and/
or platinum-based triplets, severe nausea has been described in 7-21% and severe 
diarrhea in 3-19% of patients.22, 33 Gastro-intestinal toxicity is less when doublet 
treatment is used compared to triplets, but still seems higher than in our regimen, 
although no direct comparison could be made. In doublets where a fluoropyrimidine 
is combined with platinum, severe nausea occurred in 7-27% and severe diarrhea in 
4-8%, and with irinotecan severe nausea occurred in 7% and severe diarrhea in 22%, 
respectively.22 Polyneuropathy was mostly low graded, and occurred in 4% of patients 
as grade 2 polyneuropathy, while grade 3 was not observed. For example, capecitabine 
combined with oxaliplatin resulted in 8% grade 3 polyneuropathy.37 However, the 
incidence of severe hematological toxicity was only 4% with that regimen, while the 
incidence of complicated neutropenia was not mentioned.37 Lastly, 22% of all patients 
developed an infusion related reaction to paclitaxel, which is most likely caused by its 
formulation vehicle Cremophor.34 But this could usually easily managed by prolonging 
the infusion time of paclitaxel. Infusion related reactions to paclitaxel are not limited to 
this treatment regimen as much higher incidences up to 44% of patients treated with 
paclitaxel have been described.34 The good clinical tolerance of this treatment regimen 
was also demonstrated by the low incidence of toxicity-related dose-reductions and 
hospitalization. Premature end of treatment due to toxicity occurred more often and 
mostly caused by general malaise, which is often multifactorial and therefore probably 
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not in all patients (fully) caused by our regimen. Furthermore, in palliative treatment 
quality of life should be considered as well, and a major advantage of the current 
regimen is that this treatment can be given as outpatient treatment for which no 
hospitalization or central line is required, although this advantage is not limited to our 
treatment regimen.
With this regimen an overall response rate of 48% in patients treated with induction 
intent and 44% in patients treated with palliative intent was achieved. These 
percentages are slightly lower than the response rate of 54% found in our previous 
phase-1 study, which can be explained by the low sample size of only 37 patients 
in that former study and the difference in WHO performance of a selected study 
population compared to our cohort of non-selected patients.26 The response rate of 
48% in patients with induction intent, is comparable to other regimens with response-
rates varying between 20-48% (Table 5).17, 33, 35-44 However, most studies included a 
mixed population of patients with locally advanced and metastatic disease. Two studies 
did include only patients with locally irresectable disease without distant metastases 
and found a response rate of 32% for treatment with cisplatin and fluorouracil, and 
45% for a treatment with docetaxel, cisplatin and fluouracil.17, 18 However, these studies 
were conducted in patients with SCC, and our induction cohort consisted also for 50% 
of patients with an adenocarcinoma which makes it difficult to compare these results. 
Furthermore, for 42% of iCT patients esophagectomy or definitive chemoradiotherapy 
followed, resulting in a median PFS of 22.1 months and median OS of 26.8 months. For 
iCT patients, who did not have an esophagectomy or definitive chemoradiation, the 
median PFS of 9.0 months and OS of 11.8 months was lower, but comparable to the 
patients treated with palliative intent.
In metastatic (gastro-)esophageal cancer we found a response rate of 44% with our 
treatment regimen, which is also comparable with the most frequent used other doublet 
regimens (20-45%) and triplet regimens (31-48%) (Table 5).33, 35-40, 42-44 When comparing 
survival rates, we found a median PFS of 8.2 months and OS of 10.9 months for palliative 
treated patients, which is longer than other doublet regimens in this patient group 
(PFS: 3.7-5.9 months; OS: 8.6-10.7) and is comparable to triplet regimens (PFS: 5.6-7.0; 
OS: 9.2-11.2) (Table 5).33, 35-40, 42-44 Although we have to interpret these comparisons 
with caution as no direct comparison can be made, weekly carboplatin and paclitaxel 
seems at least equally effective, and possibly even more effective compared to other 
frequently used treatment regimens and was better tolerated than other regimens.
As a secondary aim of the analysis, we tried to identify predictive and prognostic 
factors. We could only identify smoking as predictive factor for patients with induction 
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treatment, while unfortunately no predictive factors for treatment outcome in palliative 
treated patients were found. Nonetheless, we identified several prognostic factors for 
progression free survival and for overall survival. For induction chemotherapy, current 
smoking behavior, elevated thrombocyte number and alkaline phosphatase levels, 
WHO status and T-stage, were identified as adverse prognostic factors. For palliative 
chemotherapy, tumor location, BSA and WHO status were identified as prognostic 
factors. We could not confirm other known prognostic factors for survival such as 
sex or location of metastases.8, 45, 46 Interestingly, smoking behavior was identified as a 
negative predictive and prognostic factor. Several reasons for this can be hypothesized, 
including sarcopenia and factors related to this unhealthy lifestyle. However, the 
underlying mechanism is not yet unraveled. 
Our study has some limitations which need to be mentioned. The retrospective nature 
of our study could have influenced the quality of the data and the selection of patients. 
Nevertheless, our patient population included all patients who were treated in a certain 
time period, hence can be considered as a real-world patient cohort and therefore 
also representative for daily clinical practice. The retrospective data collection will be 
mainly of influence on the incidence of low grade adverse events as they are not always 
recorded, but has no effect on the higher graded adverse events as they have more 
clinical consequences and were described in detail. Furthermore, we included patients 
who were considered non-resectable by the multidisciplinary team based on general 
criteria, but we could not retrospectively retrieve if this decision was possibly (in part) 
based on certain co-morbidities. Also, we could not retrieve data on HER2 expression 
of the tumor, as this was not determined in individual patients, which potentially could 
have influenced the results. Lastly, it was impossible to include a quality of life analysis, 
which is especially important in treatments with palliative intent. 
We demonstrated that weekly paclitaxel and carboplatin is an effective and well-
tolerated treatment regimen and could therefore be a valid induction or palliative 
treatment option in advanced (gastro)esophageal cancer. Despite the fact that 
chemotherapy in general has limited efficacy in esophageal cancer with only minor 
differences between different schedules, it will remain the backbone of treatment 
in metastatic (gastro)esophageal cancer until new treatments are developed. Future 
research should therefore focus on predictive factors and biomarkers to identify 
patients on beforehand who will benefit from a certain treatment. Furthermore, the 
tumor biology should be included in patient selection. Several molecular subtypes of 
(gastro)esophageal cancer have been identified and provides a rationale to develop 
tailored treatment for the different subtypes instead of treating all (gastro)esophageal 
cancers in the same manner.47 Currently investigated targeted therapies focusses on 
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targeting the human epidermal growth factor receptor type 2 (HER2) and the vascular 
endothelial growth factor receptor (VEGF) with limited effect, nevertheless several 
combination therapies are being evaluated.48 Lastly, the immune micro-environment 
of the tumor might be a possible treatment target as demonstrated by the promising 
results of nivolumab and/or ipilimumab in recent phase-II studies.49, 50 Furthermore, 
the phase-III ATTRACTION trial demonstrated that nivolumab significantly increased 
OS compared to placebo in heavily pretreated Asian patients with metastatic (gastro)
esophageal cancer independent of the PD-L1 status.51 The phase-III KEYNOTE-181 
study demonstrated that pembrolizumab as second-line therapy significantly improved 
OS compared to chemotherapy in patients with metastatic esophageal cancer with a 
high PD-L1 combined score.52 Currently, the results of multiple clinical trials evaluating 
the combination of immunotherapy and chemotherapy are awaited.48 
In conclusion, we demonstrated that weekly paclitaxel and carboplatin is an effective 
and well-tolerated induction or palliative treatment regimen in a real-life patient 
cohort. Future research should directly compare this treatment regimen with other 
first-line treatment options to determine its true value for clinical practice.  
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Table 5. Summary of induction and palliative treatment regimens mentioned
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* If GEJ was not separately mentioned as tumor location; patients were grouped as esophageal tumor 
a Mean age instead of median age 
b Median overall survival was not reached, 1-year survival rate was 67.9% 
Abbreviations: GEJ = gastro-esophageal junction; N = number; NR = not reported; OS = overall survival; PFS 
= progression free survival
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SUPPLEMENTARY INFORMATION
Supplementary Table 1. Predictive factors for treatment response in patients treated with 
induction or palliative chemotherapy
BASELINE FACTORS
Treatment Response (iCT) Treatment Response (pCT)
Univariate Analysis (CR/PR vs SD/
PD)
Univariate Analysis (CR/PR vs 
SD/PD)
OR 95% CI P-value OR 95% CI P-value
SEX (M vs F) 0.89 0.37-2.10 0.786 0.84 0.37-1.89 0.672
AGE 1.01 0.97-1.05 0.666 0.98 0.94-1.01 0.207
BSA 0.99 0.19-5.08 0.993 0.65 0.15-2.87 0.566
WHO (1 vs 0) 1.19 0.50-2.83 0.702 0.86 0.42-1.76 0.678
ALCOHOL (vs never/history
   Current 1.48 0.66-3.29 0.341 0.93 0.47-1.80 0.820
SMOKING (vs never/history)
   Current 2.30 1.02-2.21 0.045 0.84 0.41-1.73 0.634
TUMOR LOCATION (vs proximal)
   Middle
   Distal
   Junction/Cardia
   Multiple locations
0.86
1.20
0.50
0.27-2.75
0.43-3.31
0.42-2.40
0.796
0.735
0.361
0.13
0.18
0.10
0.01-1.25
0.02-1.51
0.01-1.29
0.078
0.113
0.077
YEAR OF DIAGNOSIS 1.07 0.97-1.18 0.177 1.04 0.95-1.14 0.400
HISTOLOGY (SCC vs AC) 0.72 0.35-1.52 0.394 1.00 0.49-2.01 0.990
DIFFERENTIATION 
(poor vs good/moderate) 1.19 0.52-2.76 0.680 0.62 0.29-1.32 0.215
T-STAGE 
(iCT: vs T2/T3, pCT: vs T1b/T2)
   T3   
   T4A/B 1.38 0.65-2.94 0.401
1.53
2.13
0.51-4.61
0.60-7.57
0.450
0.245
N-STAGE (vs N0)
   N1
   N2
   N3
1.71
1.57
0.94
0.43-6.91
0.40-6.27
0.17-5.07
0.449
0.527
0.940
0.80
0.78
0.68
0.30-2.16
0.28-2.19
0.19-2.35
0.657
0.639
0.537
M-STAGE (vs M0) 1.03 0.49-2.20 0.935 1.55 0.46-5.10 0.474
METASTASES LOCATION
(vs no metastases)
   Nodal
   Liver
   Other
   Multiple locations
2.11
0.87
4.48
1.24
0.62-7.16
0.20-3.90
0.99-20.4
0.34-4.47
0.229
0.858
0.052
0.746
LIVER METASTASES (Y vs No) 0.67 0.34-1.33 0.254
HEMOGLOBIN (mmol/L) 0.83 0.57-1.20 0.313 1.01 0.76-1.35 0.921
THROMBOCYTES (109/L) 1.00 1.00-1.00 0.487 1.00 0.99-1.00 0.121
LEUKOCYTES (109/L) 1.05 0.92-1.19 0.462 0.99 0.95-1.03 0.560
NEUTROPHILS (109/L) 1.04 0.89-1.20 0.641 0.97 0.91-1.05 0.487
AST (U/L) 0.98 0.94-1.03 0.449 1.00 0.99-1.01 0.590
ALT (U/L) 1.00 0.98-1.02 0.824 1.00 0.99-1.01 0.455
LD (U/L) 1.00 1.00-1.00 0.794 1.00 1.00-1.00 0.807
GGT (U/L) 1.00 0.98-1.01 0.535 1.00 1.00-1.00 0.631
AP (U/L) 1.01 0.99-1.03 0.220 1.00 1.00-1.00 0.413
BILIRUBIN (μmol/L) 0.99 0.90-1.10 0.910 1.00 0.93-1.07 0.967
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Supplementary Table 1 continued.
BASELINE FACTORS
Treatment Response (iCT) Treatment Response (pCT)
Univariate Analysis (CR/PR vs SD/
PD)
Univariate Analysis (CR/PR vs 
SD/PD)
OR 95% CI P-value OR 95% CI P-value
KREATININ (μmol/L) 1.01 0.99-1.04 0.163 1.01 0.99-1.03 0.276
P-values < 0.05 are considered statistically significant and are depicted in bold.
Abbreviations: AC = adenocarcinoma; ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = 
aspartate aminotransferase; F = female; GGT = gamma-glutamyltransferase; iCT = induction chemotherapy; 
LD = lactate dehydrogenase; M = male; N = number; OR = odds ratio; pCT = palliative chemotherapy; SCC = 
squamous cell carcinoma; vs = versus (reference category); World Health Organization Performance Status; Y 
= yes
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ASSOCIATION BETWEEN 
PACLITAXEL CLEARANCE AND 
TUMOR RESPONSE IN PATIENTS 
WITH ESOPHAGEAL CANCER
12
ABSTRACT
BACKGROUND
Inter-individual variability in paclitaxel pharmacokinetics may play a role in the response 
to chemotherapy. Therefore, we studied the association between paclitaxel clearance 
and treatment response in patients with esophageal cancer. 
METHODS
Patients who received paclitaxel (plus carboplatin) treatment for esophageal cancer 
between 2007 and 2013 were included. Treatment was given as neoadjuvant 
chemoradiotherapy (nCRT), induction chemotherapy (iCT), or palliative chemotherapy 
(pCT). Treatment response was assessed by tumour regression grade (TRG) or RECIST1.1, 
respectively. Unbound paclitaxel clearance (CL) was estimated with NONMEM. Log-
transformed clearance was related to response with ANOVA and independent  sample 
t-tests. 
RESULTS
A total of 166 patients were included, of whom 113 received nCRT, 23 iCT and 30 
pCT. In patients receiving nCRT, paclitaxel clearance was not associated with tumour 
regression grade (P=0.25), nor with pathologically complete response (geometric mean 
561.6 L/h) and residual disease (geometric mean 566.1 L/h, P=0.90). In patients who 
underwent iCT or pCT, also no association between paclitaxel clearance and RECIST 
outcome was identified (iCT: P=0.08 and pCT: P=0.81, respectively). 
CONCLUSION
Systemic paclitaxel exposure is not associated with response to common paclitaxel 
based treatment regimens for esophageal cancer. Future studies should focus on 
tumour exposure in relation to systemic exposure and treatment outcome.
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INTRODUCTION
 
The incidence of esophageal cancer is still rising in the United States and Western 
Europe and mortality is high.1, 2 Esophageal cancer is often diagnosed at an advanced 
stage. Therefore, curative treatment is only attempted in less than fifty percent of 
patients.3 Based on the evidence from the Dutch randomised CROSS trial, paclitaxel can 
be used in combination with carboplatin and radiotherapy as an effective neoadjuvant 
treatment strategy.4, 5 In approximately 30% of patients, no vital tumour cells are left in 
the oesophagectomy specimen following neoadjuvant chemoradiotherapy (nCRT).4, 6, 
7 In another 30% of patients, partial regression of the tumour is observed (1-10% vital 
tumour cells), while in 25% of patients the resection specimen does not show changes 
in regression (>50% vital tumour cells). In patients with extensive disease not amendable 
for surgery, induction or palliative chemotherapy (iCT or pCT respectively) is given, where 
paclitaxel is also combined with carboplatin.8-11 In this setting, the dose of paclitaxel is 
higher (weekly 100 mg/m2) than in the neoadjuvant setting (weekly 50 mg/m2).
Paclitaxel is a classic chemotherapeutic agent which stabilises cellular microtubules, 
thereby blocking chromosomal segregation and mitosis, and eventually inducing 
apoptosis.12,13 There is a suggested dose-response relationship for this agent.14,15 
Unfortunately, paclitaxel is also known for its huge inter-individual variability in 
pharmacokinetics, which is largely explained by (pharmaco-)genetic and environmental 
differences between patients.14 As a consequence, differences in (dose-limiting) 
toxicities may be explained by differences in systemic exposure between patients.14, 16, 
17 However, if differences in outcome could also be explained by variation in systemic 
paclitaxel exposure is currently unknown. 
Therefore, we hypothesized that an increased systemic paclitaxel exposure due to low 
clearance is associated with a better response to treatment for patients with esophageal 
cancer. Therefore, in this study, for the first time, the association between systemic 
exposure to paclitaxel and therapeutic effect in patients with esophageal cancer was 
studied. 
METHODS
PATIENTS
All patients were treated at the Erasmus MC Cancer Institute, Rotterdam, the Netherlands, 
which is a tertiary referral centre for patients with esophageal cancer. Patients, aged 
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18 years or older, treated with paclitaxel for histologically proven carcinoma of the 
intrathoracic esophagus or gastro-esophageal junction between November 2007 and 
May 2013 were identified from an institutional database (based on a prospective trial 
registered at www.trialregister.nl as NTR2311, study number MEC 03.264). In this study, 
all patients who received paclitaxel mono- or combination-therapy, were included. 
For pharmacokinetic purposes, a limited sampling strategy was used. All patients with 
esophageal cancer received either paclitaxel in a neoadjuvant chemo-radiotherapy 
regimen, as induction treatment or in a palliative setting. For each individual patient, a 
treatment plan was conducted and evaluated during a weekly multidisciplinary team 
meeting. Ethical approval was given by the ethical committee of the Erasmus MC as an 
amendment to the prospective trial (NTR2311). All patients provided written informed 
consent for the mentioned trial.
 
STAGING
Tumours were (re-)staged according to the 7th UICC-AJCC TNM staging manual.18 Every 
patient underwent physical examination and routine biochemical and haematological 
tests. In every patient, an upper gastro-intestinal endoscopy with biopsies, computed 
tomography (CT) of the neck, chest and abdomen, and external ultrasonography of 
the neck with FNA in case of suspected lymph nodes, was performed according to the 
Dutch esophageal cancer guidelines. Only in T3 tumours PET was proven to be of any 
additional value at that time, and was not yet standardised.
NEOADJUVANT CHEMO-RADIOTHERAPY
On days 1, 8, 15, 22, and 29, paclitaxel and carboplatin were administered intravenously. 
A paclitaxel dose of 50 mg/m2 was administered and the targeted area under the curve 
(AUC) was 2 mg/mL/min for carboplatin. A total 3D conformal radiation dose of 41.4 
Gy was given in 23 fractions of 1.8 Gy each, with 5 fractions administered per week. 
Radiotherapy started at the first day of the first chemotherapy cycle.4, 19
INDUCTION OR PALLIATIVE CHEMOTHERAPY
Weekly 100 mg/m2 paclitaxel was given together with carboplatin targeting at an 
AUC of 4 mg/mL/min.20, 21 In some patients, induction or palliative chemotherapy was 
continued beyond the planned number of six cycles. This was done to either sustain 
tumour regression, or in case of partial response, for further downsizing tumour volume. 
The regimen these patients received consisted of 175 mg/m2 paclitaxel and carboplatin 
(targeted at an AUC of 6 mg/mL/min) and administered in three 3-weekly cycles.
SURGERY
If surgery was feasible (after neoadjuvant chemoradiotherapy or after successful 
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induction chemotherapy), operations were performed or strictly supervised by 
experienced upper-GI surgeons in four hospitals specialised in esophageal surgery. 
For tumours of the intrathoracic esophagus and for junctional tumours with positive 
lymph nodes at or above the carina a transthoracic approach with two-field lymph 
node dissection was generally performed. In patients with a poor performance status 
(WHO performance score of 2 or higher) or for tumours substantially involving the 
gastro-esophageal junction, a transhiatal resection was favoured. 22, 23
RESPONSE EVALUATION
In patients treated with neoadjuvant chemoradiotherapy, treatment response was 
based on assessment of the resection specimen. After surgery, the resection specimens 
were immediately sent to the Department of Pathology and instantly examined by the 
attending pathologist. Samples of the tumour, lymph nodes and resection margins were 
obtained before the specimen was fixed in formalin. A radical resection (ypR0, where 
yp means pathological after neoadjuvant treatment) was defined as no tumour cells 
within 1 mm of the circumferential, proximal or distal resection margins.4 Hence, when 
tumour cells were detected at or within 1 mm of the resection plane it was classified as 
ypR1. The number of lymph nodes removed and the number of tumour positive lymph 
nodes removed were assessed. The tumour regression grade (TRG), used to assess 
the response to neoadjuvant chemoradiotherapy or to induction chemotherapy, was 
classified into four categories according to a modified Mandard score. TRG 1 means no 
vital tumour cells in the resection specimen (pathologically complete response of the 
primary tumour and removed lymph nodes, ypT0N0M0); TRG 2 means less than 10% 
residual vital tumour cells and/or any residual vital tumour cells in the lymph nodes; 
TRG 3 means between 10 and 50% residual vital tumour cells; and TRG 4 means more 
than 50% residual vital tumour cells.6, 24 For this study, all samples were re-analysed by 
one pathologist (K.B.).
In patients treated with induction or palliative chemotherapy, treatment response 
was assessed using CT images after six weekly cycles of chemotherapy and scored 
according to the response evaluation criteria in solid tumours (RECIST) classification 
system. A modified RECIST 1.1. score was used, where smaller lesions than required 
according to definitions for RECIST 1.1 were taken into account as well. All CT images 
were (re-)evaluated by a single radiologist (N.K.). If no tumour lesions were seen on CT 
imaging after induction or palliative chemotherapy, patients were classified as having a 
complete response (CR). When imaging showed regression of the primary tumour and/
or lymph nodes or the presence of novel metastatic lesions, patients were classified 
as having a partial response (PR). If there was no difference in tumour and/or lymph 
node size and metastatic lesions, patients were classified as having stable disease (SD). 
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In case of progression in size of the primary tumour and/or lymph nodes or metastatic 
lesions or development of new lesions, patients were classified as having progressive 
disease (PD).25 
PACLITAXEL PHARMACOKINETIC ANALYSES
The analyses for paclitaxel pharmacokinetics were performed according to previous 
studies.14, 16, 17 In brief, from each patient blood was taken during one of the five or 
six (dependent on type of treatment) weekly chemotherapy cycles, using a formerly 
endorsed limited sampling strategy with 4 to 5 samples within approximately 24 
hours after start of paclitaxel infusion.14, 26 To prevent coagulation, lithium heparin 
was used in all samples. Subsequent to sample collection, paclitaxel concentrations 
were determined using a validated method.16 Next to individual total paclitaxel plasma 
concentrations, a well-established population pharmacokinetic model and NONMEM 
software (Icon Development Solutions, Leopardstown Dublin, Ireland) were used to 
determine the paclitaxel clearance (CL, L/h)  in each individual patient.14 
STATISTICAL ANALYSIS
The primary outcome of this study was the association between paclitaxel clearance 
and response to systemic treatment in patients with esophageal cancer. Analyses of the 
unbound paclitaxel clearance were performed on log-transformed clearance values 
since they were assumed to follow lognormal distribution. Hence, clearance was 
described by means of geometric means and corresponding coefficients of variation 
(CV). Differences in clearance between TRG groups were tested by means of ANOVA. 
Post-hoc tests were only performed if the overall (omnibus) test was significant at 
the 5% level without correction for multiple testing. The difference between patients 
with a complete response (TRG1) and patients with residual disease (TRG2-4) was 
tested by means of the independent samples t-test. In order to interpret the difference 
found on the log-scale, the difference and corresponding 95% confidence interval (CI) 
boundaries were exponentiated to represent the geometric mean ratio and its CI on 
the original scale.  Statistical analyses were performed with the use of SPSS software, 
version 22.0 (SPSS, IBM, New York, NY, USA). 
RESULTS
 
A total of 166 patients with esophageal cancer was included from a prospectively 
collected database, of whom 113 patients underwent neoadjuvant chemoradiotherapy 
followed by surgery. Another 23 patients received induction chemotherapy (of whom 
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11 proceeded to oesophagectomy) and 30 patients underwent palliative treatment. 
Patient and tumour characteristics of all enrolled patients are listed in Table 1. The 
majority of the patients was male and had an oesophageal adenocarcinoma. In 
patients receiving neoadjuvant chemoradiotherapy, as well as induction and palliative 
chemotherapy; cT3 status, cN1 status, a moderately differentiated tumour, and located 
at the distal oesophagus was seen most. Not all patients received the initially planned 
courses due to toxicity or the patient’s condition (Table 1).
Results for individual paclitaxel clearance as measure for paclitaxel exposure is listed 
per treatment and response group in Table 2. Paclitaxel clearance is expressed as 
geometric mean (GM) with coefficient of variation (CV).
Table 1: Patient and tumour characteristics 
Sex
Male 91 (80.5%) 16 (69.6%) 29 (96.7%)
Age
Median years (Range) 63 (39-82) 64 (52-77) 64 (47-76)
Tumour type
Adenocarcinoma 90 (79.6%) 13 (56.5%) 24 (80.0%)
Squamous cell carcinoma 22 (19.5%) 9 (39.1%) 6 (20.0%)
Other+ 1 (0.9%) 1 (4.3%)
Histopathological grading
G1 3 (2.5%) 0 2 (6.7%)
G2 51 (45.1%) 7 (30.4%) 5 (16.7%)
G3 32 (28.3%) 10 (43.5%) 13 (43.3%)
G4 1 (0.9%) 0 0
Gx or Missing 26 (23.0%) 6 (26.1%) 10 (33.3%)
Tumour localization
Proximal 0 2 (8.7%) 0
Middle 18 (15.9%) 5 (21.7%) 4 (13.3%)
Distal 80 (70.8%) 10 (43.5%) 19 (63.3%)
Gastro-esophageal junction 15 (13.3%) 6 (26.1%) 7 (23.3%)
Clinical T stage
cT1 4 (3.5%)* 0 0
cT2 26 (23.0%)* 0 2 (6.7%)
cT3 80 (70.8%)* 17 (73.9%) 16 (53.3%)
cT4 3 (2.7%)* 5 (21.7%) 3 (10.0%)
Missing 0 1 (4.3%) 9 (30.0%)
Clinical N stage
N0 35 (31.0%)# 3 (13.0%) 3 (10.0%)
N1 41 (36.3%)# 5 (21.7%) 6 (20.0%)
N2 34 (30.1%)# 11 (47.8%) 10 (33.3%)
N3 3 (2.7%)# 4 (17.4%) 5 (16.7%)
Missing 0 0 6 (20.0%)
Clinical M stage
M0 113 (100%) 21 (91.3%) 2 (6.7%)
M1 0 2 (8.7%)^ 28 (93.3%)
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Table 1 continued.
TREATMENT REGIMEN
Neoadjuvant chemoradiotherapy 113 (100%) X X
4 courses of Paclitaxel 3 (2.7%) X X
5 courses of Paclitaxel 109 (96.5%) X X
6 courses of Paclitaxel 1 (0.9%) X X
Induction or palliative chemotherapy X 23 (100%) 30 (100%)
6 courses of Paclitaxel X 8 (34.8%) 13 (43.3%)
6 + 3 courses of Paclitaxel X 15 (65.2%) 17 (56.7%)
Resection 113 (100%) 11 (47.8%) X
Other treatment X X 1 (3.3%)£
Abbreviations: nCRT: neoadjuvant chemoradiotherapy, iCT: induction chemotherapy, pCT: palliative 
chemotherapy, + Other: neuroendocrine tumour. 
* uTstage (endosonography) in patients treated with neoadjuvant chemoradiotherapy. 
# uNstage (endosonography) in patients treated with neoadjuvant chemoradiotherapy. 
$ no location possible due to only radiological diagnostics.
^ Submucosal metastasis and suspicion of lung metastasis. 
£ brachytherapy
Table 2: Paclitaxel clearance per treatment and response group
Response Clearance (L/h)
Geometric mean (CV, %) 
P-value 
nCRT (n=113) 0.25
TRG1 (n=36) 561.6 (34)
TRG2 (n=28) 591.4 (20)
TRG3 (n=37) 578.5 (29)
TRG4 (n=12) 478.5 (56)
iCT (n=23) 0.08
CR (n=2) 358.1 (37)
PR (n=12) 409.9 (29)
SD (n=9) 500.7 (8)
PD (n=0) X
pCT (n=30)
0.81
CR (n=2) 488.0 (16)
PR (n=11) 447.1 (35)
SD (n=9) 440.5 (33)
PD (n=8) 500.2 (23)
Abbreviations: nCRT = neoadjuvant chemoradiotherapy; iCT = induction chemotherapy; pCT = palliative 
chemotherapy; CV = coefficient of variation; TRG = tumour regression grade; CR = complete response, PR = 
partial response, SD = stable disease, PD = progressive disease. 
Thirty-six patients who underwent neoadjuvant CRT had a pathologically complete 
response (32%) and 77 patients (68%) had a partial or no response based on their 
oesophagectomy specimen. The tumour regression grade was not significantly 
associated with paclitaxel clearance (P-value=0.25, Table 2). Post-hoc tests were not 
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performed because of the non-significant overall effect. Also, when comparing the 
clearance of patients with a pathologically complete response (TRG1) to the clearance 
of patients with residual disease (TRG 2-4) no difference was seen (geometric mean 
ratio = 0.99, 95% CI [0.87-1.13], P-value=0.90, Table 3). 
The radiological classification of patients --treated either by induction or by palliative 
chemotherapy-- is also listed in Table 2. In none of the 23 patients who underwent 
induction chemotherapy, progression of disease was seen. A complete response was 
seen in 2 patients, partial response in 12 patients and stable disease in 9 patients. The 
response grade according to modified RECIST1.1 was not statistically significantly 
associated with response (P-value=0.08, Table 2). However, a possible trend was 
seen towards a better response in patients with an increasing paclitaxel exposure, 
although the number of patients with a clinical complete response was only two. 
Some 30 patients treated with palliative intent were evaluated in the current analysis of 
whom 8 patients (27%) had progression of disease at moment of response evaluation 
after 6 cycles of chemotherapy. Also in this group we could not identify an association 
between paclitaxel clearance and tumour response (P-value 0.81, Table 2). 
Table 3: Paclitaxel clearance of patients with pathologically complete response versus patients 
with residual disease after neoadjuvant chemoradiotherapy followed by surgery 
Response Clearance (L/h)
Geometric mean (CV, %)
P-value Geometric mean ratio
nCRT (n=113) 0.90 0.99 (0.87-1.13)
TRG 1 (n=36) 561.6 (34)
TRG 2-4 (n=77) 566.1 (32)
Abbreviations: nCRT = neoadjuvant chemoradiotherapy; CV = coefficient of variation; TRG = tumour regression 
grade.
DISCUSSION
To our knowledge, this is the first study that investigated the association between 
systemic exposure to paclitaxel and tumour response in patients with esophageal 
cancer. Response to paclitaxel in patients receiving neoadjuvant chemoradiotherapy 
(nCRT), induction chemotherapy or palliative chemotherapy was analysed. In contrast 
to what was hypothesized, systemic concentrations of paclitaxel were not associated 
with pathological response or radiological tumour regression. 
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In patients receiving induction chemotherapy, a possible trend was seen towards 
patients with a clinically complete response having a lower paclitaxel clearance than 
patients with a partial response or stable disease. However, as only two patients had a 
clinically complete response in this subgroup, no hard conclusions can be drawn on 
this point. 
One of the potential reasons why a relation between pharmacokinetics and response 
was not seen could be that in patients receiving neoadjuvant chemoradiotherapy, 
the chemotherapy mainly acts as a radiosensitizer. 27-29 Thus, the effects of paclitaxel 
exposure on treatment outcome can be overshadowed by the combination with 
radiotherapy. Also the combination with carboplatin chemotherapy (of which no drug 
concentrations were measured) could have influenced the outcomes of the analyses. 
Furthermore, the type of tumour (adenocarcinoma versus squamous cell carcinoma) 
affects the response to chemoradiotherapy. Squamous cell carcinoma reacts more 
effectively to chemoradiotherapy, as indicated by the fact that a pathological response 
occurs more often in patients with squamous cell carcinomas. However, the CROSS 
regimen does not distinguish between the two tumour types in clinical practice.4, 5, 19 In 
the present study the majority of patients were diagnosed with adenocarcinoma of the 
esophagus, in line with the incidence in Western world.30 
Another important reason for the lack of correlation between paclitaxel plasma 
pharmacokinetics and tumour response is a potential weak correlation between 
paclitaxel plasma exposure and paclitaxel tumour exposure. As one of its potential 
resistance mechanisms a tumour may use efflux transporters (i.e. ATP-binding cassette 
(ABC) transporters) to limit intra-tumoural chemotherapy concentrations. Taxanes, 
including paclitaxel, are known substrates for these transporters.31,32 Although we did 
not measure intra-tumoural drug concentrations in this study, due to its retrospective 
nature, we speculate that intra-tumoural paclitaxel concentrations differ substantially 
from plasma chemotherapy concentrations. To further explore this, we recently set up a 
new prospective clinical trial (i.e. the PAREO study; registered at www.trialregister.nl as 
NTR6356, study number MEC 16.696) in which plasma paclitaxel exposure is compared 
with intra-tumoural concentrations by serial tumour biopsies and simultaneous blood 
sampling in patients treated for esophageal cancer. 
Our study has several limitations. The limited sample size of the induction and palliative 
treatment group could have influenced our results. However, we do think that a strong 
relationship between paclitaxel clearance and response still could have been detected. 
Nevertheless, the results of these two treatment groups should be interpreted with 
caution. Not all blood samples were collected during the first treatment cycle resulting 
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in different paclitaxel dosages, especially in the induction and palliative treatment 
group. However, we used clearance as measure for systemic exposure, which will not 
be strongly influenced by drug dosage. Next to this, most patients receiving palliative 
chemotherapy were treated with 6 cycles, while others received more. Response 
evaluation was performed after six weekly cycles (for the first time) in every patient, 
but the obtained blood samples for clearance were not strictly regulated to these first 
six weeks. This feature can be of clinical influence on response, but numbers were too 
small to characterize. 
In summary, in this study, the association between systemic exposure to paclitaxel 
and pathological response/clinical outcome in patients with oesophageal cancer was 
studied. The current analysis demonstrates that systemic paclitaxel exposure is not 
related to response to common paclitaxel based treatment regimens for oesophageal 
cancer. Future studies should therefore focus on intra-tumoural exposure in relation to 
systemic exposure and treatment outcome.
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This thesis describes several pharmacokinetic and pharmacogenetic studies on four 
important anti-cancer drugs that are commonly used in the systemic treatment of 
malignancies in the gastrointestinal tract. In this chapter the results of studies in this 
thesis will be summarized and discussed per drug. Furthermore, in each part future 
perspectives will be given on how to translate these results into clinical practice to 
eventually personalize the oncologic treatment for every patient to reduce toxicity and 
improve efficacy. 
PART I: FLUOROPYRIMIDINES
Fluoropyrimidines are a group of chemotherapeutic agents, which are widely used in 
the treatment of solid tumors and include intravenously administered 5-fluorouracil (5-
FU) and orally administered 5-FU prodrugs capecitabine and tegafur. Depending on the 
different types of treatment regimens, capecitabine is given either as monotherapy, in 
combination with other chemotherapeutic agents, or it is combined with radiotherapy. 
Like other chemotherapeutic agents, capecitabine is in general dosed on body-surface 
area (BSA) to reduce inter-individual variability in its pharmacokinetics. Fixed-dosing 
is an alternative dosing strategy, which means that the dose is not adjusted for body 
size measures. In Chapter 2 toxicity and effectiveness of fixed-dosed capecitabine in 
four commonly used treatment regimens is described in a cohort of 1126 patients, and 
compared to BSA-dosed patients in another cohort of 1193 comparable patients. We 
found no difference in toxicity between fixed-dosed and BSA-dosed patients, while 
the prescribed capecitabine dose was 7.1% higher when dosed on BSA compared to 
fixed-dosed. Interestingly, both cohorts showed only a higher incidence of toxicity, 
especially diarrhea, in patients of the lowest BSA quartile when capecitabine was 
combined with radiotherapy. This finding was unexpected and is likely to be caused by 
the interaction of the two treatment modalities instead of the type of dosing strategy. 
Several hypotheses for the fact that patients with a lower BSA experience more toxicity 
from capecitabine combined with radiotherapy can be given; namely: local effects 
due to the radiosensitizing effect of capecitabine1, a higher amount of radiated small 
bowel volume2, 3 or local rectal irritation by the tumor itself.4 Future research should 
therefore be conducted on the potential effects of radiotherapy and BSA on toxicity of 
this combination treatment in patients with a low BSA.
Besides toxicity, we also investigated the effectiveness of given treatments. No survival 
difference was identified between the patients with a low BSA and patients with a 
high BSA per treatment and indication within the fixed-dosed cohort. In addition, the 
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observed progression free survival (PFS) for capecitabine-oxaliplatin for metastatic 
colorectal cancer and capecitabine triplet therapy for gastric cancer was comparable 
to literature data (8.6 and 24.6 months versus 8.0 and 19.2 months, respectively).5, 6 
Several other small studies did not find a survival difference either 7-10, which is in line 
with our results. Our results indicate that fixed dosing of capecitabine is a reasonable 
and practical alternative for BSA-based dosing. Therefore, we would recommend 
implementing fixed dosing in future clinical studies and we have found no arguments 
why it could not be used in daily clinical care. Unfortunately, we could not compare 
our results concerning survival with the BSA-dosed cohort as in that second cohort no 
survival data were collected. Future research should therefore directly compare both 
dosing strategies with survival as an endpoint. It would be even better if this would 
be done in a randomized controlled trial setting, however it seems unlikely that this 
will ever happen. Furthermore, it would be interesting to investigate whether a fixed 
dosing strategy for capecitabine would lead to fewer prescribing mistakes and possibly 
reduced costs, as has been demonstrated for some other drugs.11-13
Fluoropyrimidines are mainly metabolized by the enzyme dihydopyrimidine 
dehydrogenase (DPD) which converts more than 80% of 5-FU into the inactive 
metabolite dihydrofluorouracil. Around 10-30% of patients experience severe or even 
fatal fluoropyrimidine-related toxicity, which is in almost 60% of these patients caused 
by reduced DPD activity.14-19 A reduced DPD activity can be the result of polymorphisms 
in the DPYD gene, which encodes for the DPD enzyme. DPYD is a large gene with 
many genetic variants described, which do not all have functional consequences. 
Based on a meta-analysis by Meulendijks et al. in 2015, currently, four DPYD variants 
are considered clinically relevant (DPYD*2A, c.1679T>G, c.2846A>T, and c.1236G>A) in 
Caucasian patients, which result in an estimated 50% or 25% reduced DPD-activity.20 It 
has already been demonstrated that prospective genotyping for the DPYD*2A variant 
and dose-reductions in heterozygote DPYD*2A carriers improves treatment safety and 
that it is cost-effective.21 In Chapter 3 the results of a large prospective trial, performed 
in 17 Dutch centers, on personalized fluoropyrimidine dosing based on these four DPYD 
variants are described. All patients were genotyped for these four DPYD allele variants 
before start of fluoropyrimidine treatment. If a variant was detected, patients received 
a 50% dose reduction for DPYD*2A and c.1679T>G, and a 25% dose reduction for both 
c.2846A>T and c.1236G>A. If a homozygote mutation or compound heterozygote 
mutations were detected, patients were excluded from the trial. All patients were 
followed during the whole treatment period. Toxicity was compared between DPYD 
variant allele carriers and wild-type patients from this study and with a historical cohort 
of DPYD variant allele carriers treated with the full dose (derived from the previously 
mentioned meta-analysis 20). Furthermore, pharmacokinetic analysis of DPYD variant 
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allele carriers treated with a reduced dose was performed. 
In total, 1103 evaluable patients were enrolled, of whom 85 DPYD variant carriers (7.7%). 
Overall, severe toxicity was still higher in DPYD variant carriers (39%) than in wild-
type patients (23%). However, when comparing to the historical cohort, upfront DPYD 
genotyping markedly reduced the relative risk for severe toxicity for DPYD*2A (from 
4.30 to 1.31) and  c.1679T>G carrier (from 4.30 to no toxicity), moderately reduced 
the relative risk for c.2846A>T (from 3.11 to 2.00), and not reduced the relative risk for 
c.1236G>A (from 1.72 to 1.69). Furthermore, pharmacokinetic analysis in DPYD variant 
allele carriers treated with a reduced dose demonstrated that fluoropyrimidine exposure 
was comparable to wild-type patients treated with a full dose. Lastly, this upfront 
genotyping strategy was likely to be cost-saving or cost-neutral with a moderate cost-
saving of €51 per patient as described in Chapter 4. Our study demonstrated that upfront 
DPYD genotyping was feasible in routine clinical practice, that it improved patient safety 
of fluoropyrimidine treatment, and that it is cost-saving. For DPYD*2A and c.1679T>G 
carriers, a 50% initial dose reduction seems adequate. For c.1236G>A and c.2846A>T 
carriers, a larger dose reduction of 50% (instead of 25%) needs further investigation.
Although the results of our pharmacokinetic analysis demonstrated that the DPYD 
variant allele carriers were not underdosed as they had an equal exposure as wildtype 
patients treated with a full dose, treatment efficacy will remain a concern of critics. A 
retrospective, matched-pair analysis of DPYD*2A treated with reduced dose, found no 
negative effect on overall survival (OS) and PFS.22 However, this study was underpowered 
and therefore no firm conclusions can be made based on these data. As no additional 
studies on survival effects of a reduced dose in DPYD variant allele carriers are available, 
future studies should address this topic. Ideally, a randomized controlled trial on safety 
and efficacy of DPYD genotyping should be performed, but this requires a large sample 
size and is considered unethical concerning the large amount of evidence currently 
available, and is therefore not likely to happen. It is therefore necessary that in future 
prospective studies efficacy of the genotype based reduced dose is included as an 
endpoint and that efficacy data of different trials by meta-analysis of individual data 
can be combined.
Based on our study we recommend to endorse worldwide implementation of DPYD 
screening before start of fluoropyrimidine treatment as standard of care to improve 
safety of fluoropyrimidine treatment. 
Henricks et al. already recommended a drug label update to include preemptive DPYD 
genotyping and dose adjustments in all fluoropyrimidine drug labels.23 The European 
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Medicine Agency (EMA) supported this request and has now asked the different 
pharmaceutical companies to adjust the drug labels. Furthermore, partly based on our 
study and at the request of the French Medicines Agency, EMA is currently reviewing 
all screening methods for DPD deficiency including DPYD genotyping, and evaluating 
if a screening method should be done in every patient treated with  fluoropyrimdines.24 
These latest developments might help to implement DPYD genotyping in clinical care. 
However, clinicians need to be supported with respect to the interpretation of  these 
genotyping results, and therefore integration of pharmacogenetic results and warning 
systems in the electronic patient file could help to prevent prescription mistakes. 
Furthermore, in 2017, the Clinical Pharmacogenetic Implementation Consortium (CPIC) 
updated their guideline on DPD genotyping with dose recommendations on different 
variants.25 However, the  results of our study were not included in that guideline as our 
data became available in 2018, and a future update will benefit from more evidence on 
the most optimal dose for c.1236G>A and c.2846A>T carriers. 
Future research can possibly further elucidate the genetic background of 
fluoropyrimidine induced toxicity. In our study we included four DPYD variants 
currently considered clinically relevant, however these variants are less common in 
non-Western populations and several other (new) DPYD variants are described in 
these populations.26-28 Further research is necessary though to determine which DPYD 
variants are clinically relevant in non-Western ethnicities. Therefore, a new prospective 
observational multicenter trial is currently initiated in the Netherlands. Secondly, DPD 
activity is not only regulated by DPYD variants but also from a post-transcriptional level, 
for instance by microRNA 27a (miR-27a).29-31 Lastly, besides DPYD, several other genetic 
variants in enzymes and transporters involved in the fluoropyrimidine metabolism 
have been related to fluoropyrimidine induced toxicity (including carboxylesterase, 
thymidylate synthase, cytidine deaminase, thymidine phosphorylase, and the SLC22A7 
transporter).32-40 To identify new variants related to fluoropyrimidine induced toxicity, 
an additional genome-wide association study (GWAS) will be performed on patient’s 
DNA of our study cohort. All these attempts will hopefully result in a gene-screenings 
panel that will detect all clinically relevant variants for every patient.   
In the previous paragraph, the current status of screening for DPD-deficiency by means 
of (DPYD) genotyping was discussed. However, DPD deficiency can also be identified 
using different phenotyping tests that measure the DPD activity (in)directly. Several 
phenotyping methods are currently described, of which DPD activity measurement 
in peripheral blood monocytes (PBMCs) is the most direct one.41 More indirect 
phenotyping tests are related to the measurement of the endogenous DPD substrate 
uracil or its product dihydrouracil (DHU) such as the ratio between those (DHU/U).41 
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Several studies demonstrated a correlation between uracil levels or the DHU/U ratio 
and fluorouracil pharmacokinetics, and with the onset of fluoropyrimidine-associated 
toxicity.42-49 In Chapter 5, in a subset of patients who participated in  the prospective trial 
(described in Chapter 3 and 4) several different phenotyping tests were evaluated for 
their additional value to identify DPD deficiency and to identify patients at risk for severe 
fluoropyrimidine-induced toxicity. In this exploratory cohort, patients underwent two 
to four tests before start of fluoropyrimidine-based therapy: endogenous dihydrouracil/
uracil (DHU/U) ratio and endogenous uracil in 1037 patients, uracil loading dose in 92 
patients 50, 51, and 2-13C-uracil breath test in 82 patients 52. Phenotyping results were 
associated with the onset of severe (grade ≥3) fluoropyrimidine-induced toxicity and 
DPD deficiency (defined as DPD activity ≤ 5.9 nmol/(mg*h) in PBMCs). Clinical validity 
parameters were calculated per test. 
Unfortunately, in our cohort, none of these four tests could predict DPD-deficiency 
or fluoropyrimidine-induced toxicity very well. Several reasons can be given for these 
results. Firstly, the sample size for the uracil loading dose and breath test was limited due 
to difficult patient accrual for these tests. Secondly, a large variation in test results was 
detected between different study centers, which represents methodological problems 
with standardization of these tests. Although we did exclude too divergent results 
per phenotyping test, this will probably have influenced our results. Furthermore, we 
performed these tests in an unselected population, in contrast to most other studies 
that evaluated these tests in populations selected or enriched for DPD deficiency or 
severe treatment-related toxicity. Lastly, the sampling time of the blood withdrawal for 
the uracil and DHU/U ratio determination was performed on a random time point in our 
study, although DPD activity exhibits a significant circadian variability.53 Furthermore, 
our samples were withdrawn at room temperature and not immediately frozen, while 
uracil levels are not stable at room temperature.54 Despite the disappointing results, 
our study is the first head-to-head comparison of these four tests and highlights 
several factors that need to be rigidly standardized in future research. Furthermore, 
the combination of genotyping and phenotyping still remains a promising strategy to 
improve the amount of patients detected with relevant DPD deficiency. Therefore, a 
new prospective clinical trial (Alpe2U trial), which recently started, will investigate if a 
personalized fluoropyrimidine dose based on the combination of  pre-treatment DPYD 
genotyping and uracil levels will improve treatment safety. These results have to be 
awaited before using uracil levels to adjust the fluoropyrimidine dose.  
In Chapter 6, several patients with multiple DPYD variants (i.e. homozygotes or 
compound heterozygotes), who were treated with personalized fluoropyrimidine 
treatment were described. In current clinical practice, fluoropyrimidine treatment is 
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avoided in these patients. However, this could have a large impact on disease outcome 
for individual patients, as fluoropyrimidines are considered effective anticancer 
agents and are included in many treatment regimens. As demonstrated in Chapter 6, 
personalized fluoropyrimidine treatment in these patients is an option and treatment 
should not be withheld. However, it is difficult to predict DPD activity in patients 
with multiple DPYD variants on the genotyping result solely. Therefore, it is strongly 
recommended to determine DPD-activity in PBMCs in these patients, and adjust the 
(starting) dose accordingly. Furthermore, these patients should be closely monitored 
for toxicity and dose-titration based on clinical tolerance is needed to reach a true 
personalized dose.
PART II: IRINOTECAN
The topoisomerase-I inhibitor irinotecan is widely used in the treatment of solid tumors 
including colorectal and pancreatic cancer.55 Irinotecan treatment is characterized 
by several dose-limiting toxicities such as severe neutropenia and diarrhea in up to 
a quarter of patients.56, 57 In Chapter 7 an overview of current evidence on irinotecan 
pharmacokinetics, pharmacodynamics, and pharmacogenetics is given. The prodrug 
irinotecan is hydrolyzed into the active metabolite SN-38 by two carboxylesterase 
isoforms (CES1 and 2) and butyrylcholinesterase in the human body.58, 59 SN-38 is 
100-1000 fold more active compared to irinotecan itself.60 SN-38 is inactivated via 
glucuronidation into SN-38G by uridine diphosphate glucuronosyl-transferase (UGT) 
and excreted into bile.61, 62 SN-38G can be deconjugated into SN-38 by β-glucuronidases 
produced by intestinal bacteria, which could result in an enterohepatic recirculation of 
SN-38.63-66 Furthermore, irinotecan is also metabolized by intrahepatic cytochrome 
P450 (CYP) enzymes, i.e. CYP3A4 and CYP3A5, into the inactive metabolites: APC and 
NPC.67 In contrast to APC, NPC can be converted to SN-38 by CES1 and CES2 in the 
liver but to a lesser amount than irinotecan.68 Clearance of irinotecan is mainly biliary 
(66%) and irinotecan is transported into the bile by several ATP-binding cassette (ABC) 
transporters (i.e. ABCB1, ABCC2, and ABCG2). 55, 69 70-72 This highly complex metabolism 
makes irinotecan prone to individual, environmental, and genetic influences which will 
partly explain the large inter-individual variability in irinotecan pharmacokinetics. Many 
drug-drug interactions have been described with potentially serious consequences. 
The most famous example is St. John’s wort, which resulted in a 42% reduction of 
SN-38 systemic exposure, primarily caused by CYP3A4 induction.73 Therefore, prior 
to start with irinotecan chemotherapy, all patients should be evaluated for possible 
interactions with co-medication. Furthermore, concomitant use of potent CYP3A4 
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inducers or inhibitors should be avoided. 
In the last decade, much progress has been made in determining the influence of 
pharmacogenetics on systemic irinotecan exposure, toxicity, and survival. The most 
frequently studied gene is UGT1A1, with currently more than one hundred reported 
genetic variants; UGT1A1 is a highly polymorphic enzyme.74 for Caucasians UGT1A1*28 
seems to be a good predictor for neutropenia (all irinotecan doses) and diarrhea (doses 
>125 mg/m2). 75-77 UGT1A1*28 is also significantly associated with an increased risk 
for diarrhea in Asian patients at irinotecan doses >125 mg/m2.77 In Asian populations, 
however, the UGT1A1*6 variant is more common and appears to be a more accurate 
predictor for neutropenia (all irinotecan doses) and diarrhea. 78, 79 80  In addition to 
UGT1A1*6 and UGT1A1*28, UGT1A1*93 is also significantly associated with irinotecan-
induced toxicity.81-86 Less extensively studied polymorphisms such as UGT1A7*3, 
UGT1A9*1, and drug transporter polymorphisms (ABCB1, ABCC5, ABCC2, ABCG1, 
SLCO1B1) may also be useful predictors for toxicity.81, 87-95 Interestingly, CYP3A4*22 has 
not been studied thus far in relation to irinotecan pharmacokinetics or toxicity, while 
this SNP has shown relevance for many other CYP3A substrates.96-98  
Several guidelines, including the U.S. Food and Drug Administration (FDA) and Health 
Canada/Santé Canada (HCSC), recommend a reduction of the irinotecan starting 
dose in patients who are homozygous for UGT1A1*28.99-102 Furthermore, the Japanese 
Pharmaceuticals and Medical Devices Agency (PMDA) recommends screening patients 
for UGT1A1*6 and *28 polymorphisms.103 Despite the establishment of these guidelines, 
UGT1A1 genotyping is currently not routinely performed.104 This could be explained by 
the fact that prospective studies evaluating the clinical effects of genotype-directed 
dosing are scarce. Therefore, in collaboration with the Catharina Hospital, Eindhoven, 
and the Leiden University Medical Center, we designed a prospective trial on genotype-
guided irinotecan dosing based on UGT1A1*28 and UGT1A1*93 genotype status which 
is currently ongoing (The IRI-28 trial: Trial ID: NTR6612). Hopefully, the results of this 
trial will endorse implementation of prospective UGT1A1 screening to personalize the 
irinotecan treatment in daily clinical care. Future research on irinotecan treatment 
should include  UGT1A1 screening also, to increase the therapeutic window as there 
are some studies suggesting that UGT1A1*1/*1 or UGT1A1*1/*28 carriers may tolerate 
higher irinotecan doses than the currently recommended doses and are therefore at 
risk of suboptimal treatment.104, 105
Besides genotyping, several other interventions to reduce treatment related toxicities 
have been investigated including dietary adjustments. Preclinical studies in animals 
have demonstrated that by fasting before irinotecan treatment, toxicity can be reduced 
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while preserving the anti-tumor effects.106, 107 After 72 hours of fasting, mice experienced 
significantly less side effects of irinotecan chemotherapy, intra-tumoral SN-38 
concentrations tended to be higher, and concentrations in both plasma and healthy 
liver were significantly lower.107 Chapter 8 describes a prospective pharmacokinetic 
crossover trial investigating a short-term combined caloric and protein restriction 
regimen (CCPR) in 19 cancer patients with liver metastases treated with irinotecan. 
Patients were randomized to receive irinotecan preceded by five days of CCPR (~30% 
calorie and ~70% protein restriction) during the first or second cycle, while the other 
cycle patients followed their normal diet. During both cycles, 24-hours blood sampling 
was performed and biopsies of healthy liver and liver metastasis 24-26 hours after 
irinotecan administration were taken. Interpatient variability in tissue irinotecan and 
SN-38 concentrations was high. No significant differences in irinotecan and SN-38 
concentrations with CCPR in biopsy tissue of healthy liver or liver metastasis were 
identified, although a trend towards higher concentrations in healthy liver compared to 
liver metastasis was observed.  CCPR significantly increased irinotecan plasma AUC
0-24h
 
with 7.1% (95% CI: 0.3-14.5%, P=0.04) compared to the normal diet, while the SN-38 
plasma AUC
0-24h
 increased with 50.3% (95% CI: 34.6-67.9%, P<0.001). CCPR was well 
tolerated and no difference in treatment-related grade ≥3 toxicity was identified during 
CCPR compared to the normal diet (53% vs 42%, P=0.69). Furthermore, no difference 
was seen with CCPR compared to the normal diet when concerning severe neutropenia 
(47% vs 32% P=0.38), severe diarrhea (5% vs 21% P=0.25), febrile neutropenia (5% vs 16% 
P=0.50) and hospitalization (11% vs 21% P=0.634). However, this trial was not designed, 
nor powered, to detect a difference in toxicity, and therefore these results need to be 
interpreted with caution. Despite the low sample size, it is still surprising that with the 
large increase in SN-38 exposure no increase in toxicity was detected, which might 
have been expected as a concentration-effect relationship has been described for 
severe diarrhea and neutropenia.108     
Several mechanisms for the increased SN-38 exposure observed with CCPR can 
be proposed. Firstly, a decreased elimination of SN-38 caused by reduced UGT-
activity or reduced activity of ABC transporters involved in the intestinal elimination 
of SN-38. In healthy subjects, indeed a reduced UGT metabolism of midazolam was 
demonstrated after 36 hours of fasting.109 Furthermore, in patients with morbus Gilbert 
fasting can induce an increase in bilirubin levels due to reduced UGT activity, which 
supports this hypothesis too.110 To further evaluate this possible mechanism, SN-38G 
concentrations will be determined in retrospect. Preclinical evidence demonstrated an 
increased ABCC2 activity in mice after 24 hours of fasting. However, to our knowledge 
this has not been demonstrated for humans, nor was it demonstrated for the other 
efflux transporters.111 Secondly, the increased SN-38 concentrations could have been 
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caused by increased formation of SN-38 by carboxylesterases or intestinal beta-
glucuronidases, although there is no evidence supporting this theory. Furthermore, the 
increased SN-38 concentrations could result from a decreased irinotecan conversion 
into inactive metabolites by CYP3A4 resulting in increased irinotecan conversion to 
SN-38. The influence of fasting on CYP3A4 is not fully elucidated as one study found 
no effect and another an increased CYP3A4 activity, but no decreased activity has been 
described. 109, 112 
Our findings were unexpected as our preclinical studies in mice demonstrated lower 
irinotecan and SN-38 concentrations in plasma and healthy tissue and a trend towards 
increased intra-tumoral concentrations after dietary restriction.107 Possible explanations 
for these differences are that in the preclinical study whole tumors and livers were used 
for pharmacokinetic measurements instead of a single biopsy and the metabolism in 
mice is not exactly equal to humans.113-117
The mechanisms behind the protective effects of dietary restriction are not completely 
understood, but are currently actively studied. Recently, several small observational 
trials investigating the beneficial effects of dietary restriction in cancer patients have 
been conducted. Two small studies demonstrated that short-term fasting resulted in 
a trend towards less hematological toxicity after chemotherapy.118, 119 Furthermore, 
Bauerfeld et al. demonstrated in 34 patients that short term fasting (i.e. 36 hours before 
till 24 hours after chemotherapy) improved quality of life and fatigue without inducing 
toxicity during different types of chemotherapeutic regimens.120 However, none of 
these studies included pharmacokinetic analyses, while our study demonstrates that 
the importance of such analyses, especially in view of the narrow therapeutic index of 
most cytostatic agents. Future studies should therefore include larger sample sizes to 
evaluate toxicity, including pharmacokinetic analyses of the different cytostatic agents 
in plasma and preferably repetitively in tumor as well, and perform quality of life analysis. 
Furthermore, additional research is necessary to determine if dietary restriction does 
not reduce treatment efficacy as intra-tumoral concentrations were highly variable in 
our study and other studies did not include efficacy end points also. 
PART III: REGORAFENIB
Regorafenib is an oral multi-kinase inhibitor that targets angiogenic and stromal 
receptor tyrosine kinases both in healthy tissue and in tumors.121 Regorafenib is 
currently registered worldwide for the treatment of colorectal cancer (except for the 
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Netherlands), gastro-intestinal stromal tumors, and hepatocellular carcinoma.122-124 After 
oral administration, regorafenib is rapidly absorbed, with a maximum concentration 
reached at 3-4 hours.125, 126 Most tyrosine kinase inhibitors (TKIs) exhibit pH-dependent 
solubility, which makes them prone for drug-drug interactions with acid suppressive 
agents like proton pump inhibitors.127 However, for regorafenib it is unknown if these 
drugs can be combined safely. In Chapter 9 we describe a prospective randomized 
three-phase cross-over study in 14 metastatic colorectal cancer patients, on the 
potential pharmacokinetic interaction between the proton pump inhibitor (PPI) 
esomeprazole and regorafenib, with special interest in the influence of timing of 
esomeprazole intake relative to that of taking regorafenib (i.e. concomitantly or three 
hours prior to the TKI). This clinical trial did not reveal a significant pharmacokinetic 
interaction between esomeprazole and regorafenib at the two time-points studied. 
Therefore, we concluded that esomeprazole can be safely combined with regorafenib 
in clinical practice, in contrast to some other TKIs. These results were not completely 
unexpected as regorafenib exhibits a low solubility, which is mainly caused by its 
chemical structure as no strong basic or acidic group is attached.128 Furthermore, to 
improve the solubility, regorafenib is formulated as a solid dispersion consisting of 
small powder particles in which the drug and excipient are integrated 129. As a result 
regorafenib absorption is, in theory, less affected by intragastric pH-alterations, which 
is in line with the results of our study. 
In this study, esomeprazole was used because it exhibits the strongest pH-reducing 
effect of all acid-reducing drugs currently available.127, 130 Also, esomeprazole does not 
influence other enzymes or transporters, such as ABCB1, that could potentially influence 
the pharmacokinetics of regorafenib’s active metabolites M-2 and M-5 131. Therefore, 
our findings cannot simply be extrapolated to other PPIs such as pantoprazole which is 
known to influence ABCB1, but this could be interesting to investigate also. We examined 
two time-points regarding the intake time of esomeprazole (i.e. concomitantly or three 
hours prior regorafenib intake), because PPIs are assumed to have their maximum 
acid-reducing effect three hours after intake and a possible interaction would be the 
strongest at this time-point.132 This unique study design can serve as a template for 
future studies evaluating the influence of PPIs on exposure of oral (anticancer) drugs.
 
Furthermore, in more than half of all patients, treatment with regorafenib is associated 
with severe and dose-limiting toxicities such as hypertension and hand foot skin 
reactions which may not always outweigh treatment benefit.133 Therefore, there is 
an urgent need for biomarkers predictive for response to identify specific patients 
who will, and who will not, benefit from regorafenib treatment. Multiple studies 
demonstrated that the detection of circulating cell free DNA (cfDNA) and circulating 
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tumor DNA (ctDNA) could be a powerful tool to monitor and understand the response 
to anti-cancer agents.134, 135 However, most of these studies only measured cfDNA and 
ctDNA at baseline and not after initiation of treatment. In Chapter 10 we describe 
an explorative analysis on early cfDNA/ctDNA dynamic changes and correlation 
with regorafenib pharmacodynamics in 20 metastatic colorectal patients. cfDNA 
concentrations significantly increased in almost all patients at days 8 and 15, which 
correlated with ctDNA increase and plasma liver enzyme increases, suggesting that 
treatment related damage of healthy cells may have confounded these measurements. 
This finding was somewhat surprising, as we expected cfDNA levels to drop during 
treatment. The increase in cfDNA could be the result of tumor cell death given the 
strong correlation with ctDNA, but normal liver tissue damage inflicted by regorafenib 
may also influence cfDNA levels.  The concept that liver damage may increase cfDNA 
concentrations is supported by a study in 14 mCRC patients treated with chemotherapy 
and hepatic trans-arterial chemo-embolization that demonstrated that 93% of patients 
had an increase in cfDNA 24-hours after the first treatment, possibly as a result from 
local liver cell damage.136 In two additional studies in non-cancer patients cfDNA 
increases correlated with several causes of liver cell damage (e.g. non-alcoholic fatty 
liver disease, liver transplantation, sepsis).137, 138 Thus, liver cell decay independent of 
its mechanism seems to increase cfDNA concentrations. These findings implicate that 
treatment related liver toxicity should be taken into account in any research on cfDNA 
as potential biomarker for treatment response.
Furthermore, ctDNA dynamics were highly variable between patients, but the majority 
of patients developed also an absolute increase of mutated molecules per mL at day 8 
or 15. An earlier study reported that an increase of ctDNA at day 14 in patients treated 
with regorafenib was associated with decreased PFS and OS.139 Our study failed to 
confirm these findings which may be due to the low sample size of both studies and the 
dynamic pattern of ctDNA alterations. These conflicting data make it impossible to draw 
a firm conclusion about the value of ctDNA quantification for response prediction. In our 
study, the early increase in ctDNA levels tend towards a correlation with increased lactic-
dehydrogenase concentration, which may be related to tissue decay, or hypothetically 
the development of hypoxia in the tumor micro-environment as the anti-angiogenic 
effects of regorafenib can occur within two weeks after initiation of treatment.140 In 
contrast to our finding, Tie et al. measured ctDNA levels in mCRC patients 3 days after 
treatment with several types of chemotherapy, and found no significant difference in 
ctDNA levels, which could be explained by the difference in administered anti-cancer 
agent.141 Furthermore, in our ctDNA analysis, we could not demonstrate the emergence 
of new resistance associated mutations or loss of mutations that mark specific therapy 
sensitive subclones. More specific inhibitors that are used in mCRC such as anti-EGFR 
324
PART V | CHAPTER 13
antibodies have been shown to induce the emergence of several resistance associated 
mutations 135, 142-144. Together these data indicate that patterns of ctDNA alterations during 
treatment depend on the type of treatment given. Our study highlights the importance 
to perform sufficient longitudinal sampling experiments for each type of treatment and 
correct the outcome for the amount of liver damage before implementing circulating 
DNA based biomarkers for response prediction.
PART IV: CARBOPLATIN / PACLITAXEL
The combination of carboplatin and paclitaxel is widely used in the treatment of 
esophageal cancer. Most patients with resectable (gastro)esophageal cancer are treated 
with carboplatin and paclitaxel based neoadjuvant chemoradiotherapy according 
to the CROSS-regimen.145, 146 However, almost half of all patients have already non-
resectable (gastro)esophageal cancer at diagnosis due to locally advanced tumors or 
distant metastasis.147 For patients with locally advanced disease, systemic treatment 
can be considered in an attempt to downstage the tumor (i.e. induction treatment), 
which can be followed by surgery or chemoradiotherapy in case of a good response. 
For patients with distant metastases, palliative chemotherapy can be considered. Many 
different induction or palliative treatment regimens are described, which are often 
fluoropyrimidine- or platinum-based doublet or triplet combination regimens.148 
At the Erasmus University Medical Center, Rotterdam, a weekly regimen consisting of 
carboplatin targeted at an area under the curve (AUC) of 4 mg x min/mL and paclitaxel 
100 mg/m2 was developed and implemented as standard of care for all patients with 
advanced or metastatic esophageal cancer.149 Chapter 11 describes the toxicity and 
efficacy of this weekly carboplatin and paclitaxel regimen as induction or palliative 
treatment in 291 advanced (gastro)esophageal cancer patients. In general, this treatment 
regimen was well-tolerated with a low incidence of severe toxicity (i.e. grade ≥3), 
except for hematological toxicity such as neutropenia. Almost two third of patients 
experienced severe neutropenia, which is higher than described for other frequently 
used regimens.150 However, severe leukopenia occurred in one third of patients and was 
therefore comparable with other frequently used regimens.150 According to our treatment 
protocol, this regimen could be safely administered on an outpatient basis at any grade 
of neutropenia as long as leukocyte number was sufficient (i.e. day 0 and 28: > 3.0 x 
109/L; day 7, 14, 35 and 42: > 1.0 x 109/L), which was also reflected by the low incidence 
of febrile neutropenia in only three percent of patients. Furthermore, the incidence of 
severe nausea or diarrhea of only one to two percent of patients was much lower than 
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in most other fluoropyrimidine-based doublet regimens with an incidence up to 8% for 
severe diarrhea and up to 20% for severe nausea, and for triplet-based regimens are 
these incidences even higher.150, 151 The good clinical tolerance of this treatment regimen 
was also demonstrated by the low incidence of toxicity-related dose-reductions in one 
percent and drug-related hospitalization in twelve percent of patients.
With this regimen an overall response rate of 48% in patients treated with induction 
intent and 44% in patients treated with palliative intent was achieved. The response 
rate of 48% in patients with induction intent, is comparable to other regimens with 
response-rates varying between 20-48% .151-163 Furthermore, for 42% of patients treated 
with induction intent, an esophagectomy or definitive chemoradiotherapy followed, 
which resulted in a median PFS of 22.1 months and median OS of 26.8 months. For the 
other patients, who did not have an esophagectomy or definitive chemoradiation, the 
median PFS of 9.0 months and OS of 11.8 months was lower, but comparable to the 
patients treated with palliative intent. In patients with metastatic (gastro-)esophageal 
cancer we found a response rate of 44%, which is also comparable with the most 
frequently used other doublet regimens (20-45%) and triplet regimens (31-48%) .151-153, 
155-158, 160-162 When comparing survival rates, we found a median PFS of 8.2 months and 
OS of 10.9 months for palliative treated patients, which is longer than other doublet 
regimens in this patient group (PFS: 3.7-5.9 months; OS: 8.6-10.7) and is comparable 
to triplet regimens (PFS: 5.6-7.0; OS: 9.2-11.2) .151-153, 155-158, 160-162 Although we have to 
interpret these comparisons with caution as we did not make a direct head to head 
comparison, the weekly combination of carboplatin and paclitaxel seems to be at least 
equally effective, and possibly even more effective compared to other frequently used 
treatment regimens and was better tolerated than other regimens.
Furthermore, we tried to identify predictive factors for treatment outcome and 
prognostic factors for PFS and OS. We could only identify smoking as predictive factor 
for patients with induction treatment, while unfortunately no predictive factors for 
treatment outcome in palliative treated patients were found. Nonetheless, we identified 
several prognostic factors for PFS and OS. For induction chemotherapy, current 
smoking behavior, elevated thrombocyte number and alkaline phosphatase levels, 
WHO status and T-stage, were identified as adverse prognostic factors. For palliative 
chemotherapy, tumor location, BSA and WHO status were identified as prognostic 
factors. In our population studied, we could not confirm other known prognostic 
factors for survival such as sex or location of metastases.164-166
Paclitaxel is also characterized by a large inter-individual variability in exposure and a 
dose-response relation has been suggested.167, 168 Therefore, we hypothesized that an 
326
PART V | CHAPTER 13
increased systemic paclitaxel exposure (lower clearance) is associated with a better 
response to treatment for patients with esophageal cancer. Unfortunately, in Chapter 
12 we demonstrate the absence of any association between paclitaxel clearance and 
treatment outcome in 166 patients with esophageal cancer treated with common 
paclitaxel-based treatment regimens (e.g. neo-adjuvant chemoradiotherapy, induction 
and palliative chemotherapy). Several reasons can be hypothesized for the absence 
of this correlation. Firstly, in neoadjuvant chemoradiotherapy, the chemotherapy 
is administered in a lower dose and mainly acts as a radiosensitizer.169, 170 Also, the 
combination with carboplatin chemotherapy (of which no drug concentrations 
were measured) could have influenced the outcomes of the analyses. Furthermore, 
the type of tumor (adenocarcinoma versus squamous cell carcinoma) affects the 
response to chemoradiotherapy indicated by the fact that a histological response 
occurs more often in patients with squamous cell carcinomas. However, the CROSS 
regimen does not distinguish between the two tumor types in clinical practice.145, 146 In 
the present study, the majority of patients were diagnosed with an adenocarcinoma 
of the esophagus, in line with the incidence in Western world.171 Another important 
reason for the lack of correlation between paclitaxel plasma pharmacokinetics and 
tumor response is a potential weak correlation between paclitaxel plasma exposure 
and paclitaxel tumor exposure. As one of its potential resistance mechanisms a tumor 
may use efflux transporters (i.e. ABC-transporters) to limit intra-tumoral chemotherapy 
concentrations. Taxanes, including paclitaxel, are known substrates for these 
transporters.172, 173 Although we did not measure intra-tumoral drug concentrations in 
this study, due to its retrospective nature, we speculate that intra-tumoral paclitaxel 
concentrations differ substantially from plasma chemotherapy concentrations. To 
further explore this, we have set up a new prospective clinical trial (i.e. the PAREO study; 
registered as NTR6356) in which plasma paclitaxel exposure is compared with intra-
tumoral concentrations by serial tumor biopsies and simultaneous blood sampling in 
patients treated for esophageal cancer. 
Although the prognosis of esophageal cancer has improved over the last decades, 
unfortunately the outcome still remains poor with an overall 5-year survival of 20%.174, 
175 Improvement in prognosis might be caused by recent advances in the treatment 
of patients with resectable (gastro)esophageal cancer by introduction of neoadjuvant 
chemoradiotherapy such as the CROSS-regimen.145, 146 However, as stated before, 
almost half of all patients already have non-resectable (gastro)esophageal cancer at 
diagnosis.147 Especially for these patients, improvement of current treatments is highly 
warranted. In general, chemotherapy has limited efficacy in advanced esophageal 
cancer with only minor differences between different schedules, but it will remain the 
backbone of treatment in metastatic (gastro)esophageal cancer until new treatments 
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are developed. Future research should therefore focus on predictive factors and 
biomarkers to identify patients beforehand who will benefit from a certain treatment. 
Furthermore, the tumor biology should be included in patient selection. Several 
molecular subtypes of (gastro)esophageal cancer have been identified and provides 
a rationale to develop tailored treatment for the different subtypes instead of treating 
all (gastro)esophageal cancers in the same manner.176 Currently investigated targeted 
therapies focusses on targeting the human epidermal growth factor receptor type 2 
(HER2) and the vascular endothelial growth factor receptor (VEGF) with limited effect, 
nevertheless several combination therapies are being evaluated.177 
Since the publication of the impressive results of immunotherapy in other tumor types 
such as melanoma, the immune micro-environment of esophageal tumors is evaluated 
as possible treatment target as well. Recent phase-II studies demonstrate promising 
results of nivolumab and/or ipilimumab in esophageal cancer.178, 179 Furthermore, the 
phase-III ATTRACTION trial demonstrated that nivolumab significantly increased OS 
compared to placebo in heavily pretreated Asian patients with metastatic (gastro)
esophageal cancer independent of the PD-L1 status.180 The phase-III KEYNOTE-181 
study demonstrated that pembrolizumab as second-line therapy significantly improved 
OS compared to chemotherapy in patients with metastatic esophageal cancer with a 
high PD-L1 combined score.181 Currently, the results of multiple clinical trials evaluating 
immunotherapy and the combination of immunotherapy and chemotherapy are 
awaited.177 Therefore, the true value of immunotherapy in (metastatic) esophageal 
cancer is not clear yet.
CONCLUSION
This thesis describes several pharmacokinetic, -dynamic and pharmacogenetic studies 
on four frequently used anti-cancer drugs in cancers of the gastro-intestinal tract. 
We used many different research methods, of which intra-tumoral pharmacokinetics 
and circulating DNA are relatively new in the field and the true potential of these 
methods needs to be further explored. Pharmacogenetic-based dosing is currently not 
yet standard of clinical care and hopefully this will change soon for fluoropyrimidine 
treatment and DPYD genotyping. The preliminary data suggest that this may also be 
the case for irintotecan treatment and UGT1A1 genotyping in the future. When the 
data from pharmacokinetic and pharmacogenetic research are combined in medical 
oncology, this will give us the tools that will eventually lead to a true personalized 
dosing regimen for every patient.  
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Dit proefschrift beschrijft verschillende onderzoeken gericht op met name de 
‘farmacokinetiek’ en ‘farmacogenetica’ van vier verschillende anti-kanker medicijnen 
die veelvuldig worden gebruikt in de behandeling van gastro-intestinale kankersoorten. 
Farmacokinetiek beschrijft alles wat het lichaam doet met het geneesmiddel, terwijl 
farmacogenetica zich meer richt op de erfelijke factoren die hiervoor van belang zijn. 
Het overkoepelende doel van al deze onderzoeken is om factoren te identificeren die 
kunnen helpen om de anti-kanker behandeling voor iedere patiënt op maat te maken 
met als voornaamste doelen de bijwerkingen (toxiciteit) te minimaliseren en (de kans 
op en de duur van) het aanslaan van de behandeling (effectiviteit) te vergroten.
DEEL I: FLUOROPYRIMIDINES
Fluoropyrimidines waaronder de geneesmiddelen 5-fluouracil en capecitabine vallen, 
behoren tot de meest gebruikte anti-kanker middelen. Afhankelijk van het type 
behandeling wordt capecitabine gegeven als monotherapie, dan wel in combinatie 
met andere anti-kanker middelen, of in combinatie met radiotherapie. Net als vele 
andere anti-kanker middelen wordt capecitabine in het algemeen gedoseerd op basis 
van het lichaamsoppervlakte (berekend uit de lengte en het gewicht) van een patiënt. 
Een alternatief hiervoor is een ‘vaste’ of ‘gefixeerde’ dosering per indicatie, waarbij 
de dosering dus niet is aangepast aan deze lichaamsmaat. In Hoofdstuk 2 wordt de 
toxiciteit en effectiviteit van het vast doseren van capecitabine in vier verschillende 
behandelregimes in een groep van 1126 patiënten vergeleken met 1193 vergelijkbare 
patiënten die op lichaamsoppervlakte zijn gedoseerd. We hebben geen verschil in 
toxiciteit gevonden tussen deze twee verschillende manieren om capecitabine te 
doseren. Daarnaast werd geen verschil in effectiviteit van de behandeling gevonden. 
Onze resultaten laten dus zien dat deze vaste dosering van capecitabine een goed en 
praktisch alternatief voor het doseren op lichaamsoppervlakte is.   
Fluoropyrimidines worden voor meer dan 80% omgezet in niet werkzame (inactieve) 
stoffen door het enzym dihydopyrimidine dehydrogenase (DPD). Ongeveer 10-30% 
van alle patiënten die behandeld worden met fluoropyrimidines ervaart helaas ernstige 
of zelfs fatale toxiciteit. Deze ernstige toxiciteit wordt in bijna 60% van deze patiënten 
veroorzaakt door een verlaagde DPD activiteit, die vaak wordt veroorzaakt door 
afwijkingen in het gen DPYD dat codeert voor het enzym DPD. Er zijn momenteel 
vier klinisch relevante genetische varianten bekend: DPYD*2A, c.1679T>G, c.2846A>T, 
en c.1236G>A, die zorgen voor een geschatte 25-50% afname van de DPD activiteit. 
In Hoofdstuk 3 wordt een groot onderzoek in 17 Nederlandse ziekenhuizen 
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beschreven, waarbij er gescreend werd op deze vier genetische varianten en daarop 
de fluoropyrimidine dosering werd aangepast (met een 25% of 50% dosisreductie 
afhankelijk van de erfelijke variant). In totaal werden er 1103 patiënten geïncludeerd, 
waarvan 85 patiënten met een DPYD variant (7.7%). De incidentie van ernstige toxiciteit 
was ondanks de dosisreducties nog steeds hoger in mensen met DPYD varianten (39%) 
vergeleken met patiënten zonder een mutatie (23%). Maar wanneer we onze resultaten 
vergelijken met een historisch cohort met DPYD variant dragers die met een volledige 
dosering werden behandeld, nam het (relatieve) risico op ernstige bijwerkingen duidelijk 
af voor de varianten DPYD*2A en c.1679T>G, verminderde het risico gedeeltelijk 
voor c.2846A>T, maar werd het risico voor mensen met de c.1236G>A variant niet 
verminderd. Patiënten met deze laatste twee varianten, kregen een dosisreductie van 
(slechts) 25% en mogelijk is dit niet voldoende om de toxiciteit te verlagen. Daarnaast 
hebben we in Hoofdstuk 4 laten zien dat deze doseermethode kosteneffectief is.  
Behalve DPYD genotyperen, kan er ook (in)direct naar de werking van het DPD-enzym 
gekeken worden door middel van zogenaamde ‘fenotyperings’-testen. Onder directe 
fenotyperingstesten verstaan we het direct meten van DPD activiteit in bijvoorbeeld 
bloedcellen. Indirecte fenotyperingstesten richten zich op de meting van het endogene 
substraat van DPD (namelijk uracil) of op de stoffen die ontstaan na verwerking door 
DPD (zoals dihydrouracil). In Hoofdstuk 5 beschrijven we vier verschillende DPD 
fenotyperingstesten die verricht zijn bij een gedeelte van de patiënten van het eerdere 
onderzoek. Helaas kon bij geen van deze vier testen DPD-deficiëntie of fluoropyrimidine 
gerelateerde bijwerkingen goed voorspellen. Er is daarom verder onderzoek naar deze 
fenotyperingstesten nodig voor we ze in de klinische praktijk kunnen gaan gebruiken.  
In Hoofdstuk 6 worden patiënten met meerdere DPYD varianten per patiënt 
beschreven die we hebben behandeld met een gepersonaliseerde fluoropyrimidine 
dosis. Dit hoofdstuk laat zien dat ondanks de genetische variatie in deze patienten een 
individuele behandeling goed mogelijk gebleken.
DEEL II: IRINOTECAN
Al twee decennia is irinotecan een anti-kanker middel wat veelvuldig gebruikt wordt 
in de behandeling van onder andere darm- en alvleesklierkanker. De behandeling met 
irinotecan wordt gekenmerkt door verschillende dosis-limiterende bijwerkingen zoals 
een daling in de witte bloedcellen en ernstige diarree. Irinotecan heeft een complex 
metabolisme waarbij irinotecan eerst moeten worden omgezet in de werkzame stof SN-
38. Hierdoor kunnen er vele indiviuele, omgevings- en genetische factoren van invloed 
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zijn op de irinotecan en SN-38 blootstelling. In Hoofdstuk 7 geven we een overzicht 
van de kennis op het gebied van irinotecan farmacokinetiek, ‘farmacodynamiek’ (wat 
het geneesmiddel met het lichaam doet) en farmacogenetica. De laatste jaren is er 
meer aandacht voor de farmacogenetica van irinotecan, waarbij varianten van het 
UGT1A1 gen gerelateerd zijn aan een verhoogde kans op bijwerkingen. Dosisaanpassing 
op basis van het UGT1A1 zou daarmee ook de toxiciteit van de behandeling kunnen 
verlagen.
 
Er zijn vele andere interventies onderzocht die het risico op toxiciteit zouden kunnen 
verlagen, waaronder dieet aanpassingen. Onderzoeken in proefdieren hebben 
aangetoond dat door te vasten voor de behandeling met irinotecan, de toxiciteit 
werd verlaagd terwijl het anti-kanker effect bleef behouden. Gezien deze positieve 
bevindingen werd in Hoofdstuk 8 een onderzoek beschreven waarbij we een vijf 
daags eiwit- en caloriebeperkt dieet onderzoeken in 19 patiënten met darmkanker 
voor behandeling met irinotecan. In dit onderzoek werd op de dag van irinotecan 
toediening verschillende bloedafnames gedaan en de dag erna een biopt van zowel 
gezond leverweefsel als een biopt uit een leveruitzaaiing verricht. Er was een hoge 
variatie in de irinotecan en SN-38 concentraties in de biopten van deze patiënten 
en daarbij werd geen duidelijk verschil gevonden met of zonder dieet. Echter, het 
dieet zorgde voor een toename van 7% in de irinotecan blootstelling en maar liefst 
50% toename in de SN-38 blootstelling in het bloed. Het dieet werd goed verdragen 
en we zagen geen verschil in bijwerkingen. Bij deze sterke toename van de SN-38 
blootstelling had een toename in de toxiciteit verwacht kunnen worden, maar dit werd 
dus niet gezien, wat veelbelovend is. Verder onderzoek moet verricht worden om te 
bepalen of de effectiviteit en toxiciteit van irinotecan inderdaad verbeterd kan worden 
met dieetrestrictie.  
DEEL III: REGORAFENIB
Regorafenib is een oraal anti-kanker middel, dat wereldwijd gebruikt wordt in de 
behandeling van darmkanker (behalve in Nederland), gastro-intestinale stromale 
tumoren en leverkanker. Na inname wordt regorafenib snel geabsorbeerd in het 
maagdarmstelsel en kan daarna worden opgenomen in het bloed. Voor vergelijkbare 
middelen is aangetoond dat voor deze absorptie de zuurgraad van de maag sterk van 
belang is. Bij het gebruik van maagzuurremmers zou daarmee de opname van het 
medicijn verlaagd kunnen worden en daarmee leiden tot een verminderde blootstelling. 
In Hoofdstuk 9 beschrijven we een onderzoek dat laat zien dat als de maagzuurremmer 
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esomeprazol gelijktijdig met of drie uur eerder dan de regorafenib wordt ingenomen, 
de blootstelling van regorafenib niet wordt beinvloed. Deze maagzuurremmer kan dus 
veilig worden gecombineerd met regorafenib.
In meer dan de helft van alle patienten geeft regorafenib ernstige bijwerkingen en de 
effectiviteit van de behandeling weegt soms niet op tegen deze toxiciteit. Daarom is 
het belangrijk om te voorspellen wie voordeel heeft van deze behandeling en wie niet. 
Circulerend DNA (erfelijk materiaal), zowel van de tumor (ctDNA) als de combinatie van 
tumor en gezonde weefsels (cfDNA), is een relatief nieuwe methode om te kijken naar 
het effect van de behandeling. In Hoofdstuk 10 beschrijven we de ctDNA en cfDNA 
dynamiek in 20 patiënten behandeld met regorafenib. Deze analyse laat zien dat ctDNA 
en cfDNA concentraties beide toenemen na 1 tot 2 weken behandeling met regorafenib 
en dat dit waarschijnlijk deels wordt veroorzaakt door schade van de regorafenib op de 
gezonde weefsels in het lichaam. 
DEEL IV: CARBOPLATIN / PACLITAXEL
De combinatie van de twee (per infuus toegediende) anti-kanker middelen carboplatin 
en paclitaxel wordt veel gebruikt in de behandeling van slokdarmkanker. Bij patiënten 
met resectabele slokdarmkanker wordt dit in combinatie met radiotherapie (bestraling) 
gegeven voorafgaand aan de operatie (we noemen dit ook wel een neo-adjuvante 
behandeling). Echter, meer dan de helft van alle patiënten heeft helaas niet-resectabele 
ziekte bij diagnose en zij kunnen dan soms een behandeling krijgen om de tumor 
kleiner te maken om alsnog een eventuele operatie mogelijk te maken (we noemen 
dit inductie therapie). Wanneer er al uitzaaiingen zijn, dan is de behandeling gericht op 
verlenging van het leven (dit is een palliatieve behandeling). In Hoofdstuk 11 beschrijven 
we de toxiciteit en effectiviteit van een wekelijks behandelschema met carboplatin en 
paclitaxel als inductie of palliatieve behandeling. De effectiviteit van deze behandeling 
bleek vergelijkbaar te zijn met andere behandelingen met deze indicatie, terwijl de 
toxiciteit milder lijkt te zijn. Dit is dus een goede behandeloptie voor patiënten met 
slokdarmcarcinoom.
Desalniettemin is er voor paclitaxel een grote variatie in farmacokinetiek tussen 
patiënten beschreven. Daarom hebben we in Hoofdstuk 12  gekeken of er een relatie 
was tussen paclitaxel blootstelling en uitkomst van de behandeling in 166 patiënten 
met slokdarmkanker (zowel neoadjuvant, inductie als palliatief). We hebben helaas 
geen relatie tussen paclitaxel blootstelling en effect van de behandeling kunnen aan 
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tonen. Verder onderzoek (zoals farmacokinetiek van paclitaxel in de tumor) is nodig 
om factoren te identificeren die het effect van de behandeling kunnen voorspellen.   
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Name PhD student:  Femke M. de Man
PhD period:    December 2015 – April 2019
Erasmus MC Department:  Medical Oncology
Research School:   Molecular Medicine
Promotors:    Prof. dr. A.H.J. Mathijssen
    Prof. T. van Gelder
Co-promoter:    Dr. M.P.J.K. Lolkema
1. PhD traininig Year Workload 
(ECTS)
General courses
BROK (GCP) course
Research Integrity 
Biomedical English Writing and Communication
2015, 2019
2017
2018
1.0
0.3
3.0
Specific courses 
OpenClinica database building
MS Excel: Basic workshop 
MS Excel: Advanced workshop 
CPO minicourse in methodology
The Molmed annual course on molecular medicine 
Basic introduction course on SPSS
Workshop Omgaan met groepen
Genetics for Dummies 
Biostatistical Methods I: Basic Principles (CCO2) 
Survival Analysis Course 
Workshop: Hoorcollege geven
Workshop: Onderhandelen
Teach the Teacher I
2015
2016
2016
2016
2016
2016
2016
2016
2016
2017
2017
2018
2018
0.4
0.3
0.3
0.3
0.3
1.0
0.5
0.5
5.7
0.6
0.3
0.3
0.7
Oral presentations
NVKF&B Scientific Meeting 
Annual Clinical Pharmacology Meeting
Translational Pharmacology Meeting
Medical Oncology Research Meeting
Scientific meeting, Medical Oncology 
2015
2016
2015-2018
2016-2018
2017
0.2
0.2
0.8
0.6
0.2
Poster presentations
ESMO congress
ESMO congress
ICPAD
NVKF&B Scientific Meeting (2x)
2017
2018
2018
2019
0.2
0.2
0.2
0.4
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(Inter)national conferences
NVKFB Scientific meeting
Young oncologist evening, Erasmus MC 
Regional GI-symposium
Daniel den Hoed day
Therapeutic sequence mCRPC and beyond
Annual clinical pharmacology meeting
CPCT symposium
ESMO congress
ICPAD
2015-2019
2016, 2017, 
2019
2016, 2018
2016
2016
2016
2016
2017, 2018
2018
2.5
1.5
1.0
0.5
0.5
0.5
0.5
4.0
0.5
Other
Scientific meeting Medical Oncology
Translational Pharmacology meetings
Clinical Pharmacology meetings
2016-2018
2015-2019
2015-2019
0.6
2.0
2.0
2. Teaching
Lecturing
Department of dietetics, Erasmus MC 
Young oncologist evening, Erasmus MC
CPO course
Internal Medicine Clinical Demonstration, Erasmus MC
2016
2017, 2019
2018
2018
0.2
0.4
0.2
0.2
Tutoring
Tutorial class first-year medical students 2016-2018 4.5
Supervising students in extracurricular research
Marijn Veerman
Ruben van Eerden
2015-2016
2016
2.0
1.0
Supervising Master’s thesis
Mirjam de With
Marijn Veerman
Ruben van Eerden
Ivo Bijl
Joris Veraart
2016
2017
2017
2018
2018
1.0
1.0
1.0
1.0
1.0
3. Other
Peer review of manuscripts
Organisation meetings (Research Meeting Translational 
Pharmacology 2017, MORM 2017-2018)
Board of medical residents (AAV), Erasmus MC 
2016-2017
2017-2018
2017-2019
0.4
2.0
5.0
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Dit proefschrift was nooit tot stand gekomen zonder de inzet, hulp en aanmoediging 
van vele mensen. Allereerst, wil ik alle patiënten en hun dierbaren heel erg bedanken 
voor hun inzet voor wetenschappelijk onderzoek, zonder jullie zou dit niet mogelijk 
zijn! Daarnaast wil ik de volgende personen graag in het bijzonder bedanken. 
Mijn promotoren Prof. dr. Ron Mathijssen en Prof. dr. Teun van Gelder ben ik beide veel 
dank verschuldigd. Ron, heel erg bedankt voor je hulp van de afgelopen jaren, jouw 
inzet is nog steeds eindeloos. Ik ben heel blij dat ik ooit bij jou begonnen ben. Mijn 
volhardende karakter en jouw enthousiasme, maakt dat we dit in korte tijd hebben 
kunnen bereiken. Ik ben heel trots dat ik onze onderzoeksgroep heb zien uitgroeien 
van een klein groepje naar een volwassen groep. Ik heb veel bewondering voor jouw 
actieve betrokkenheid bij iedereen en je enthousiasme voor de wetenschap. Ik ben je 
dankbaar voor alle vrijheid en vertrouwen die je mij hebt gegeven om zelf de richting 
van mijn boekje en projecten te bepalen. Ik kijk uit naar alle gezamelijke projecten 
die er zeker nog aan zullen komen. Teun, vanaf het eerste moment dat ik jou als 
student heb leren kennen heb je mij enthousiast gemaakt over de wetenschap en de 
klinische farmacologie in het bijzonder. Bedankt dat je er altijd was voor wijze raad 
en een kritische noot, maar ook voor je oprechte interesse en je gezelligheid bij de 
verschillende borrels. Ik wens je veel succes bij je nieuwe uitdaging, hopelijk kunnen 
we in de toekomst nog samen aan projecten werken.  
Dr Lolkema, Martijn, als mijn copromoter heb je mij een hele nieuwe kant van het 
onderzoek laten zien. Ondanks dat we allebei teleurgesteld waren dat de preklinische 
experimenten niet veel opleverden, heb ik er veel van geleerd en genoten van onze 
meetings. Jouw enthousiasme en humor gaven mij de spirit om weer door te gaan 
met soms moeizame projecten. Ik ben erg trots op het cfDNA project waarbij je mij en 
Lindsay alle vrijheid hebt gegeven om onze hypotheses te exploreren. Ik hoop in de 
toekomst nog veel van je te mogen leren als wetenschapper, als oncoloog en niet te 
vergeten als grill master van de green egg. 
Prof. dr. van Schaik, Prof. dr. Huitema, Prof. dr. Gelderblom, bedankt dat jullie dit 
manuscript hebben willen beoordelen als leescommissie. Prof.dr. IJzermans, Prof. dr. 
van der Kuy, dr. Steeghs, dr. van der Gaast, bedankt dat jullie bereid zijn om in de 
oppositie plaats te nemen. 
Ik wil alle co-auteurs van de verschillende manuscripten in dit proefschrift van harte 
bedanken voor jullie bijdrage. 
Esther Oomen, bedankt voor je hulp bij de statistiek van verschillende projecten. Het 
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was altijd fijn om samen achter jouw computer door onze analyses te gaan. Bedankt 
voor al je betrokkenheid. 
Alle betrokkenen van het Alpe-DPD projectteam en de deelnemende ziekenhuizen 
van de M14DPD studie wil ik graag bedanken voor jullie enorme inzet. Linda en Carin, 
bedankt voor de fijne samenwerking, waarin we van elkaar hebben kunnen leren en 
vanuit verschillende achtergronden elkaar mooi konden aanvullen. Ik ben trots op wat 
we bereikt hebben en ik ben blij dat we daar op de ESMO even bij stil hebben kunnen 
staan. Carin, onze dates op de meest gekke locaties om pakketjes uit te wisselen 
zullen me zeker bij blijven. Ik wens jullie allebei veel succes in jullie verdere carrieres. 
Dr. van Meerten, Esther, van harte bedankt voor het meedenken bij onze retrospectieve 
capecitabine analyse en voor je begeleiding tijdens mijn klinische werkzaamheden, ik 
kijk ernaar uit om nog meer van je te kunnen leren. 
Andrew, bedankt voor de prettige samenwerking bij het irinotecan review ondanks dat 
het voor jou geen makkelijke tijd was. Ik ben trots op wat we samen bereikt hebben.
 
Stijn, bedankt dat je mij in het begin op weg hebt geholpen met de DIRINO, jouw 
suggesties waren altijd zeer waardevol. Ondanks dat je bij mijn vele andere projecten 
niet direct betrokken was, ben ik je dankbaar dat je altijd met mij mee wilde denken. 
Ron de Bruin en Martijn Dolleé, bedankt voor jullie betrokkenheid bij het ontwerp van 
de DIRINO studie en de aanvullende analyses. 
Gerdien, ik wil je graag bedanken voor jouw enorme inzet en betrokkenheid bij de 
patienten van de DIRINO studie. Het was heel fijn om met je samen te werken. Patty 
en Lucie, bedankt dat jullie het stokje tijdelijk van Gerdien konden overnemen en het 
enthousiasme waarmee jullie dat deden. 
Emma Hulshof, bedankt dat je me zo betrokken hebt bij de IRI-28 studie, het was leuk 
om samen te brainstormen over de studie. Ik kijk uit naar de resultaten en de grote 
hoeveelheid data waar we hopelijk nog meer mooi analyses op kunnen doen. 
Eelke en Nadine, ik wil jullie graag bedanken voor de samenwerking, mooi om van 
jullie te leren hoe een chirurg (in spé) toch anders tegen dingen aan kijkt. Nadine, ik 
kijk uit naar de resultaten van de INTERACT studie en ben blij dat ik je heb kunnen 
helpen bij de opstart van deze studie. 
Dr. van der Gaast en Dr. Spaander, Ate en Manon, bedankt voor jullie hulp bij het 
ontwerp van de PAREO studie. Helaas heb ik deze niet zelf kunnen afronden, maar het 
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einde komt in zicht. Ate, bedankt voor je bereidheid om mij altijd uit te dagen en meer 
te leren op het gebied van de behandeling van het slokdarmcarcinoom. 
Dr. Eskens, Ferry, bedankt voor je begeleiding tijdens mijn poli, ik ben dankbaar dat ik 
van je heb mogen leren. Dr. van Zuylen, Lia, we hebben maar een paar gezamenlijke 
patienten gehad, desondanks heb ik veel van je geleerd, veel dank daarvoor. 
Wesley en Harmen, bedankt voor de samenwerking bij het CPCT irinotecan project, 
helaas hoort het ook bij de wetenschap dat de data soms tegen valt. Desondanks 
hebben jullie mij wel veel geleerd en ik jullie hopelijk ook wat vanaf de klinische kant. 
Peter, Inge en Mei, heel erg bedankt voor al jullie hulp met de analyse van mijn PK-
samples. Jullie zijn de basis van ons lab en ik ben heel blij dat ik met jullie heb kunnen 
werken. En jullie gezelligheid natuurlijk niet te vergeten; de (foto’s en) verhalen van 
mooie reizen, fossielen, en lekker koken, waren altijd goed om de week mee te 
beginnen. Bimla, bedankt voor al je hulp bij logistiek, je gezelligheid en alle verwennerij 
niet te vergeten. Het was een mooie tijd in jouw domein op B0-zuid en we gaan zeker 
nog een keer samen koken. Robert, bedankt dat je er altijd was om mij op te beuren 
hoe druk we het allebei ook hadden, wat hebben we veel lol gehad bij de centrifuges 
en bij de borrels. Ik ga jouw humor zeker missen! 
Oncologie verpleegkundigen vanuit zowel de kliniek als de dagbehandeling, jullie geven 
elke dag alles om onze patiënten een klein beetje beter te laten voelen. Bedankt dat ik 
veel van jullie heb mogen leren en dat jullie altijd bereid waren om mij te helpen met mijn 
studies. In het bijzonder dank aan Jan, Frank, Sophie, Petra, bedankt dat jullie er waren.
José, bedankt voor je hulp bij het maken van onmogelijke afspraken in de overvolle 
agenda van Ron en natuurlijk al je hulp met HoraFinita. Gerdien en Eline, jullie ben ik 
ook dankbaar voor jullie hulp en de altijd wijze raad over logistieke zaken. 
Roelof, dankzij jou ben ik enthousiast geraakt over geneesmiddelinteracties en daar wil 
ik je graag voor bedanken. Ondanks dat je me vaak gezegd hebt dat ik (te) eigenwijs 
was, kijk ik met goede herinneringen terug op onze samenwerking en de borrels /skitrip. 
Sander, ooit was jij de oude rot die mij op weg hielp in het lab, veel dank daarvoor. 
Van jouw nuchtere en droge humor heb ik erg genoten, maar nog meer heeft jouw 
‘hangmatmodus’ mij geleerd niet te stressen als het niet nodig is. Bedankt voor je hulp 
bij het irinotecan review, schrappen is inderdaad een kunst. Ik kijk ernaar uit om in de 
toekomst weer samen te werken en te filosoferen over de wetenschap. 
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Bodine en Florence, we starten ongeveer gelijk met onze promoties en er is in korte tijd 
een hechte vriendschap gegroeid waarbij naast veel gezelligheid we ook privé-zaken 
met elkaar konden delen. Bo, je hebt een heerlijk karakter en sterke eigen mening, blijf 
wie je bent. Flo, ook al lijk je zo georganiseerd, er is niemand die zo chaotisch is als jij 
en daar hebben we veel lol om gehad, maar je hebt echt een hart van goud. Meiden, 
ik ben heel blij dat jullie ook op deze laatste dag van mijn promotie achter mij willen 
staan als mijn paranimfen. Ik weet zeker dat we in de toekomst nog veel mooie dingen 
samen gaan beleven en dat jullie ook een fantastische promotie tegemoet gaan.  
Koen, afgelopen jaren ben je een goede vriend geworden. De intensieve samenwerking 
bij de REGORA met al onze niet zo fitte patienten, heeft ervoor gezorgd dat we het 
toch mooi hebben kunnen afronden. Heel fijn om het laatste jaar de dag met een 
kop koffie en slap gelul samen te beginnen en de week te eindigen met een speciaal 
biertje. Jouw positiviteit en rust waren een grote steun tijdens stressvolle periodes. 
Leni, bedankt voor onze fijne samenwerking bij de COCA en de PAREO. Daarnaast ook 
bedankt voor al je hulp en interesse in mijn andere projecten. Ik heb veel bewondering 
voor hoe je het onderzoek naast je normale werk doet en ik weet zeker dat je een heel 
mooi proefschrift krijgt! 
Daan en Louwrens, bedankt voor jullie gezelligheid in onze overvolle kamer in Be. Daan, 
altijd mooi om te sparren over onze verschillende onderzoeksgebieden, bedankt voor 
alle leuke gesprekken over van alles en nog wat. Louwrens, fijn dat je altijd even wilde 
meedenken ten aanzien van farmacologie en dat ik jou kon helpen op medisch gebied, mooi 
om zo onze achtergronden zo te mixen. Edwin en Nikki, bedankt voor jullie gezelligheid. 
Ivo, Joris, Nadia, Mirjam, Niels, Ruben en Marijn, bedankt voor al jullie hulp, ik ben blij 
dat ik jullie (deels) heb mogen begeleiden. Mirjam, Ruben en Marijn, heel erg leuk dat 
jullie nu zelf bezig zijn met jullie promotie-onderzoek bij onze groep. Ruben, jou ben ik 
extra dank verschuldigd voor de fijne samenwerking bij de DIRINO, de retrospectieve 
carbotaxol analyse, en natuurlijk je humor en heerlijke muzieksmaak. 
  
Lindsay, ik vind het mooi dat wij vanaf Junior Med School hetzelfde pad bewandelen. 
Ik vond het erg leuk om samen aan het cfDNA project te werken en ben trots op het 
resultaat. Bedankt voor al je gezelligheid en die etentjes zetten we zeker door, ik kijk 
ernaar uit om in de toekomst (opnieuw) collega’s te worden!
Marjolein, Nick, Inge, bedankt voor jullie gezelligheid, altijd goed om even bij elkaar te 
buurten en we gaan elkaar in de toekomst zeker nog zien.
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Lotte, Anouk, Bernard, Wesley, Julia, Mélanie, Rob, Ton, Celine, bedankt voor onze tijd 
als AAV-bestuur. Ik ben trots op wat we bereikt hebben en het mij veel geleerd naast 
mijn promotie. Het was mooi om het met jullie te doen!
Christa, van coschappen af aan, ben je er altijd voor mij geweest. Bedankt voor je 
vriendschap en gezelligheid!
STUKkies, sinds onze studententijd een hechte vriendinnengroep, bedankt dat jullie 
er altijd zijn met een luisterend oor en een flinke dosis humor. Ondanks dat we elkaar 
niet wekelijks kunnen zien, is het altijd als vanouds. Ik kijk ernaar uit om nog vele 
avonturen met jullie te beleven!
Meiden van de VUUR Verticale, bedankt voor jullie steun en gezelligheid, niet voor 
niets door VUUR en VLAM. Mandy en Tamara, ik heb genoten van onze tijd als 
waakvlammenbestuur, laten we de borrels en etentjes erin houden.
Kim en Tim, in Delft begon onze dierbare vriendschap met biertjes op het terras en 
een rondje rennen, daarna van wielrennen tot wijnproeven, van tent tot kasteel, te veel 
verhalen om op te noemen. Bedankt voor jullie steun en gezelligheid!
Put, Car, Bob, Liek, Ar en Jo, wat zijn jullie fijne vrienden, bedankt dat jullie altijd klaar 
staan voor gezellige afleiding! 
Lieve pap en mam, ik wil jullie heel erg bedanken voor jullie onuitputtelijk steun en 
liefde. Mam, bedankt dat je altijd met mij leeft en voor me klaar staat als ik je nodig 
heb. Pap, bedankt dat je mij altijd stimuleert het beste uit mezelf te halen en altijd klaar 
staat met goede raad of een knuffel. (Schoon)broers en (schoon)zussen, bedankt dat 
jullie er zijn, ik ben trots op onze familie. 
Lieve Gijs en Marianne, bedankt voor al jullie liefde en steun, ook al is het soms op 
afstand, bedankt dat ik altijd op jullie kan rekenen. 
Lieve André en Karin, betere schoonouders kan ik me niet wensen, bedankt voor hoe 
jullie er altijd voor mij zijn. 
Lieve Remco, al meer dan 10 jaar ben jij mijn beste vriend, mijn geliefde en mijn 
maatje. Elke dag met jou is zoveel leuker dan alleen. Zonder jou was dit proefschrift er 
absoluut niet geweest, we hebben het echt samen gedaan. Ik kijk uit naar al het moois 
wat we nog gaan beleven.   
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